fbpx
Wikipedia

Hepatitis

December 27, 2022

"Hepatite" redirects here. For the mineral of that name, see Baryte.

Hepatitis is inflammation of the liver tissue.[3][5] Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea.[1][2] Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months.[1][6] Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure.[7] Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.[3]

Hepatitis
Alcoholic hepatitis as seen with a microscope, showing fatty changes (white circles), remnants of dead liver cells, and Mallory bodies (twisted-rope shaped inclusions within some liver cells). (H&E stain)
SpecialtyInfectious disease, gastroenterology, hepatology
SymptomsYellowish skin, poor appetite, abdominal pain[1][2]
ComplicationsScarring of the liver, liver failure, liver cancer[3]
DurationShort term or long term[1]
CausesViruses, alcohol, toxins, autoimmune[2][3]
PreventionVaccination (for viral hepatitis),[2] avoiding excessive alcohol
TreatmentMedication, liver transplant[1][4]
Frequency> 500 million cases[3]
Deaths> One million a year[3]

Hepatitis is most commonly caused by the virus hepatovirus A, B, C, D, and E.[2][3] Other viruses can also cause liver inflammation, including cytomegalovirus, Epstein–Barr virus, and yellow fever virus. Other common causes of hepatitis include heavy alcohol use, certain medications, toxins, other infections, autoimmune diseases,[2][3] and non-alcoholic steatohepatitis (NASH).[8] Hepatitis A and E are mainly spread by contaminated food and water.[3] Hepatitis B is mainly sexually transmitted, but may also be passed from mother to baby during pregnancy or childbirth and spread through infected blood.[3] Hepatitis C is commonly spread through infected blood such as may occur during needle sharing by intravenous drug users.[3] Hepatitis D can only infect people already infected with hepatitis B.[3]

Hepatitis A, B, and D are preventable with immunization.[2] Medications may be used to treat chronic viral hepatitis.[1] Antiviral medications are recommended in all with chronic hepatitis C, except those with conditions that limit their life expectancy.[9] There is no specific treatment for NASH; physical activity, a healthy diet, and weight loss are recommended.[8] Autoimmune hepatitis may be treated with medications to suppress the immune system.[10] A liver transplant may be an option in both acute and chronic liver failure.[4]

Worldwide in 2015, hepatitis A occurred in about 114 million people, chronic hepatitis B affected about 343 million people and chronic hepatitis C about 142 million people.[11] In the United States, NASH affects about 11 million people and alcoholic hepatitis affects about 5 million people.[8][12] Hepatitis results in more than a million deaths a year, most of which occur indirectly from liver scarring or liver cancer.[3][13] In the United States, hepatitis A is estimated to occur in about 2,500 people a year and results in about 75 deaths.[14] The word is derived from the Greek hêpar (ἧπαρ), meaning "liver", and -itis (-ῖτις), meaning "inflammation".[15]

Signs and symptoms

 
Jaundiced eyes

Hepatitis has a broad spectrum of presentations that range from a complete lack of symptoms to severe liver failure.[16][17][18] The acute form of hepatitis, generally caused by viral infection, is characterized by constitutional symptoms that are typically self-limiting.[16][17] Chronic hepatitis presents similarly, but can manifest signs and symptoms specific to liver dysfunction with long-standing inflammation and damage to the organ.[18][19]

Acute hepatitis

Acute viral hepatitis follows three distinct phases:

  1. The initial prodromal phase (preceding symptoms) involves non-specific and flu-like symptoms common to many acute viral infections. These include fatigue, nausea, vomiting, poor appetite, joint pain, and headaches.[16][17] Fever, when present, is most common in cases of hepatitis A and E.[16] Late in this phase, people can experience liver-specific symptoms, including choluria (dark urine) and clay-colored stools.[16][17]
  2. Yellowing of the skin and whites of the eyes follow the prodrome after about 1–2 weeks and can last for up to 4 weeks.[16][17] The non-specific symptoms seen in the prodromal typically resolve by this time, but people will develop an enlarged liver and right upper abdominal pain or discomfort.[16] 10–20% of people will also experience an enlarged spleen, while some people will also experience a mild unintentional weight loss.[16][18]
  3. The recovery phase is characterized by resolution of the clinical symptoms of hepatitis with persistent elevations in liver lab values and potentially a persistently enlarged liver.[16] All cases of hepatitis A and E are expected to fully resolve after 1–2 months.[16] Most hepatitis B cases are also self-limiting and will resolve in 3–4 months. Few cases of hepatitis C will resolve completely.[16]

Both drug-induced hepatitis and autoimmune hepatitis can present very similarly to acute viral hepatitis, with slight variations in symptoms depending on the cause.[20][21] Cases of drug-induced hepatitis can manifest with systemic signs of an allergic reaction including rash, fever, serositis (inflammation of membranes lining certain organs), elevated eosinophils (a type of white blood cell), and suppression of bone marrow activity.[20]

Fulminant hepatitis

Fulminant hepatitis, or massive hepatic cell death, is a rare and life-threatening complication of acute hepatitis that can occur in cases of hepatitis B, D, and E, in addition to drug-induced and autoimmune hepatitis.[16][20][21] The complication more frequently occurs in instances of hepatitis B and D co-infection at a rate of 2–20% and in pregnant women with hepatitis E at rate of 15–20% of cases.[16][17] In addition to the signs of acute hepatitis, people can also demonstrate signs of coagulopathy (abnormal coagulation studies with easy bruising and bleeding) and encephalopathy (confusion, disorientation, and sleepiness).[16][17] Mortality due to fulminant hepatitis is typically the result of various complications including cerebral edema, gastrointestinal bleeding, sepsis, respiratory failure, or kidney failure.[16]

Chronic hepatitis

Acute cases of hepatitis are seen to be resolved well within a six-month period. When hepatitis is continued for more than six months it is termed chronic hepatitis.[22] Chronic hepatitis is often asymptomatic early in its course and is detected only by liver laboratory studies for screening purposes or to evaluate non-specific symptoms.[18][19] As the inflammation progresses, patients can develop constitutional symptoms similar to acute hepatitis, including fatigue, nausea, vomiting, poor appetite, and joint pain.[19] Jaundice can occur as well, but much later in the disease process and is typically a sign of advanced disease.[19] Chronic hepatitis interferes with hormonal functions of the liver which can result in acne, hirsutism (abnormal hair growth), and amenorrhea (lack of menstrual period) in women.[19] Extensive damage and scarring of the liver over time defines cirrhosis, a condition in which the liver's ability to function is permanently impeded.[18] This results in jaundice, weight loss, coagulopathy, ascites (abdominal fluid collection), and peripheral edema (leg swelling).[19] Cirrhosis can lead to other life-threatening complications such as hepatic encephalopathy, esophageal varices, hepatorenal syndrome, and liver cancer.[18]

Causes

Causes of hepatitis can be divided into the following major categories: infectious, metabolic, ischemic, autoimmune, genetic, and other. Infectious agents include viruses, bacteria, and parasites. Metabolic causes include prescription medications, toxins (most notably alcohol), and non-alcoholic fatty liver disease. Autoimmune and genetic causes of hepatitis involve genetic predispositions and tend to affect characteristic populations.[citation needed]

Infectious

Viral hepatitis

Main article: Viral hepatitis

Viral hepatitis is the most common type of hepatitis worldwide, especially in Asia and Africa.[23] Viral hepatitis is caused by five different viruses (hepatitis A, B, C, D, and E).[16] Hepatitis A and hepatitis E behave similarly: they are both transmitted by the fecal–oral route, are more common in developing countries, and are self-limiting illnesses that do not lead to chronic hepatitis.[16][24][25]

Hepatitis B, hepatitis C, and hepatitis D are transmitted when blood or mucous membranes are exposed to infected blood and body fluids, such as semen and vaginal secretions.[16] Viral particles have also been found in saliva and breastmilk. Kissing, sharing utensils, and breastfeeding do not lead to transmission unless these fluids are introduced into open sores or cuts.[26] Many families who do not have safe drinking water or live in unhygienic homes have contracted hepatitis because saliva and blood droplets are often carried through the water and blood-borne illnesses spread quickly in unsanitary settings.[citation needed]

Hepatitis B and C can present either acutely or chronically.[16] Hepatitis D is a defective virus that requires hepatitis B to replicate and is only found with hepatitis B co-infection.[16] In adults, hepatitis B infection is most commonly self-limiting, with less than 5% progressing to chronic state, and 20 to 30% of those chronically infected developing cirrhosis or liver cancer.[27] Infection in infants and children frequently leads to chronic infection.[27]

Unlike hepatitis B, most cases of hepatitis C lead to chronic infection.[28] Hepatitis C is the second most common cause of cirrhosis in the US (second to alcoholic hepatitis).[29] In the 1970s and 1980s, blood transfusions were a major factor in spreading hepatitis C virus.[28] Since widespread screening of blood products for hepatitis C began in 1992, the risk of acquiring hepatitis C from a blood transfusion has decreased from approximately 10% in the 1970s to 1 in 2 million currently.[16]

Parasitic hepatitis

 
Echinococcus granulosus

Parasites can also infect the liver and activate the immune response, resulting in symptoms of acute hepatitis with increased serum IgE (though chronic hepatitis is possible with chronic infections).[30] Of the protozoans, Trypanosoma cruzi, Leishmania species, and the malaria-causing Plasmodium species all can cause liver inflammation.[30] Another protozoan, Entamoeba histolytica, causes hepatitis with distinct liver abscesses.[30]

Of the worms, the cestode Echinococcus granulosus, also known as the dog tapeworm, infects the liver and forms characteristic hepatic hydatid cysts.[30] The liver flukes Fasciola hepatica and Clonorchis sinensis live in the bile ducts and cause progressive hepatitis and liver fibrosis.[30]

Bacterial hepatitis

Bacterial infection of the liver commonly results in pyogenic liver abscesses, acute hepatitis, or granulomatous (or chronic) liver disease.[31] Pyogenic abscesses commonly involve enteric bacteria such as Escherichia coli and Klebsiella pneumoniae and are composed of multiple bacteria up to 50% of the time.[31] Acute hepatitis is caused by Neisseria meningitidis, Neisseria gonorrhoeae, Bartonella henselae, Borrelia burgdorferi, salmonella species, brucella species and campylobacter species.[31] Chronic or granulomatous hepatitis is seen with infection from mycobacteria species, Tropheryma whipplei, Treponema pallidum, Coxiella burnetii, and rickettsia species.[31]

Metabolic

Alcoholic hepatitis

Main article: Alcoholic hepatitis

Excessive alcohol consumption is a significant cause of hepatitis and is the most common cause of cirrhosis in the U.S.[29] Alcoholic hepatitis is within the spectrum of alcoholic liver disease. This ranges in order of severity and reversibility from alcoholic steatosis (least severe, most reversible), alcoholic hepatitis, cirrhosis, and liver cancer (most severe, least reversible).[29] Hepatitis usually develops over years-long exposure to alcohol, occurring in 10 to 20% of alcoholics.[32] The most important risk factors for the development of alcoholic hepatitis are quantity and duration of alcohol intake.[32] Long-term alcohol intake in excess of 80 grams of alcohol a day in men and 40 grams a day in women is associated with development of alcoholic hepatitis (1 beer or 4 ounces of wine is equivalent to 12g of alcohol).[29] Alcoholic hepatitis can vary from asymptomatic hepatomegaly (enlarged liver) to symptoms of acute or chronic hepatitis to liver failure.[29]

Toxic and drug-induced hepatitis

Many chemical agents, including medications, industrial toxins, and herbal and dietary supplements, can cause hepatitis.[33][34] The spectrum of drug-induced liver injury varies from acute hepatitis to chronic hepatitis to acute liver failure.[33] Toxins and medications can cause liver injury through a variety of mechanisms, including direct cell damage, disruption of cell metabolism, and causing structural changes.[35] Some drugs such as paracetamol exhibit predictable dose-dependent liver damage while others such as isoniazid cause idiosyncratic and unpredictable reactions that vary by person.[33] There are wide variations in the mechanisms of liver injury and latency period from exposure to development of clinical illness.[29]

Many types of drugs can cause liver injury, including the analgesic paracetamol; antibiotics such as isoniazid, nitrofurantoin, amoxicillin-clavulanate, erythromycin, and trimethoprim-sulfamethoxazole; anticonvulsants such as valproate and phenytoin; cholesterol-lowering statins; steroids such as oral contraceptives and anabolic steroids; and highly active anti-retroviral therapy used in the treatment of HIV/AIDS.[29] Of these, amoxicillin-clavulanate is the most common cause of drug-induced liver injury, and paracetamol toxicity the most common cause of acute liver failure in the United States and Europe.[33]

Herbal remedies and dietary supplements are another important cause of hepatitis; these are the most common causes of drug-induced hepatitis in Korea.[36] The United-States-based Drug Induced Liver Injury Network linked more than 16% of cases of hepatotoxicity to herbal and dietary supplements.[37] In the United States, herbal and dietary supplements – unlike pharmaceutical drugs – are unregulated by the Food and Drug Administration.[37] The National Institutes of Health maintains the LiverTox 2019-07-24 at the Wayback Machine database for consumers to track all known prescription and non-prescription compounds associated with liver injury.[38]

Exposure to other hepatotoxins can occur accidentally or intentionally through ingestion, inhalation, and skin absorption. The industrial toxin carbon tetrachloride and the wild mushroom Amanita phalloides are other known hepatotoxins.[33][34][39]

Non-alcoholic fatty liver disease

Main article: Non-alcoholic fatty liver disease

Non-alcoholic hepatitis is within the spectrum of non-alcoholic liver disease (NALD), which ranges in severity and reversibility from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) to cirrhosis to liver cancer, similar to the spectrum of alcoholic liver disease.[40]

Non-alcoholic liver disease occurs in people with little or no history of alcohol use, and is instead strongly associated with metabolic syndrome, obesity, insulin resistance and diabetes, and hypertriglyceridemia.[29] Over time, non-alcoholic fatty liver disease can progress to non-alcoholic steatohepatitis, which additionally involves liver cell death, liver inflammation and possible fibrosis.[29] Factors accelerating progression from NAFLD to NASH are obesity, older age, non-African American ethnicity, female gender, diabetes mellitus, hypertension, higher ALT or AST level, higher AST/ALT ratio, low platelet count, and an ultrasound steatosis score.[29]

In the early stages (as with NAFLD and early NASH), most patients are asymptomatic or have mild right upper quadrant pain, and diagnosis is suspected on the basis of abnormal liver function tests.[29] As the disease progresses, symptoms typical of chronic hepatitis may develop.[41] While imaging can show fatty liver, only liver biopsy can demonstrate inflammation and fibrosis characteristic of NASH.[42] 9 to 25% of patients with NASH develop cirrhosis.[29] NASH is recognized as the third most common cause of liver disease in the United States.[41]

Autoimmune

Main article: Autoimmune hepatitis

Autoimmune hepatitis is a chronic disease caused by an abnormal immune response against liver cells.[43] The disease is thought to have a genetic predisposition as it is associated with certain human leukocyte antigens involved in the immune response.[44] As in other autoimmune diseases, circulating auto-antibodies may be present and are helpful in diagnosis.[45] Auto-antibodies found in patients with autoimmune hepatitis include the sensitive but less specific anti-nuclear antibody (ANA), smooth muscle antibody (SMA), and atypical perinuclear antineutrophil cytoplasmic antibody (p-ANCA).[45] Other autoantibodies that are less common but more specific to autoimmune hepatitis are the antibodies against liver kidney microsome 1 (LKM1) and soluble liver antigen (SLA).[45] Autoimmune hepatitis can also be triggered by drugs (such as nitrofurantoin, hydralazine, and methyldopa), after liver transplant, or by viruses (such as hepatitis A, Epstein-Barr virus, or measles).[29]

Autoimmune hepatitis can present anywhere within the spectrum from asymptomatic to acute or chronic hepatitis to fulminant liver failure.[29] Patients are asymptomatic 25–34% of the time, and the diagnosis is suspected on the basis of abnormal liver function tests.[45] Some studies show between 25% and 75% of cases present with signs and symptoms of acute hepatitis.[29][46] As with other autoimmune diseases, autoimmune hepatitis usually affects young females (though it can affect patients of either sex of any age), and patients can exhibit classic signs and symptoms of autoimmunity such as fatigue, anemia, anorexia, amenorrhea, acne, arthritis, pleurisy, thyroiditis, ulcerative colitis, nephritis, and maculopapular rash.[29] Autoimmune hepatitis increases the risk for cirrhosis, and the risk for liver cancer is increased by about 1% for each year of the disease.[29]

Many people with autoimmune hepatitis have other autoimmune diseases.[47] Autoimmune hepatitis is distinct from the other autoimmune diseases of the liver, primary biliary cirrhosis and primary sclerosing cholangitis, both of which can also lead to scarring, fibrosis, and cirrhosis of the liver.[29][45]

Genetic

Genetic causes of hepatitis include alpha-1-antitrypsin deficiency, hemochromatosis, and Wilson's disease.[29] In alpha-1-antitrypsin deficiency, a co-dominant mutation in the gene for alpha-1-antitrypsin results in the abnormal accumulation of the mutant AAT protein within liver cells, leading to liver disease.[48] Hemochromatosis and Wilson's disease are both autosomal recessive diseases involving abnormal storage of minerals.[29] In hemochromatosis, excess amounts of iron accumulate in multiple body sites, including the liver, which can lead to cirrhosis.[29] In Wilson's disease, excess amounts of copper accumulate in the liver and brain, causing cirrhosis and dementia.[29]

When the liver is involved, alpha-1-antitrypsin deficiency and Wilson's disease tend to present as hepatitis in the neonatal period or in childhood.[29] Hemochromatosis typically presents in adulthood, with the onset of clinical disease usually after age 50.[29]

Ischemic hepatitis

Main article: Ischemic hepatitis

Ischemic hepatitis (also known as shock liver) results from reduced blood flow to the liver as in shock, heart failure, or vascular insufficiency.[49] The condition is most often associated with heart failure but can also be caused by shock or sepsis. Blood testing of a person with ischemic hepatitis will show very high levels of transaminase enzymes (AST and ALT). The condition usually resolves if the underlying cause is treated successfully. Ischemic hepatitis rarely causes permanent liver damage.[50]

Other

Main article: Neonatal hepatitis

Hepatitis can also occur in neonates and is attributable to a variety of causes, some of which are not typically seen in adults.[51] Congenital or perinatal infection with the hepatitis viruses, toxoplasma, rubella, cytomegalovirus, and syphilis can cause neonatal hepatitis.[51] Structural abnormalities such as biliary atresia and choledochal cysts can lead to cholestatic liver injury leading to neonatal hepatitis.[51] Metabolic diseases such as glycogen storage disorders and lysosomal storage disorders are also implicated.[51] Neonatal hepatitis can be idiopathic, and in such cases, biopsy often shows large multinucleated cells in the liver tissue.[52] This disease is termed giant cell hepatitis and may be associated with viral infection, autoimmune disorders, and drug toxicity.[53][54]

Mechanism

The specific mechanism varies and depends on the underlying cause of the hepatitis. Generally, there is an initial insult that causes liver injury and activation of an inflammatory response, which can become chronic, leading to progressive fibrosis and cirrhosis.[16]

Viral hepatitis

 
Stages of liver disease

The pathway by which hepatic viruses cause viral hepatitis is best understood in the case of hepatitis B and C.[16] The viruses do not directly activate apoptosis (cell death).[16][55] Rather, infection of liver cells activates the innate and adaptive arms of the immune system leading to an inflammatory response which causes cellular damage and death, including viral-induced apoptosis via the induction of the death receptor-mediated signaling pathway.[16][55][56][57] Depending on the strength of the immune response, the types of immune cells involved and the ability of the virus to evade the body's defense, infection can either lead to clearance (acute disease) or persistence (chronic disease) of the virus.[16] The chronic presence of the virus within liver cells results in multiple waves of inflammation, injury and wound healing that over time lead to scarring or fibrosis and culminate in hepatocellular carcinoma.[55][58] People with impaired immune response are at greater risk of developing chronic infection.[16] Natural killer cells are the primary drivers of the initial innate response and create a cytokine environment that results in the recruitment of CD4 T-helper and CD8 cytotoxic T-cells.[59][60] Type I interferons are the cytokines that drive the antiviral response.[60] In chronic Hepatitis B and C, natural killer cell function is impaired.[59]

Steatohepatitis

Steatohepatitis is seen in both alcoholic and non-alcoholic liver disease and is the culmination of a cascade of events that began with injury. In the case of non-alcoholic steatohepatitis, this cascade is initiated by changes in metabolism associated with obesity, insulin resistance, and lipid dysregulation.[61][62] In alcoholic hepatitis, chronic excess alcohol use is the culprit.[63] Though the inciting event may differ, the progression of events is similar and begins with accumulation of free fatty acids (FFA) and their breakdown products in the liver cells in a process called steatosis.[61][62][63] This initially reversible process overwhelms the hepatocyte's ability to maintain lipid homeostasis leading to a toxic effect as fat molecules accumulate and are broken down in the setting of an oxidative stress response.[61][62][63] Over time, this abnormal lipid deposition triggers the immune system via toll-like receptor 4 (TLR4) resulting in the production of inflammatory cytokines such as TNF that cause liver cell injury and death.[61][62][63] These events mark the transition to steatohepatitis and in the setting of chronic injury, fibrosis eventually develops setting up events that lead to cirrhosis and hepatocellular carcinoma.[61] Microscopically, changes that can be seen include steatosis with large and swollen hepatocytes (ballooning), evidence of cellular injury and cell death (apoptosis, necrosis), evidence of inflammation in particular in zone 3 of the liver, variable degrees of fibrosis and Mallory bodies.[61][64][65]

Diagnosis

Most elevated aminotransferase Cause
ALT Chronic hepatitis B, C, and D
Nonalcoholic liver disease
Acute viral hepatitis
Medications/toxins
Autoimmune hepatitis
Wilson's disease
Alpha-1-antitrypsin deficiency
Hemochromatosis
Ischemic hepatitis (severe elevation up to thousands)
AST Alcoholic liver disease
Cirrhosis
 
Histopathology of acute hepatitis with lobular disarray and associated lymphocytic inflammation, acidophil body formation (arrow) and bilirubinostasis.

Diagnosis of hepatitis is made on the basis of some or all of the following: a person's signs and symptoms, medical history including sexual and substance use history, blood tests, imaging, and liver biopsy.[29] In general, for viral hepatitis and other acute causes of hepatitis, the person's blood tests and clinical picture are sufficient for diagnosis.[16][29] For other causes of hepatitis, especially chronic causes, blood tests may not be useful.[29] In this case, liver biopsy is the gold standard for establishing the diagnosis: histopathologic analysis is able to reveal the precise extent and pattern of inflammation and fibrosis.[29] Biopsy is typically not the initial diagnostic test because it is invasive and is associated with a small but significant risk of bleeding that is increased in people with liver injury and cirrhosis.[66]

Blood testing includes liver enzymes, serology (i.e. for autoantibodies), nucleic acid testing (i.e. for hepatitis virus DNA/RNA), blood chemistry, and complete blood count.[29] Characteristic patterns of liver enzyme abnormalities can point to certain causes or stages of hepatitis.[67][68] Generally, AST and ALT are elevated in most cases of hepatitis regardless of whether the person shows any symptoms.[29] The degree of elevation (i.e. levels in the hundreds vs. in the thousands), the predominance for AST vs. ALT elevation, and the ratio between AST and ALT are informative of the diagnosis.[29]

Ultrasound, CT, and MRI can all identify steatosis (fatty changes) of the liver tissue and nodularity of the liver surface suggestive of cirrhosis.[69][70] CT and especially MRI are able to provide a higher level of detail, allowing visualization and characterize such structures as vessels and tumors within the liver.[71] Unlike steatosis and cirrhosis, no imaging test is able to detect liver inflammation (i.e. hepatitis) or fibrosis.[29] Liver biopsy is the only definitive diagnostic test that is able to assess inflammation and fibrosis of the liver.[29]

Viral hepatitis

Main article: Viral hepatitis

Viral hepatitis is primarily diagnosed through blood tests for levels of viral antigens (such as the hepatitis B surface or core antigen), anti-viral antibodies (such as the anti-hepatitis B surface antibody or anti-hepatitis A antibody), or viral DNA/RNA.[16][29] In early infection (i.e. within 1 week), IgM antibodies are found in the blood.[29] In late infection and after recovery, IgG antibodies are present and remain in the body for up to years.[29] Therefore, when a patient is positive for IgG antibody but negative for IgM antibody, he is considered immune from the virus via either prior infection and recovery or prior vaccination.[29]

In the case of hepatitis B, blood tests exist for multiple virus antigens (which are different components of the virion particle) and antibodies.[72] The combination of antigen and antibody positivity can provide information about the stage of infection (acute or chronic), the degree of viral replication, and the infectivity of the virus.[72]

Alcoholic versus non-alcoholic

The most apparent distinguishing factor between alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH) is a history of excessive alcohol use.[73] Thus, in patients who have no or negligible alcohol use, the diagnosis is unlikely to be alcoholic hepatitis. In those who drink alcohol, the diagnosis may just as likely be alcoholic or nonalcoholic hepatitis especially if there is concurrent obesity, diabetes, and metabolic syndrome. In this case, alcoholic and nonalcoholic hepatitis can be distinguished by the pattern of liver enzyme abnormalities; specifically, in alcoholic steatohepatitis AST>ALT with ratio of AST:ALT>2:1 while in nonalcoholic steatohepatitis ALT>AST with ratio of ALT:AST>1.5:1.[73]

Liver biopsies show identical findings in patients with ASH and NASH, specifically, the presence of polymorphonuclear infiltration, hepatocyte necrosis and apoptosis in the form of ballooning degeneration, Mallory bodies, and fibrosis around veins and sinuses.[29]

Virus screening

The purpose of screening for viral hepatitis is to identify people infected with the disease as early as possible, even before symptoms and transaminase elevations may be present. This allows for early treatment, which can both prevent disease progression and decrease the likelihood of transmission to others.[citation needed]

Hepatitis A

Hepatitis A causes an acute illness that does not progress to chronic liver disease. Therefore, the role of screening is to assess immune status in people who are at high risk of contracting the virus, as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure.[74][75] People in these groups who are not already immune can receive the hepatitis A vaccine.

Those at high risk and in need of screening include:[76][77][78]

  • People with poor sanitary habits such as not washing hands after using the restroom or changing diapers
  • People who do not have access to clean water
  • People in close contact (either living with or having sexual contact) with someone who has hepatitis A
  • People who use illicit drugs
  • People with liver disease
  • People traveling to an area with endemic hepatitis A

The presence of anti-hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination.[79]

Hepatitis B

 
Hepatitis B virus v2

The CDC, WHO, USPSTF, and ACOG recommend routine hepatitis B screening for certain high-risk populations.[80][81][82][83] Specifically, these populations include people who are:

Screening consists of a blood test that detects hepatitis B surface antigen (HBsAg). If HBsAg is present, a second test – usually done on the same blood sample – that detects the antibody for the hepatitis B core antigen (anti-HBcAg) can differentiate between acute and chronic infection.[80][84] People who are high-risk whose blood tests negative for HBsAg can receive the hepatitis B vaccine to prevent future infection.[80][81][82][83]

Hepatitis C

 
HCV structure
ABHD5CGI-58-the-Chanarin-Dorfman-Syndrome-Protein-Mobilises-Lipid-Stores-for-Hepatitis-C-Virus-ppat.1005568.s014

The CDC, WHO, USPSTF, AASLD, and ACOG recommend screening people at high risk for hepatitis C infection.[83][85][86][87][9] These populations include people who are:

  • Intravenous drug users (past or current)[85][86][87][9]
  • Intranasal illicit drug users[85][86][87][9]
  • HIV-positive[85][86][87][9]
  • Men who have sex with men[9]
  • Incarcerated, or who have been in the past[85][86][87][9]
  • On long-term hemodialysis, or who have been in the past[85][86][87][9]
  • Recipients of tattoos in an "unregulated setting"[87][9]
  • Recipients of blood products or organs prior to 1992 in the United States[85][87][9]
  • Adults in the United States born between 1945 and 1965[87][9]
  • Born to HCV-positive mothers[9]
  • Pregnant, and engaging in high-risk behaviors[83]
  • Workers in a healthcare setting who have had a needlestick injury[9]
  • Blood or organ donors.[9]
  • Sex workers[86]

For people in the groups above whose exposure is ongoing, screening should be periodic, though there is no set optimal screening interval.[87] The AASLD recommends screening men who have sex with men who are HIV-positive annually.[9] People born in the US between 1945 and 1965 should be screened once (unless they have other exposure risks).[85][87][9]

Screening consists of a blood test that detects anti-hepatitis C virus antibody. If anti-hepatitis C virus antibody is present, a confirmatory test to detect HCV RNA indicates chronic disease.[86][9]

Hepatitis D

The CDC, WHO, USPSTF, AASLD, and ACOG recommend screening people at high risk for hepatitis D infection.[83][85][86][87][9] These populations include people who are:

Hepatitis D is extremely rare. Symptoms include chronic diarrhea, anal and intestinal blisters, purple urine, and burnt popcorn scented breath.[80][81][82] Screening consists of a blood test that detects the anti-hepitits D virus antibbody. If anti-hepitits D virus antibody is present, a confirmatory test to detect HDV RNA DNA inidicates chronic disease.[86][9]

Prevention

Vaccines

Hepatitis A

Main article: Hepatitis A vaccine
 
Havrix vaccine

The CDC recommends the hepatitis A vaccine for all children beginning at age one, as well as for those who have not been previously immunized and are at high risk for contracting the disease.[76][77]

For children 12 months of age or older, the vaccination is given as a shot into the muscle in two doses 6–18 months apart and should be started before the age 24 months.[88]  The dosing is slightly different for adults depending on the type of the vaccine.  If the vaccine is for hepatitis A only, two doses are given 6–18 months apart depending on the manufacturer.[78]  If the vaccine is combined hepatitis A and hepatitis B, up to 4 doses may be required.[78]

Hepatitis B

Main article: Hepatitis B vaccine
 
WHO-UNICEF estimates of hepatitis B vaccine (HepB-BD) coverage in countries from the European WHO region in the years 2000-2015

The CDC recommends the routine vaccination of all children under the age of 19 with the hepatitis B vaccine.[89] They also recommend it for those who desire it or are at high risk.[77]

Routine vaccination for hepatitis B starts with the first dose administered as  a shot into the muscle before the newborn is discharged from the hospital. An additional two doses should be administered before the child is 18 months.[88]

For babies born to a mother with hepatitis B surface antigen positivity, the first dose is unique – in addition to the vaccine, the hepatitis immune globulin should also be administered, both within 12 hours of birth.  These newborns should also be regularly tested for infection for at least the first year of life.[88]

There is also a combination formulation that includes both hepatitis A and B vaccines.[90]

Other

There are currently no vaccines available in the United States for hepatitis C or E.[86][91][92] In 2015, a group in China published an article regarding the development of a vaccine for hepatitis E.[93] As of March 2016, the United States government was in the process of recruiting participants for the phase IV trial of the hepatitis E vaccine.[94]

Behavioral changes

Hepatitis A

Because hepatitis A is transmitted primarily through the oral-fecal route, the mainstay of prevention aside from vaccination is good hygiene, access to clean water and proper handling of sewage.[77]

Hepatitis B and C

As hepatitis B and C are transmitted through blood and multiple bodily fluids, prevention is aimed at screening blood prior to transfusion, abstaining from the use of injection drugs, safe needle and sharps practices in healthcare settings, and safe sex practices.[27][86]

Hepatitis D

 
Worldwide prevalence of HDV among HBV carriers in 2015. Eight genotypes have been identified worldwide by comparative phylogenetic analysis. Genotype 1 is the most frequent and has variable pathogenicity, Genotypes 2 and 4 are found in East Asia causing relatively mild disease. Genotype 3 is found in South America in association with severe hepatitis. Genotypes 5, 6, 7, 8 have been found only in Africa.[95]

The hepatitis D virus requires that a person first be infected with hepatitis B virus, so prevention efforts should focus on limiting the spread of hepatitis B. In people who have chronic hepatitis B infection and are at risk for superinfection with the hepatitis D virus, the preventive strategies are the same as for hepatitis B.[92]

Hepatitis E

Hepatitis E is spread primarily through the oral-fecal route but may also be spread by blood and from mother to fetus. The mainstay of hepatitis E prevention is similar to that for hepatitis A (namely, good hygiene and clean water practices).[91]

Alcoholic hepatitis

As excessive alcohol consumption can lead to hepatitis and cirrhosis, the following are maximal recommendations for alcohol consumption:[96]

  • Women – ≤ 3 drinks on any given day and ≤ 7 drinks per week
  • Men – ≤ 4 drinks on any given day and ≤ 14 drinks per week

Successes

Hepatitis A

In the United States, universal immunization has led to a two-thirds decrease in hospital admissions and medical expenses due to hepatitis A.[97]

Hepatitis B

In the United States new cases of hepatitis B decreased 75% from 1990 to 2004.[98]  The group that saw the greatest decrease was children and adolescents, likely reflecting the implementation of the 1999 guidelines.[99]

Hepatitis C

Hepatitis C infections each year had been declining since the 1980s, but began to increase again in 2006.[100] The data are unclear as to whether the decline can be attributed to needle exchange programmes.[101]

Alcoholic hepatitis

 
Depiction of a liver failure patient

Because people with alcoholic hepatitis may have no symptoms, it can be difficult to diagnose and the number of people with the disease is probably higher than many estimates.[102] Programs such as Alcoholics Anonymous have been successful in decreasing death due to cirrhosis, but it is difficult to evaluate their success in decreasing the incidence of alcoholic hepatitis.[103]

Treatment

The treatment of hepatitis varies according to the type, whether it is acute or chronic, and the severity of the disease.

  • Activity: Many people with hepatitis prefer bed rest, though it is not necessary to avoid all physical activity while recovering.[16]
  • Diet: A high-calorie diet is recommended.[16] Many people develop nausea and cannot tolerate food later in the day, so the bulk of intake may be concentrated in the earlier part of the day.[16] In the acute phase of the disease, intravenous feeding may be needed if patients cannot tolerate food and have poor oral intake subsequent to nausea and vomiting.[16]
  • Drugs: People with hepatitis should avoid taking drugs metabolized by the liver.[16] Glucocorticoids are not recommended as a treatment option for acute viral hepatitis and may even cause harm, such as development of chronic hepatitis.[16]
  • Precautions: Universal precautions should be observed. Isolation is usually not needed, except in cases of hepatitis A and E who have fecal incontinence, and in cases of hepatitis B and C who have uncontrolled bleeding.[16]

Hepatitis A

Main article: Hepatitis A

Hepatitis A usually does not progress to a chronic state, and rarely requires hospitalization.[16][76] Treatment is supportive and includes such measures as providing intravenous (IV) hydration and maintaining adequate nutrition.[16][76]

Rarely, people with the hepatitis A virus can rapidly develop liver failure, termed fulminant hepatic failure, especially the elderly and those who had a pre-existing liver disease, especially hepatitis C.[16][76] Mortality risk factors include greater age and chronic hepatitis C.[16] In these cases, more aggressive supportive therapy and liver transplant may be necessary.[16]

Hepatitis B

Main article: Hepatitis B

Acute

In healthy patients, 95–99% recover with no long-lasting effects, and antiviral treatment is not warranted.[16] Age and comorbid conditions can result in a more prolonged and severe illness. Certain patients warrant hospitalization, especially those who present with clinical signs of ascites, peripheral edema, and hepatic encephalopathy, and laboratory signs of hypoglycemia, prolonged prothrombin time, low serum albumin, and very high serum bilirubin.[16]

In these rare, more severe acute cases, patients have been successfully treated with antiviral therapy similar to that used in cases of chronic hepatitis B, with nucleoside analogues such as entecavir or tenofovir. As there is a dearth of clinical trial data and the drugs used to treat are prone to developing resistance, experts recommend reserving treatment for severe acute cases, not mild to moderate.[16]

Chronic

Chronic hepatitis B management aims to control viral replication, which is correlated with progression of disease.[19] Seven drugs are approved in the United States:[19]

  • Injectable interferon alpha was the first therapy approved for chronic hepatitis B.[19] It has several side effects, most of which are reversible with removal of therapy, but it has been supplanted by newer treatments for this indication.[19] These include long-acting interferon bound to polyethylene glycol (pegylated interferon) and the oral nucleoside analogues.[19]
  • Pegylated interferon (PEG IFN) is dosed just once a week as a subcutaneous injection and is both more convenient and effective than standard interferon.[19] Although it does not develop resistance as do many of the oral antivirals, it is poorly tolerated and requires close monitoring.[19] PEG IFN is estimated to cost about $18,000 per year in the United States, compared to $2,500–8,700 for the oral medications. Its treatment duration is 48 weeks, unlike oral antivirals which require indefinite treatment for most patients (minimum one year).[19] PEG IFN is not effective in patients with high levels of viral activity and cannot be used in immunosuppressed patients or those with cirrhosis.[19]
  • Lamivudine was the first approved oral nucleoside analogue.[19] While effective and potent, lamivudine has been replaced by newer, more potent treatments in the Western world and is no longer recommended as first-line treatment.[19] It is still used in areas where newer agents either have not been approved or are too costly.[19] Generally, the course of treatment is a minimum of one year with a minimum of six additional months of "consolidation therapy."[19] Based on viral response, longer therapy may be required, and certain patients require indefinite long-term therapy.[19] Due to a less robust response in Asian patients, consolidation therapy is recommended to be extended to at least a year.[19] All patients should be monitored for viral reactivation, which if identified, requires restarting treatment.[19] Lamivudine is generally safe and well tolerated.[19] Many patients develop resistance, which is correlated with longer treatment duration.[19] If this occurs, an additional antiviral is added.[19] Lamivudine as a single treatment is contraindicated in patients coinfected with HIV, as resistance develops rapidly, but it can be used as part of a multidrug regimen.[19]
  • Adefovir dipivoxil, a nucleotide analogue, has been used to supplement lamivudine in patients who develop resistance, but is no longer recommended as first-line therapy.[19]
  • Entecavir is safe, well tolerated, less prone to developing resistance, and the most potent of the existing hepatitis B antivirals; it is thus a first-line treatment choice.[19] It is not recommended for lamivudine-resistant patients or as monotherapy in patients who are HIV positive.[19]
  • Telbivudine is effective but not recommended as first-line treatment; as compared to entecavir, it is both less potent and more resistance prone.[19]
  • Tenofovir is a nucleotide analogue and an antiretroviral drug that is also used to treat HIV infection.[19] It is preferred to adefovir both in lamivudine-resistant patients and as initial treatment since it is both more potent and less likely to develop resistance.[19]

First-line treatments currently used include PEG IFN, entecavir, and tenofovir, subject to patient and physician preference.[19] Treatment initiation is guided by recommendations issued by The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) and is based on detectable viral levels, HBeAg positive or negative status, ALT levels, and in certain cases, family history of HCC and liver biopsy.[19] In patients with compensated cirrhosis, treatment is recommended regardless of HBeAg status or ALT level, but recommendations differ regarding HBV DNA levels; AASLD recommends treating at DNA levels detectable above 2x103 IU/mL; EASL and WHO recommend treating when HBV DNA levels are detectable at any level.[19][82] In patients with decompensated cirrhosis, treatment and evaluation for liver transplantation are recommended in all cases if HBV DNA is detectable.[19][82] Currently, multidrug treatment is not recommended in treatment of chronic HBV as it is no more effective in the long term than individual treatment with entecavir or tenofovir.[19]

Hepatitis C

Main article: Hepatitis C

The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) recommend antiviral treatment for all patients with chronic hepatitis C infection except for those with additional chronic medical conditions that limit their life expectancy.[9]

Once it is acquired, persistence of the hepatitis C virus is the rule, resulting in chronic hepatitis C. The goal of treatment is prevention of hepatocellular carcinoma (HCC).[104] The best way to reduce the long-term risk of HCC is to achieve sustained virological response (SVR).[104] SVR is defined as an undetectable viral load at 12 weeks after treatment completion and indicates a cure.[105][106] Currently available treatments include indirect and direct acting antiviral drugs.[105][106] The indirect acting antivirals include pegylated interferon (PEG IFN) and ribavirin (RBV), which in combination have historically been the basis of therapy for HCV.[105][106] Duration of and response to these treatments varies based on genotype.[105][106] These agents are poorly tolerated but are still used in some resource-poor areas.[105][106] In high-resource countries, they have been supplanted by direct acting antiviral agents, which first appeared in 2011; these agents target proteins responsible for viral replication and include the following three classes:[105][106]

These drugs are used in various combinations, sometimes combined with ribavirin, based on the patient's genotype, delineated as genotypes 1–6.[106] Genotype 1 (GT1), which is the most prevalent genotype in the United States and around the world, can now be cured with a direct acting antiviral regimen.[106] First-line therapy for GT1 is a combination of sofosbuvir and ledipasvir (SOF/LDV) for 12 weeks for most patients, including those with advanced fibrosis or cirrhosis.[106] Certain patients with early disease need only 8 weeks of treatment while those with advanced fibrosis or cirrhosis who have not responded to prior treatment require 24 weeks.[106] Cost remains a major factor limiting access to these drugs, particularly in low-resource nations; the cost of the 12-week GT1 regimen (SOF/LDV) has been estimated at US$94,500.[105]

Hepatitis D

Main article: Hepatitis D

Hepatitis D is difficult to treat, and effective treatments are lacking. Interferon alpha has proven effective at inhibiting viral activity but only on a temporary basis.[107]

Hepatitis E

Main article: Hepatitis E
 
Hepatitis E virus

Similar to hepatitis A, treatment of hepatitis E is supportive and includes rest and ensuring adequate nutrition and hydration.[108] Hospitalization may be required for particularly severe cases or for pregnant women.[108]

Alcoholic hepatitis

First-line treatment of alcoholic hepatitis is treatment of alcoholism.[32] For those who abstain completely from alcohol, reversal of liver disease and a longer life are possible; patients at every disease stage have been shown to benefit by prevention of additional liver injury.[32][63] In addition to referral to psychotherapy and other treatment programs, treatment should include nutritional and psychosocial evaluation and treatment.[32][63][109] Patients should also be treated appropriately for related signs and symptoms, such as ascites, hepatic encephalopathy, and infection.[63]

Severe alcoholic hepatitis has a poor prognosis and is notoriously difficult to treat.[32][63][109] Without any treatment, 20-50% of patients may die within a month, but evidence shows treatment may extend life beyond one month (i.e., reduce short-term mortality).[32][109][110] Available treatment options include pentoxifylline (PTX), which is a nonspecific TNF inhibitor, corticosteroids, such as prednisone or prednisolone (CS), corticosteroids with N-acetylcysteine (CS with NAC), and corticosteroids with pentoxifylline (CS with PTX).[109] Data suggest that CS alone or CS with NAC are most effective at reducing short-term mortality.[109] Unfortunately, corticosteroids are contraindicated in some patients, such as those who have active gastrointestinal bleeding, infection, kidney failure, or pancreatitis.[32][63] In these cases PTX may be considered on a case-by-case basis in lieu of CS; some evidence shows PTX is better than no treatment at all and may be comparable to CS while other data show no evidence of benefit over placebo.[109][110] Unfortunately, there are currently no drug treatments that decrease these patients' risk of dying in the longer term, at 3–12 months and beyond.[109]

Weak evidence suggests milk thistle extracts may improve survival in alcoholic liver disease and improve certain liver tests (serum bilirubin and GGT) without causing side effects, but a firm recommendation cannot be made for or against milk thistle without further study.[111] 

The modified Maddrey's discriminant function may be used to evaluate the severity and prognosis in alcoholic hepatitis and evaluates the efficacy of using alcoholic hepatitis corticosteroid treatment.

Autoimmune hepatitis

Autoimmune hepatitis is commonly treated by immunosuppressants such as the corticosteroids prednisone or prednisolone, the active version of prednisolone that does not require liver synthesis, either alone or in combination with azathioprine, and some have suggested the combination therapy is preferred to allow for lower doses of corticosteroids to reduce associated side effects,[46] although the result of treatment efficacy is comparative.[112]

Treatment of autoimmune hepatitis consists of two phases; an initial and maintenance phase. The initial phase consists of higher doses of corticosteroids which are tapered down over a number of weeks to a lower dose. If used in combination, azathioprine is given during the initial phase as well. Once the initial phase has been completed, a maintenance phase that consists of lower dose corticosteroids, and in combination therapy, azathioprine until liver blood markers are normalized. Treatment results in 66-91% of patients achieving normal liver test values in two years, with the average being 22 months.[46]

Prognosis

Acute hepatitis

Nearly all patients with hepatitis A infections recover completely without complications if they were healthy prior to the infection. Similarly, acute hepatitis B infections have a favorable course towards complete recovery in 95–99% of patients.[16] Certain factors may portend a poorer outcome, such as co-morbid medical conditions or initial presenting symptoms of ascites, edema, or encephalopathy.[16] Overall, the mortality rate for acute hepatitis is low: ~0.1% in total for cases of hepatitis A and B, but rates can be higher in certain populations (super infection with both hepatitis B and D, pregnant women, etc.).[16]

In contrast to hepatitis A & B, hepatitis C carries a much higher risk of progressing to chronic hepatitis, approaching 85–90%.[113] Cirrhosis has been reported to develop in 20–50% of patients with chronic hepatitis C.[citation needed]

Other rare complications of acute hepatitis include pancreatitis, aplastic anemia, peripheral neuropathy, and myocarditis.[16]

Fulminant hepatitis

Despite the relatively benign course of most viral cases of hepatitis, fulminant hepatitis represents a rare but feared complication. Fulminant hepatitis most commonly occurs in hepatitis B, D, and E. About 1–2% of cases of hepatitis E can lead to fulminant hepatitis, but pregnant women are particularly susceptible, occurring in up to 20% of cases.[114] Mortality rates in cases of fulminant hepatitis rise over 80%, but those patients that do survive often make a complete recovery. Liver transplantation can be life-saving in patients with fulminant liver failure.[115]

Hepatitis D infections can transform benign cases of hepatitis B into severe, progressive hepatitis, a phenomenon known as superinfection.[116]

Chronic hepatitis

Acute hepatitis B infections become less likely to progress to chronic forms as the age of the patient increases, with rates of progression approaching 90% in vertically transmitted cases of infants compared to 1% risk in young adults.[19] Overall, the five-year survival rate for chronic hepatitis B ranges from 97% in mild cases to 55% in severe cases with cirrhosis.[19]

Most patients who acquire hepatitis D at the same time as hepatitis B (co-infection) recover without developing a chronic infection. In people with hepatitis B who later acquire hepatitis D (superinfection), chronic infection is much more common at 80-90%, and liver disease progression is accelerated.[107][117]

Chronic hepatitis C progresses towards cirrhosis, with estimates of cirrhosis prevalence of 16% at 20 years after infection.[118] While the major causes of mortality in hepatitis C is end stage liver disease, hepatocellular carcinoma is an important additional long term complication and cause of death in chronic hepatitis.

Rates of mortality increase with progression of the underlying liver disease. Series of patients with compensated cirrhosis due to HCV have shown 3,5, and 10-year survival rates of 96, 91, and 79% respectively.[119] The 5-year survival rate drops to 50% upon if the cirrhosis becomes decompensated.

Epidemiology

Viral hepatitis

Hepatitis A

Hepatitis A is found throughout the world and manifests as large outbreaks and epidemics associated with fecal contamination of water and food sources.[99] Hepatitis A viral infection is predominant in children ages 5–14 with rare infection of infants.[99] Infected children have little to no apparent clinical illness, in contrast to adults in whom greater than 80% are symptomatic if infected.[120] Infection rates are highest in low resource countries with inadequate public sanitation and large concentrated populations.[16][121] In such regions, as much as 90% of children younger than 10 years old have been infected and are immune, corresponding both to lower rates of clinically symptomatic disease and outbreaks.[99][121][122] The availability of a childhood vaccine has significantly reduced infections in the United States, with incidence declining by more than 95% as of 2013.[123] Paradoxically, the highest rates of new infection now occur in young adults and adults who present with worse clinical illness.[16] Specific populations at greatest risk include: travelers to endemic regions, men who have sex with men, those with occupational exposure to non-human primates, people with clotting disorders who have received clotting factors, people with history of chronic liver disease in whom co-infection with hepatitis A can lead to fulminant hepatitis, and intravenous drug users (rare).[99]

Hepatitis B

Main article: Hepatitis B
 
HBV replication

Hepatitis B is the most common cause of viral hepatitis in the world with more than 240 million chronic carriers of the virus, 1 million of whom are in the United States.[27][99] In approximately two-thirds of patients who develop acute hepatitis B infection, no identifiable exposure is evident.[16] Of those acutely infected, 25% become lifetime carriers of the virus.[99] Risk of infection is highest among intravenous drug users, people with high-risk sexual behaviors, healthcare workers, people who had multiple transfusions, organ transplant patients, dialysis patients and newborns infected during the birthing process.[99] Close to 780,000 deaths in the world are attributed to hepatitis B.[27] The most endemic regions are in sub-Saharan Africa and East Asia, where as many as 10% of adults are chronic carriers.[27] Carrier rates in developed nations are significantly lower, encompassing less than 1% of the population.[27] In endemic regions, transmission is thought to be associated with exposure during birth and close contact between young infants.[16][27]

Hepatitis C

Main article: Hepatitis C
 
HepC replication

Chronic hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma.[124] It is a common medical reason for liver transplantation due to its severe complications.[124] It is estimated that 130–180 million people in the world are affected by this disease representing a little more than 3% of the world population.[86][99][124] In the developing regions of Africa, Asia and South America, prevalence can be as high as 10% of the population.[99] In Egypt, rates of hepatitis C infection as high as 20% have been documented and are associated with iatrogenic contamination related to schistosomiasis treatment in the 1950s–1980s.[16][99] Currently in the United States, approximately 3.5 million adults are estimated to be infected.[125] Hepatitis C is particularly prevalent among people born between 1945 and 1965, a group of about 800,000 people, with prevalence as high as 3.2% versus 1.6% in the general U.S. population.[16] Most chronic carriers of hepatitis C are unaware of their infection status.[16] The most common mode of transmission of hepatitis C virus is exposure to blood products via blood transfusions (prior to 1992) and intravenous drug injection.[16][99] A history of intravenous drug injection is the most important risk factor for chronic hepatitis C.[124] Other susceptible populations include those engaged in high-risk sexual behavior, infants of infected mothers, and healthcare workers.[99]

Hepatitis D

Main article: Hepatitis D

The hepatitis D virus causes chronic and fulminant hepatitis in the context of co-infection with the hepatitis B virus.[99] It is primarily transmitted via non-sexual contact and via needles.[16][99] Susceptibility to hepatitis D differs by geographic region.[16][99] In the United States and Northern Europe, populations at risk are intravenous drug users and people who receive multiple transfusions.[16][99] In the Mediterranean, hepatitis D is predominant among hepatitis B virus co-infected people.[16][99]

Hepatitis E

Main article: Hepatitis E

Similar to Hepatitis A, hepatitis E manifests as large outbreaks and epidemics associated with fecal contamination of water sources.[16] It accounts for more than 55,000 deaths annually with approximately 20 million people worldwide thought to be infected with the virus.[91] It affects predominantly young adults, causing acute hepatitis.[16][126] In infected pregnant women, Hepatitis E infection can lead to fulminant hepatitis with third trimester mortality rates as high as 30%.[99][126] Those with weakened immune systems, such as organ transplant recipients, are also susceptible.[126] Infection is rare in the United States but rates are high in the developing world (Africa, Asia, Central America, Middle East).[16][126] Many genotypes exist and are differentially distributed around the world.[91] There is some evidence of hepatitis E infection of animals, serving as a reservoir for human infection.[99]

Alcoholic hepatitis

Alcoholic hepatitis (AH) in its severe form has a one-month mortality as high as 50%.[63][64][127] Most people who develop AH are men but women are at higher risk of developing AH and its complications likely secondary to high body fat and differences in alcohol metabolism.[64] Other contributing factors include younger age <60, binge pattern drinking, poor nutritional status, obesity and hepatitis C co-infection.[64] It is estimated that as much as 20% of people with AH are also infected with hepatitis C.[128] In this population, the presence of hepatitis C virus leads to more severe disease with faster progression to cirrhosis, hepatocellular carcinoma and increased mortality.[64][128][129] Obesity increases the likelihood of progression to cirrhosis in cases of alcoholic hepatitis.[64] It is estimated that 70% of people who have AH will progress to cirrhosis.[64]

Non-alcoholic steatohepatitis

Non-alcoholic steatohepatitis (NASH) is projected to become the top reason for liver transplantation in the United States by 2020, supplanting chronic liver disease due to hepatitis C.[130] About 20–45% of the U.S. population have NAFLD and 6% have NASH.[29][40] The estimated prevalence of NASH in the world is 3–5%.[131] Of NASH patients who develop cirrhosis, about 2% per year will likely progress to hepatocellular carcinoma.[131] Worldwide, the estimated prevalence of hepatocellular carcinoma related to NAFLD is 15–30%.[132] NASH is thought to be the primary cause of cirrhosis in approximately 25% of patients in the United States, representing 1–2% of the general population.[132]

History

Early observations

Initial accounts of a syndrome that we now think is likely to be hepatitis begin to occur around 3000 B.C. Clay tablets that served as medical handbooks for the ancient Sumerians described the first observations of jaundice. The Sumerians believed that the liver was the home of the soul, and attributed the findings of jaundice to the attack of the liver by a devil named Ahhazu.[133]

Around 400 B.C., Hippocrates recorded the first documentation of an epidemic jaundice, in particular noting the uniquely fulminant course of a cohort of patients who all died within two weeks. He wrote, "The bile contained in the liver is full of phlegm and blood, and erupts...After such an eruption, the patient soon raves, becomes angry, talks nonsense and barks like a dog."[134]

Given the poor sanitary conditions of war, infectious jaundice played a large role as a major cause of mortality among troops in the Napoleonic Wars, the American Revolutionary War, and both World Wars.[135] During World War II, estimates of soldiers affected by hepatitis were upwards of 10 million.

During World War II, soldiers received vaccines against diseases such as yellow fever, but these vaccines were stabilized with human serum, presumably contaminated with hepatitis viruses, which often created epidemics of hepatitis.[136] It was suspected these epidemics were due to a separate infectious agent, and not due to the yellow fever virus itself, after noting 89 cases of jaundice in the months after vaccination out of a total 3,100 patients that were vaccinated. After changing the seed virus strain, no cases of jaundice were observed in the subsequent 8,000 vaccinations.[137]

Willowbrook State School experiments

A New York University researcher named Saul Krugman continued this research into the 1950s and 1960s, most infamously with his experiments on mentally disabled children at the Willowbrook State School in New York, a crowded urban facility where hepatitis infections were highly endemic to the student body. Krugman injected students with gamma globulin, a type of antibody. After observing the temporary protection against infection this antibody provided, he then tried injected live hepatitis virus into students. Krugman also controversially took feces from infected students, blended it into milkshakes, and fed it to newly admitted children.[138]

His research was received with much controversy, as people protested the questionable ethics surrounding the chosen target population. Henry Beecher was one of the foremost critics in an article in the New England Journal of Medicine in 1966, arguing that parents were unaware to the risks of consent and that the research was done to benefit others at the expense of children.[139] Moreover, he argued that poor families with mentally disabled children often felt pressured to join the research project to gain admission to the school, with all of the educational and support resources that would come along with it.[140] Others in the medical community spoke out in support of Krugman's research in terms of its widespread benefits and understanding of the hepatitis virus, and Willowbrook continues to be a commonly cited example in debates about medical ethics.[141]

Australia antigen

The next insight regarding hepatitis B was a serendipitous one by Dr. Baruch Blumberg, a researcher at the NIH who did not set out to research hepatitis, but rather studied lipoprotein genetics. He travelled across the globe collecting blood samples, investigating the interplay between disease, environment, and genetics with the goal of designing targeted interventions for at-risk people that could prevent them from getting sick.[142] He noticed an unexpected interaction between the blood of a patient with hemophilia that had received multiple transfusions and a protein found in the blood of an indigenous Australian person.[143] He named the protein the "Australia antigen" and made it the focus of his research. He found a higher prevalence of the protein in the blood of patients from developing countries, compared to those from developed ones, and noted associations of the antigen with other diseases like leukemia and Down Syndrome.[144] Eventually, he came to the unifying conclusion that the Australia antigen was associated with viral hepatitis.

In 1970, David Dane first isolated the hepatitis B virion at London's Middlesex Hospital, and named the virion the 42-nm "Dane particle".[140] Based on its association with the surface of the hepatitis B virus, the Australia antigen was renamed to "hepatitis B surface antigen" or HBsAg.

Blumberg continued to study the antigen, and eventually developed the first hepatitis B vaccine using plasma rich in HBsAg, for which he received the Nobel Prize in Medicine in 1976.[145]

Society and culture

Economic burden

Overall, hepatitis accounts for a significant portion of healthcare expenditures in both developing and developed nations, and is expected to rise in several developing countries.[146][147] While hepatitis A infections are self-limited events, they are associated with significant costs in the United States.[148] It has been estimated that direct and indirect costs are approximately $1817 and $2459 respectively per case, and that an average of 27 work days is lost per infected adult.[148] A 1997 report demonstrated that a single hospitalization related to hepatitis A cost an average of $6,900 and resulted in around $500 million in total annual healthcare costs.[149] Cost effectiveness studies have found widespread vaccination of adults to not be feasible, but have stated that a combination hepatitis A and B vaccination of children and at risk groups (people from endemic areas, healthcare workers) may be.[150]

Hepatitis B accounts for a much larger percentage of health care spending in endemic regions like Asia.[151][152] In 1997 it accounted for 3.2% of South Korea's total health care expenditures and resulted in $696 million in direct costs.[152] A large majority of that sum was spent on treating disease symptoms and complications.[153] Chronic hepatitis B infections are not as endemic in the United States, but accounted for $357 million in hospitalization costs in the year 1990.[146] That number grew to $1.5 billion in 2003, but remained stable as of 2006, which may be attributable to the introduction of effective drug therapies and vaccination campaigns.[146][147]

People infected with chronic hepatitis C tend to be frequent users of the health care system globally.[154] It has been estimated that a person infected with hepatitis C in the United States will result in a monthly cost of $691.[154] That number nearly doubles to $1,227 for people with compensated (stable) cirrhosis, while the monthly cost of people with decompensated (worsening) cirrhosis is almost five times as large at $3,682.[154] The wide-ranging effects of hepatitis make it difficult to estimate indirect costs, but studies have speculated that the total cost is $6.5 billion annually in the United States.[146] In Canada, 56% of HCV related costs are attributable to cirrhosis and total expenditures related to the virus are expected to peak at CAD$396 million in the year 2032.[155]

2003 Monaca outbreak

The largest outbreak of hepatitis A virus in United States history occurred among people who ate at a now-defunct Mexican food restaurant located in Monaca, Pennsylvania in late 2003.[156] Over 550 people who visited the restaurant between September and October 2003 were infected with the virus, three of whom died as a direct result.[156] The outbreak was brought to the attention of health officials when local emergency medicine physicians noticed a significant increase in cases of hepatitis A in the county.[157] After conducting its investigation, the CDC attributed the source of the outbreak to the use of contaminated raw green onion. The restaurant was purchasing its green onion stock from farms in Mexico at the time.[156] It is believed that the green onions may have been contaminated through the use of contaminated water for crop irrigation, rinsing, or icing or by handling of the vegetables by infected people.[156] Green onion had caused similar outbreaks of hepatitis A in the southern United States prior to this, but not to the same magnitude.[156] The CDC believes that the restaurant's use of a large communal bucket for chopped raw green onion allowed non-contaminated plants to be mixed with contaminated ones, increasing the number of vectors of infection and amplifying the outbreak.[156] The restaurant was closed once it was discovered to be the source, and over 9,000 people were given hepatitis A immune globulin because they had either eaten at the restaurant or had been in close contact with someone who had.[156]

Special populations

HIV co-infection

Persons infected with HIV have a particularly high burden of HIV-HCV co-infection.[158][159] In a recent study by the WHO, the likelihood of being infected with hepatitis C virus was six times greater in those who also had HIV.[159] The prevalence of HIV-HCV co-infection worldwide was estimated to be 6.2% representing more than 2.2 million people.[159] Intravenous drug use was an independent risk factor for HCV infection.[124] In the WHO study, the prevalence of HIV-HCV co-infection was markedly higher at 82.4% in those who injected drugs compared to the general population (2.4%).[159] In a study of HIV-HCV co-infection among HIV positive men who have sex with men (MSM), the overall prevalence of anti-hepatitis C antibodies was estimated to be 8.1% and increased to 40% among HIV positive MSM who also injected drugs.[158]

Pregnancy

Hepatitis B

Vertical transmission is a significant contributor of new HBV cases each year, with 35–50% of transmission from mother to neonate in endemic countries.[83][160] Vertical transmission occurs largely via a neonate's exposure to maternal blood and vaginal secretions during birth.[160] While the risk of progression to chronic infection is approximately 5% among adults who contract the virus, it is as high as 95% among neonates subject to vertical transmission.[83][161] The risk of viral transmission is approximately 10–20% when maternal blood is positive for HBsAg, and up to 90% when also positive for HBeAg.[83]

Given the high risk of perinatal transmission, the CDC recommends screening all pregnant women for HBV at their first prenatal visit.[83][162] It is safe for non-immune pregnant women to receive the HBV vaccine.[83][160] Based on the limited available evidence, the American Association for the Study of Liver Diseases (AASLD) recommends antiviral therapy in pregnant women whose viral load exceeds 200,000 IU/mL.[163] A growing body of evidence shows that antiviral therapy initiated in the third trimester significantly reduces transmission to the neonate.[160][163] A systematic review of the Antiretroviral Pregnancy Registry database found that there was no increased risk of congenital anomalies with Tenofovir; for this reason, along with its potency and low risk of resistance, the AASLD recommends this drug.[163][164] A 2010 systematic review and meta-analysis found that Lamivudine initiated early in the third trimester also significantly reduced mother-to-child transmission of HBV, without any known adverse effects.[165]

The ACOG states that the evidence available does not suggest any particular mode of delivery (i.e. vaginal vs. cesarean) is better at reducing vertical transmission in mothers with HBV.[83]

The WHO and CDC recommend that neonates born to mothers with HBV should receive hepatitis B immune globulin (HBIG) as well as the HBV vaccine within 12 hours of birth.[80][82] For infants who have received HBIG and the HBV vaccine, breastfeeding is safe.[83][160]

Hepatitis C

Estimates of the rate of HCV vertical transmission range from 2–8%; a 2014 systematic review and meta-analysis found the risk to be 5.8% in HCV-positive, HIV-negative women.[83][166] The same study found the risk of vertical transmission to be 10.8% in HCV-positive, HIV-positive women.[166] Other studies have found the risk of vertical transmission to be as high as 44% among HIV-positive women.[83] The risk of vertical transmission is higher when the virus is detectable in the mother's blood.[166]

Evidence does not indicate that mode of delivery (i.e. vaginal vs. cesarean) has an effect on vertical transmission.[83]

For women who are HCV-positive and HIV-negative, breastfeeding is safe. CDC guidelines suggest avoiding it if a woman's nipples are cracked or bleeding to reduce the risk of transmission.[83][85]

Hepatitis E

Pregnant women who contract HEV are at significant risk of developing fulminant hepatitis with maternal mortality rates as high as 20–30%, most commonly in the third trimester .[16][83][160] A 2016 systematic review and meta-analysis of 47 studies that included 3968 people found maternal case-fatality rates (CFR) of 20.8% and fetal CFR of 34.2%; among women who developed fulminant hepatic failure, CFR was 61.2%.[167]

See also

References

  1. ^ a b c d e f "Hepatitis". MedlinePlus. from the original on 11 November 2016. Retrieved 10 November 2016.
  2. ^ a b c d e f g "What is hepatitis?". WHO. July 2016. from the original on 7 November 2016. Retrieved 10 November 2016.
  3. ^ a b c d e f g h i j k l m "Hepatitis". NIAID. from the original on 4 November 2016. Retrieved 2 November 2016.
  4. ^ a b . NIDDK. April 2012. Archived from the original on 11 November 2016. Retrieved 10 November 2016.
  5. ^ "Hepatitis". MedlinePlus. 2020-05-20. Retrieved 2020-07-19. Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Hepatitis is an inflammation of the liver.
  6. ^ "Hepatitis (Hepatitis A, B, and C) | ACG Patients". patients.gi.org. from the original on 2017-02-23.
  7. ^ Bernal W.; Wendon J. (2013). "Acute Liver Failure". New England Journal of Medicine. 369 (26): 2525–2534. doi:10.1056/nejmra1208937. PMID 24369077. S2CID 205116503.
  8. ^ a b c . NIDDK. May 2014. Archived from the original on 11 November 2016. Retrieved 10 November 2016.
  9. ^ a b c d e f g h i j k l m n o p q r s t u v w x y AASLD/IDSA HCV Guidance Panel (2015-09-01). "Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus". Hepatology. 62 (3): 932–954. doi:10.1002/hep.27950. ISSN 1527-3350. PMID 26111063.
  10. ^ . NIDDK. March 2014. Archived from the original on 11 November 2016. Retrieved 10 November 2016.
  11. ^ Vos, Theo; Allen, Christine; Arora, Megha; Barber, Ryan M.; Bhutta, Zulfiqar A.; Brown, Alexandria; Carter, Austin; Casey, Daniel C.; Charlson, Fiona J.; Chen, Alan Z.; Coggeshall, Megan; Cornaby, Leslie; Dandona, Lalit; Dicker, Daniel J.; Dilegge, Tina; Erskine, Holly E.; Ferrari, Alize J.; Fitzmaurice, Christina; Fleming, Tom; Forouzanfar, Mohammad H.; Fullman, Nancy; Gething, Peter W.; Goldberg, Ellen M.; Graetz, Nicholas; Haagsma, Juanita A.; Hay, Simon I.; Johnson, Catherine O.; Kassebaum, Nicholas J.; Kawashima, Toana; et al. (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
  12. ^ Basra, Sarpreet (2011). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–13. doi:10.4254/wjh.v3.i5.108. PMC 3124876. PMID 21731902.
  13. ^ Wang, Haidong; Naghavi, Mohsen; Allen, Christine; Barber, Ryan M.; Bhutta, Zulfiqar A.; Carter, Austin; Casey, Daniel C.; Charlson, Fiona J.; Chen, Alan Zian; Coates, Matthew M.; Coggeshall, Megan; Dandona, Lalit; Dicker, Daniel J.; Erskine, Holly E.; Ferrari, Alize J.; Fitzmaurice, Christina; Foreman, Kyle; Forouzanfar, Mohammad H.; Fraser, Maya S.; Fullman, Nancy; Gething, Peter W.; Goldberg, Ellen M.; Graetz, Nicholas; Haagsma, Juanita A.; Hay, Simon I.; Huynh, Chantal; Johnson, Catherine O.; Kassebaum, Nicholas J.; Kinfu, Yohannes; et al. (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". The Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
  14. ^ "Statistics & Surveillance Division of Viral Hepatitis CDC". CDC. from the original on 11 November 2016. Retrieved 10 November 2016.
  15. ^ "Online Etymology Dictionary". Etymonline.com. from the original on 2012-10-20. Retrieved 2012-08-26.
  16. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl Dienstag, JL (2015). "Chapter 360: Acute Viral Hepatitis". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill. ISBN 978-0-07-180215-4.
  17. ^ a b c d e f g Rutherford, A; Dienstag, JL (2016). "Chapter 40: Viral Hepatitis". In Greenberger, NJ; Blumberg, RS; Burakoff, R (eds.). CURRENT Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy, 3e. New York, NY: McGraw-Hill. ISBN 978-0-07-183772-9.
  18. ^ a b c d e f Khalili, M; Burman, B (2013). "Chapter 14: Liver Disease". In Hammer, GD; McPhee, SJ (eds.). Pathophysiology of Disease: An Introduction to Clinical Medicine, 7e. McGraw-Hill. ISBN 978-1-25-925144-3.
  19. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am Dienstag, JL (2015). "Chapter 362: Chronic Hepatitis". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine, 19e. New York, NY: McGraw-Hill. ISBN 978-0-07-180215-4.
  20. ^ a b c Fontana, Robert; Hayashi, Paul (2014-05-01). "Clinical Features, Diagnosis, and Natural History of Drug-Induced Liver Injury". Seminars in Liver Disease. 34 (2): 134–144. doi:10.1055/s-0034-1375955. PMID 24879979.
  21. ^ a b Manns, Michael P.; Lohse, Ansgar W.; Vergani, Diego (2015). "Autoimmune hepatitis – Update 2015". Journal of Hepatology. 62 (1): S100–S111. doi:10.1016/j.jhep.2015.03.005. PMID 25920079.
  22. ^ Munjal, Y. P.; Sharm, Surendra K. (2012). API Textbook of Medicine, Ninth Edition, Two Volume Set. JP Medical Ltd. p. 870. ISBN 9789350250747. from the original on 2017-09-10.
  23. ^ World Health Organization. "Hepatitis". World Health Organization. from the original on 2 December 2013. Retrieved 25 November 2013.
  24. ^ "Hepatitis A Questions and Answers for the Public | Division of Viral Hepatitis | CDC". www.cdc.gov. from the original on 2016-03-12. Retrieved 2016-03-14.
  25. ^ "Hepatitis E". World Health Organization. from the original on 2016-03-12. Retrieved 2016-03-14.
  26. ^ Centers for Disease Control & Prevention (June 2010). "When Someone Close to You Has Hepatitis" (PDF). (PDF) from the original on March 6, 2016. Retrieved March 14, 2016.
  27. ^ a b c d e f g h "Hepatitis B". World Health Organization. from the original on 2014-11-09. Retrieved 2016-03-09.
  28. ^ a b "Hepatitis C FAQs for the Public | Division of Viral Hepatitis | CDC". www.cdc.gov. from the original on 2016-03-15. Retrieved 2016-03-14.
  29. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am Friedman, Lawrence S. (2015). "Chapter 16: Liver, Biliary Tract, & Pancreas Disorders". In Papadakis, M; McPhee, SJ; Rabow, MW (eds.). Current Medical Diagnosis & Treatment 2016 55e. McGraw Hill. ISBN 978-0071845090.
  30. ^ a b c d e Harder, A; Mehlhorn, H (2008). "Diseases Caused by Adult Parasites or Their Distinct Life Cycle Stages". In Weber, O; Protzer, U (eds.). Comparative Hepatitis. Birkhauser. pp. 161–216. ISBN 978-3764385576.
  31. ^ a b c d Wisplinghoff, H; Appleton, DL (2008). "Bacterial Infections of the Liver". In Weber, O; Protzer, U (eds.). Comparative Hepatitis. Birkhauser. pp. 143–160. ISBN 978-3764385576.
  32. ^ a b c d e f g h Mailliard, ME; Sorrell, MF (2015). "Chapter 363: Alcoholic Liver Disease". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine 19e. McGraw-Hill. ISBN 978-0-07-180215-4.
  33. ^ a b c d e Lee, WM; Dienstag, JL (2015). "Chapter 361: Toxic and Drug-Induced Hepatitis". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine 19e. McGraw-Hill. ISBN 978-0-07-180215-4.
  34. ^ a b Malaguarnera, Giulia; Cataudella, E; Giordano, M; Nunnari, G; Chisari, G; Malaguarnera, M (2012). "Toxic hepatitis in occupational exposure to solvents". World Journal of Gastroenterology. 18 (22): 2756–66. doi:10.3748/wjg.v18.i22.2756. PMC 3374978. PMID 22719183.
  35. ^ Lee, William M. (31 July 2003). "Drug-Induced Hepatotoxicity". New England Journal of Medicine. 349 (5): 474–485. doi:10.1056/NEJMra021844. PMID 12890847.
  36. ^ Suk, Ki Tae; Kim, Dong Joon (2012). "Drug-induced liver injury: present and future". Clinical and Molecular Hepatology. 18 (3): 249–57. doi:10.3350/cmh.2012.18.3.249. PMC 3467427. PMID 23091804.
  37. ^ a b "Herbals_and_Dietary_Supplements". livertox.nih.gov. from the original on 2016-05-08. Retrieved 2016-03-14.
  38. ^ "NIH launches free database of drugs associated with liver injury". National Institutes of Health (NIH). 2015-09-30. Retrieved 2018-09-18.
  39. ^ O'Mara SR, Gebreyes K (2011). "Chapter 83. Hepatic Disorders, Jaundice, and Hepatic Failure" (Online). In Cydulka RK, Meckler GD (eds.). Tintinalli's Emergency Medicine: A Comprehensive Study Guide (7th ed.). New York: McGraw-Hill. from the original on 2 December 2013. Retrieved 26 November 2013.
  40. ^ a b Abdelmalek, MF; Diehl AM (2015). "Chapter 364: Nonalcoholic Liver Diseases and Nonalcoholic Steatohepatitis". In Kasper, D; Fauci, A; Hauser, S; Longo, D; Jameson, J; Loscalzo, J (eds.). Harrison's Principles of Internal Medicine 19e. McGraw-Hill. ISBN 978-0-07-180215-4.
  41. ^ a b National Digestive Diseases Information Clearinghouse (NDDIC). "Nonalcoholic Steatohepatitis". National Digestive Diseases Information Clearinghouse (NDDIC). from the original on 2 December 2013. Retrieved 27 November 2013.
  42. ^ Masuoka, Howard C.; Chalasani, Naga (April 2013). "Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals". Annals of the New York Academy of Sciences. 1281 (1): 106–122. Bibcode:2013NYASA1281..106M. doi:10.1111/nyas.12016. PMC 3646408. PMID 23363012.
  43. ^ National Digestive Diseases Information Clearinghouse (NDDIC). . National Digestive Diseases Information Clearinghouse (NDDIC). Archived from the original on 15 September 2010. Retrieved 27 November 2013.
  44. ^ Teufel, Andreas; Galle, PR; Kanzler, S (2009). "Update on autoimmune hepatitis". World Journal of Gastroenterology. 15 (9): 1035–41. doi:10.3748/wjg.15.1035. PMC 2655176. PMID 19266594.
  45. ^ a b c d e Czaja, Albert J (2016). "Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions". Gut and Liver. 10 (2): 177–203. doi:10.5009/gnl15352. PMC 4780448. PMID 26934884.
  46. ^ a b c Czaja, Albert J. (2016-03-15). "Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions". Gut and Liver. 10 (2): 177–203. doi:10.5009/gnl15352. ISSN 1976-2283. PMC 4780448. PMID 26934884.
  47. ^ Krawitt, Edward-L (2008). "Clinical features and management of autoimmune hepatitis". World Journal of Gastroenterology. 14 (21): 3301–5. doi:10.3748/wjg.14.3301. PMC 2716584. PMID 18528927.
  48. ^ Teckman, Jeffrey H. (2013-03-07). "Liver Disease in Alpha-1 Antitrypsin Deficiency: Current Understanding and Future Therapy". COPD: Journal of Chronic Obstructive Pulmonary Disease. 10 (sup1): 35–43. doi:10.3109/15412555.2013.765839. ISSN 1541-2555. PMID 23527737. S2CID 35451941.
  49. ^ Medline Plus (2012-08-10). "Hepatic ischemia". National Library of Medicine. from the original on 8 December 2013. Retrieved 4 December 2013.
  50. ^ Feldman, Friedman; Feldman, Brandt, eds. (2010). "Chapter 83 Vascular Diseases of the Liver" (Online). Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Saunders. ISBN 978-1416061892. from the original on 4 March 2016. Retrieved 4 December 2013.
  51. ^ a b c d Samyn, M; Mieli-Vergani, G (November 2015). "Liver and Biliary Disease in Infancy". Medicine. 43 (11): 625–630. doi:10.1016/j.mpmed.2015.08.008.
  52. ^ Roberts, Eve A. (2003-10-01). "Neonatal hepatitis syndrome". Seminars in Neonatology. 8 (5): 357–374. doi:10.1016/S1084-2756(03)00093-9. ISSN 1084-2756. PMID 15001124.
  53. ^ Sokol, Ronald J.; Narkewicz, Michael R. (2012-06-21). "Chapter 22: Liver & Pancreas". In Hay, William W.; et al. (eds.). Current diagnosis & treatment: pediatrics (21st ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-177970-8. from the original on 10 December 2013. Retrieved 2 December 2013.
  54. ^ Alexopoulou, Alexandra; Deutsch, Melanie; Ageletopoulou, Johanna; Delladetsima, Johanna K.; Marinos, Evangelos; Kapranos, Nikiforos; Dourakis, Spyros P. (May 2003). "A fatal case of postinfantile giant cell hepatitis in a patient with chronic lymphocytic leukaemia". European Journal of Gastroenterology & Hepatology. 15 (5): 551–555. doi:10.1097/01.meg.0000050026.34359.7c. PMID 12702915.
  55. ^ a b c Nakamoto, Yasunari; Kaneko, Shuichi (2003-09-01). "Mechanisms of viral hepatitis induced liver injury". Current Molecular Medicine. 3 (6): 537–544. doi:10.2174/1566524033479591. ISSN 1566-5240. PMID 14527085.
  56. ^ Lin, Shaoli; Zhang, Yan-Jin (August 2017). "Interference of Apoptosis by Hepatitis B Virus". Viruses. 9 (8): 230. doi:10.3390/v9080230. PMC 5580487. PMID 28820498.
  57. ^ Cao, Lei; Quan, Xi-Bing; Zeng, Wen-Jiao; Yang, Xiao-Ou; Wang, Ming-Jie (2016). "Mechanism of Hepatocyte Apoptosis". Journal of Cell Death. 9: 19–29. doi:10.4137/JCD.S39824. PMC 5201115. PMID 28058033.
  58. ^ Wong, Grace Lai-Hung (2014-09-01). "Prediction of fibrosis progression in chronic viral hepatitis". Clinical and Molecular Hepatology. 20 (3): 228–236. doi:10.3350/cmh.2014.20.3.228. ISSN 2287-285X. PMC 4197170. PMID 25320725.
  59. ^ a b Rehermann, Barbara (2015-11-01). "Natural Killer Cells in Viral Hepatitis". Cellular and Molecular Gastroenterology and Hepatology. 1 (6): 578–588. doi:10.1016/j.jcmgh.2015.09.004. ISSN 2352-345X. PMC 4678927. PMID 26682281.
  60. ^ a b Heim, Markus H.; Thimme, Robert (2014-11-01). "Innate and adaptive immune responses in HCV infections". Journal of Hepatology. 61 (1 Suppl): S14–25. doi:10.1016/j.jhep.2014.06.035. ISSN 1600-0641. PMID 25443342.
  61. ^ a b c d e f Hardy, Timothy; Oakley, Fiona; Anstee, Quentin M.; Day, Christopher P. (2016-03-03). "Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum". Annual Review of Pathology. 11: 451–96. doi:10.1146/annurev-pathol-012615-044224. ISSN 1553-4014. PMID 26980160.[permanent dead link]
  62. ^ a b c d Yoon, Hye-Jin; Cha, Bong Soo (2014-11-27). "Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease". World Journal of Hepatology. 6 (11): 800–811. doi:10.4254/wjh.v6.i11.800. ISSN 1948-5182. PMC 4243154. PMID 25429318.
  63. ^ a b c d e f g h i j Chayanupatkul, Maneerat; Liangpunsakul, Suthat (2014-05-28). "Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment". World Journal of Gastroenterology. 20 (20): 6279–6286. doi:10.3748/wjg.v20.i20.6279. ISSN 2219-2840. PMC 4033465. PMID 24876748.
  64. ^ a b c d e f g Basra, Sarpreet; Anand, Bhupinderjit S. (2011-05-27). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–113. doi:10.4254/wjh.v3.i5.108. ISSN 1948-5182. PMC 3124876. PMID 21731902.
  65. ^ Haga, Yuki; Kanda, Tatsuo; Sasaki, Reina; Nakamura, Masato; Nakamoto, Shingo; Yokosuka, Osamu (2015-12-14). "Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis". World Journal of Gastroenterology. 21 (46): 12989–12995. doi:10.3748/wjg.v21.i46.12989. ISSN 2219-2840. PMC 4674717. PMID 26675364.
  66. ^ Grant, A; Neuberger J (1999). "Guidelines on the use of liver biopsy in clinical practice". Gut. 45 (Suppl 4): 1–11. doi:10.1136/gut.45.2008.iv1. PMC 1766696. PMID 10485854. The main cause of mortality after percutaneous liver biopsy is intraperitoneal haemorrhage as shown in a retrospective Italian study of 68 000 percutaneous liver biopsies in which all six patients who died did so from intraperitoneal haemorrhage. Three of these patients had had a laparotomy, and all had either cirrhosis or malignant disease, both of which are risk factors for bleeding.
  67. ^ Green, RM; Flamm, S (October 2002). "AGA technical review on the evaluation of liver chemistry tests". Gastroenterology. 123 (4): 1367–84. doi:10.1053/gast.2002.36061. PMID 12360498.
  68. ^ Pratt, DS; Kaplan, MM (Apr 27, 2000). "Evaluation of abnormal liver-enzyme results in asymptomatic patients". The New England Journal of Medicine. 342 (17): 1266–71. doi:10.1056/NEJM200004273421707. PMID 10781624.
  69. ^ Ito, Katsuyoshi; Mitchell, Donald G. (2004). "Imaging Diagnosis of Cirrhosis and Chronic Hepatitis". Intervirology. 47 (3–5): 134–143. doi:10.1159/000078465. PMID 15383722. S2CID 36112368.
  70. ^ Allan, Richard; Thoirs, Kerry; Phillips, Maureen (2010-07-28). "Accuracy of ultrasound to identify chronic liver disease". World Journal of Gastroenterology. 16 (28): 3510–3520. doi:10.3748/wjg.v16.i28.3510. ISSN 1007-9327. PMC 2909550. PMID 20653059.
  71. ^ Sahani, Dushyant V.; Kalva, Sanjeeva P. (2004-07-01). "Imaging the Liver". The Oncologist. 9 (4): 385–397. doi:10.1634/theoncologist.9-4-385. ISSN 1083-7159. PMID 15266092.
  72. ^ a b Villar LM, Cruz HM, Barbosa JR, Bezerra CS, Portilho MM, Scalioni Lde P (2015). "Update on hepatitis B and C virus diagnosis". World Journal of Virology. 4 (4): 323–42. doi:10.5501/wjv.v4.i4.323. PMC 4641225. PMID 26568915.
  73. ^ a b Neuman, Manuela G.; French, Samuel W.; French, Barbara A.; Seitz, Helmut K.; Cohen, Lawrence B.; Mueller, Sebastian; Osna, Natalia A.; Kharbanda, Kusum K.; Seth, Devanshi (2014-12-01). "Alcoholic and non-alcoholic steatohepatitis". Experimental and Molecular Pathology. 97 (3): 492–510. doi:10.1016/j.yexmp.2014.09.005. PMC 4696068. PMID 25217800.
  74. ^ "Guidelines For Viral Hepatitis Surveillance And Case Management". www.cdc.gov. from the original on 2016-03-10. Retrieved 2016-03-12.
  75. ^ Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J. eds. (2013). Harrison's Manual of Medicine, 18e, Chapter 164: Chronic Hepatitis. New York, NY: McGraw-Hill. {{cite book}}: |last= has generic name (help)CS1 maint: multiple names: authors list (link)
  76. ^ a b c d e "Hepatitis A Fact sheet N°328". WHO Media Centre. from the original on February 21, 2014. Retrieved March 7, 2016.
  77. ^ a b c d Voise, Nathan (Oct 2011). "Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. A shot at hepatitis prevention". J Am Osteopath Assoc. 111 (10 Suppl 6): S13–6. PMID 22086888.
  78. ^ a b c "Adult Immunization Schedule by Vaccine and Age Group". www.CDC.gov. from the original on March 5, 2016. Retrieved March 7, 2016.
  79. ^ Longo, Dan L.; et al. (2013). Chapter 163: "Acute Hepatitis." Harrison's Manual of Medicine, 18e. New York, NY: McGraw-Hill.
  80. ^ a b c d e f g h i j k l m n o "Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection". www.cdc.gov. from the original on 2016-03-06. Retrieved 2016-03-11.
  81. ^ a b c d e f g h i j Chou, Roger; Dana, Tracy; Bougatsos, Christina; Blazina, Ian; Zakher, Bernadette; Khangura, Jessi (2014-01-01). Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). PMID 24921112.
  82. ^ a b c d e f g h i j k l . World Health Organization. Archived from the original on 2016-02-20. Retrieved 2016-03-11.
  83. ^ a b c d e f g h i j k l m n o p q r "ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Viral Hepatitis in Pregnancy". www.acog.org. Retrieved 2016-03-12.
  84. ^ Esherick JS; Clark DS; Slater ED; et al. (2015). CURRENT Practice Guidelines in Primary Care 2015. New York, NY: McGraw-Hill.
  85. ^ a b c d e f g h i j k l m "Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease". MMWR. 47 (RR-19): 1–39. October 16, 1998. PMID 9790221. from the original on March 24, 2016. Retrieved March 16, 2016.
  86. ^ a b c d e f g h i j k l m n o p q "Hepatitis C". World Health Organization. from the original on 2016-01-31. Retrieved 2016-03-08.
  87. ^ a b c d e f g h i j k l m n o "Final Recommendation Statement: Hepatitis C: Screening - US Preventive Services Task Force". www.uspreventiveservicestaskforce.org. from the original on 2016-03-21. Retrieved 2016-03-21.
  88. ^ a b c "Birth-18 Years and Catchup Immunization Schedules for Providers". www.CDC.gov. from the original on March 6, 2016. Retrieved March 7, 2016.
  89. ^ Centers for Disease Control (1999). "Update: recommendations to prevent hepatitis B virus transmission—United States. MMWR 1999". 48: 33–4. from the original on May 14, 2016. Retrieved March 7, 2016. {{cite journal}}: Cite journal requires |journal= (help)
  90. ^ "Hepatitis A And Hepatitis B Vaccine (Intramuscular Route)". Mayo Clinic. Retrieved 25 January 2018.
  91. ^ a b c d "Hepatitis E". World Health Organization. from the original on 2016-03-06. Retrieved 2016-03-09.
  92. ^ a b "WHO | Hepatitis D". www.who.int. from the original on 2016-03-08. Retrieved 2016-03-09.
  93. ^ Zhang; et al. (March 5, 2015). "Long-Term Efficacy of a Hepatitis E Vaccine". NEJM. 372 (10): 914–22. doi:10.1056/NEJMoa1406011. PMID 25738667.
  94. ^ "Phase IV Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin） - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. from the original on 2016-03-09. Retrieved 2016-03-09.
  95. ^ Rizzetto M (2020). "Epidemiology of the Hepatitis D virus". WikiJournal of Medicine. 7: 7. doi:10.15347/wjm/2020.001.
  96. ^ "Drinking Levels Defined | National Institute on Alcohol Abuse and Alcoholism (NIAAA)". www.niaaa.nih.gov. 14 September 2011. from the original on 2016-03-23. Retrieved 2016-03-09.
  97. ^ Franco, Elisabetta; Meleleo, Cristina; Serino, Laura; Sorbara, Debora; Zaratti, Laura (2012-03-27). "Hepatitis A: Epidemiology and prevention in developing countries". World Journal of Hepatology. 4 (3): 68–73. doi:10.4254/wjh.v4.i3.68. ISSN 1948-5182. PMC 3321492. PMID 22489258.
  98. ^ "Pinkbook | Hepatitis B | Epidemiology of Vaccine Preventable Diseases | CDC". www.cdc.gov. from the original on 2016-03-07. Retrieved 2016-03-09.
  99. ^ a b c d e f g h i j k l m n o p q r s t Carroll, Karen (2015). "Chapter 35: Hepatitis Viruses". Medical Microbiology. New York: McGraw-Hill. ISBN 978-0071824989.
  100. ^ "Commentary | U.S. 2013 Surveillance Data for Viral Hepatitis | Statistics & Surveillance  | Division of Viral Hepatitis | CDC". www.cdc.gov. from the original on 2016-03-05. Retrieved 2016-03-09.
  101. ^ Wright NMJ, Millson CE, Tompkins CNE (2005). What is the evidence for the effectiveness of interventions to reduce hepatitis C infection and the associated morbidity? Copenhagen, WHO Regional Office for Europe (Health Evidence Network report; "Archived copy" (PDF). (PDF) from the original on 2010-05-01. Retrieved 2016-03-09.{{cite web}}: CS1 maint: archived copy as title (link), accessed 9 Mar 2016).
  102. ^ Basra, Sarpreet; Anand, Bhupinderjit S (2011-05-27). "Definition, epidemiology and magnitude of alcoholic hepatitis". World Journal of Hepatology. 3 (5): 108–113. doi:10.4254/wjh.v3.i5.108. ISSN 1948-5182. PMC 3124876. PMID 21731902.
  103. ^ "The Epidemiology of Alcoholic Liver Disease". pubs.niaaa.nih.gov. from the original on 2016-03-03. Retrieved 2016-03-09.
  104. ^ a b Messori, Andrea; Badiani, Brigitta; Trippoli, Sabrina (2015-12-01). "Achieving Sustained Virological Response in Hepatitis C Reduces the Long-Term Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis Employing Relative and Absolute Outcome Measures". Clinical Drug Investigation. 35 (12): 843–850. doi:10.1007/s40261-015-0338-y. ISSN 1179-1918. PMID 26446006. S2CID 41365729.
  105. ^ a b c d e f g Thiagarajan, Prarthana; Ryder, Stephen D. (2015-12-01). "The hepatitis C revolution part 1: antiviral treatment options". Current Opinion in Infectious Diseases. 28 (6): 563–571. doi:10.1097/QCO.0000000000000205. ISSN 1473-6527. PMID 26524328. S2CID 11926260.
  106. ^ a b c d e f g h i j Gogela, Neliswa A.; Lin, Ming V.; Wisocky, Jessica L.; Chung, Raymond T. (2015-03-01). "Enhancing our understanding of current therapies for Hepatitis C virus (HCV)". Current HIV/AIDS Reports. 12 (1): 68–78. doi:10.1007/s11904-014-0243-7. ISSN 1548-3568. PMC 4373591. PMID 25761432.
  107. ^ a b Abbas, Zaigham; Khan, Muhammad Arsalan; Salih, Mohammad; Jafri, Wasim (2011-12-07). "Interferon alpha for chronic hepatitis D". Cochrane Database of Systematic Reviews (12): CD006002. doi:10.1002/14651858.cd006002.pub2. PMC 6823236. PMID 22161394.
  108. ^ a b "HEV FAQs for Health Professionals | Division of Viral Hepatitis | CDC". www.cdc.gov. from the original on 2016-03-08. Retrieved 2016-03-17.
  109. ^ a b c d e f g Singh, Siddharth; Murad, Mohammad Hassan; Chandar, Apoorva K.; Bongiorno, Connie M.; Singal, Ashwani K.; Atkinson, Stephen R.; Thursz, Mark R.; Loomba, Rohit; Shah, Vijay H. (2015-10-01). "Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis". Gastroenterology. 149 (4): 958–970.e12. doi:10.1053/j.gastro.2015.06.006. ISSN 1528-0012. PMID 26091937.
  110. ^ a b Thursz, Mark; Forrest, Ewan; Roderick, Paul; Day, Christopher; Austin, Andrew; O'Grady, John; Ryder, Stephen; Allison, Michael; Gleeson, Dermot (2015-12-01). "The clinical effectiveness and cost-effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis (STOPAH): a 2 × 2 factorial randomised controlled trial". Health Technology Assessment. 19 (102): 1–104. doi:10.3310/hta191020. ISSN 2046-4924. PMC 4781103. PMID 26691209.
  111. ^ Rambaldi, Andrea; Jacobs, Bradly P; Gluud, Christian (2007-10-17). "Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases". Protocols. 2009 (4): CD003620. doi:10.1002/14651858.cd003620.pub3. ISSN 1465-1858. PMC 8724782. PMID 17943794.
  112. ^ Summerskill, W. H.; Korman, M. G.; Ammon, H. V.; Baggenstoss, A. H. (1975-11-01). "Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared". Gut. 16 (11): 876–883. doi:10.1136/gut.16.11.876. ISSN 0017-5749. PMC 1413126. PMID 1104411.
  113. ^ Bartenschlager, ed. (2013). Hepatitis C Virus: From Molecular Virology to Antiviral Therapy. Springer.
  114. ^ Khuroo, MS (1981). "Incidence and severity of viral hepatitis in pregnancy". Am J Med. 70 (2): 252–5. doi:10.1016/0002-9343(81)90796-8. PMID 6781338.
  115. ^ Gill, RQ (2001). "Acute Liver Failure". J Clin Gastroenterol. 33 (3): 191–8. doi:10.1097/00004836-200109000-00005. PMID 11500606.
  116. ^ Smedile, A; et al. (1981). "Infection with the delta agent in chronic HBsAg carriers". Gastroenterology. 81 (6): 992–7. doi:10.1016/S0016-5085(81)80003-0. PMID 7286594.
  117. ^ Abbas, Zaigham; Ali, Syed Salman; Shazi, Lubna (2015-06-02). "Interferon alpha versus any other drug for chronic hepatitis D". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd011727. S2CID 70629280.
  118. ^ Thein, Hla-Hla; Yi, Qilong; Dore, Gregory J.; Krahn, Murray D. (2008-08-01). "Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression". Hepatology. 48 (2): 418–431. doi:10.1002/hep.22375. ISSN 1527-3350. PMID 18563841. S2CID 20771903.
  119. ^ Fattovich, G (1997). "Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients". Gastroenterology. 112 (2): 463–72. doi:10.1053/gast.1997.v112.pm9024300. PMID 9024300.
  120. ^ "Hepatitis A Information | Division of Viral Hepatitis | CDC". www.cdc.gov. from the original on 2016-03-04. Retrieved 2016-03-08.
  121. ^ a b Aggarwal, Rakesh; Goel, Amit (2015). "Hepatitis A". Current Opinion in Infectious Diseases. 28 (5): 488–496. doi:10.1097/qco.0000000000000188. PMID 26203853. S2CID 22340290.
  122. ^ "WHO | Hepatitis A". www.who.int. from the original on 2014-02-21. Retrieved 2016-03-08.
  123. ^ "Hepatitis A Questions and Answers for Health Professionals | Division of Viral Hepatitis | CDC". www.cdc.gov. from the original on 2016-03-06. Retrieved 2016-03-08.
  124. ^ a b c d e Rosen, Hugo R. (2011-06-23). "Clinical practice. Chronic hepatitis C infection". The New England Journal of Medicine. 364 (25): 2429–2438. doi:10.1056/NEJMcp1006613. ISSN 1533-4406. PMID 21696309.
  125. ^ Edlin, Brian R.; Eckhardt, Benjamin J.; Shu, Marla A.; Holmberg, Scott D.; Swan, Tracy (2015-11-01). "Toward a more accurate estimate of the prevalence of hepatitis C in the United States". Hepatology. 62 (5): 1353–1363. doi:10.1002/hep.27978. ISSN 1527-3350. PMC 4751870. PMID 26171595.
  126. ^ a b c d "HEV FAQs for Health Professionals | Division of Viral Hepatitis | CDC". www.cdc.gov. from the original on 2016-03-08. Retrieved 2016-03-09.
  127. ^ Singal, Ashwani K.; Kamath, Patrick S.; Gores, Gregory J.; Shah, Vijay H. (2014-04-01). "Alcoholic hepatitis: current challenges and future directions". Clinical Gastroenterology and Hepatology. 12 (4): 555–564, quiz e31–32. doi:10.1016/j.cgh.2013.06.013. ISSN 1542-7714. PMC 3883924. PMID 23811249.
  128. ^ a b Shoreibah, Mohamed; Anand, Bhupinderjit S.; Singal, Ashwani K. (2014-09-14). "Alcoholic hepatitis and concomitant hepatitis C virus infection". World Journal of Gastroenterology. 20 (34): 11929–11934. doi:10.3748/wjg.v20.i34.11929. ISSN 2219-2840. PMC 4161778. PMID 25232227.
  129. ^ Singal, Ashwani K.; Anand, Bhupinder S. (2007-09-01). "Mechanisms of synergy between alcohol and hepatitis C virus". Journal of Clinical Gastroenterology. 41 (8): 761–772. doi:10.1097/MCG.0b013e3180381584. ISSN 0192-0790. PMID 17700425. S2CID 19482895.
  130. ^ Wree, Alexander; Broderick, Lori; Canbay, Ali; Hoffman, Hal M.; Feldstein, Ariel E. (2013-11-01). "From NAFLD to NASH to cirrhosis-new insights into disease mechanisms". Nature Reviews. Gastroenterology & Hepatology. 10 (11): 627–636. doi:10.1038/nrgastro.2013.149. ISSN 1759-5053. PMID 23958599. S2CID 6899033.
  131. ^ a b Weiß, Johannes; Rau, Monika; Geier, Andreas (2014-06-27). "Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatment". Deutsches Ärzteblatt International. 111 (26): 447–452. doi:10.3238/arztebl.2014.0447. ISSN 1866-0452. PMC 4101528. PMID 25019921.
  132. ^ a b Michelotti, Gregory A.; Machado, Mariana V.; Diehl, Anna Mae (2013-11-01). "NAFLD, NASH and liver cancer". Nature Reviews. Gastroenterology & Hepatology. 10 (11): 656–665. doi:10.1038/nrgastro.2013.183. ISSN 1759-5053. PMID 24080776. S2CID 22315274.
  133. ^ Trepo, Christian (February 2014). "A brief history of hepatitis milestones". Liver International. 34 (Supplement s1): 29–37. doi:10.1111/liv.12409. PMID 24373076. S2CID 41215392.
  134. ^ Oon, GC (July 2012). "Viral hepatitis—the silent killer". Annals of the Academy of Medicine, Singapore. 41 (7): 279–80. PMID 22892603.
  135. ^ Lee, Christine A.; Thomas, Howard C., eds. (1988). Classic papers in viral hepatitis. Foreword by Dame Sheila Sherlock. London, England: Science Press. ISBN 978-1-870026-10-9.
  136. ^ Purcell, RH (April 1993). "The discovery of the hepatitis viruses". Gastroenterology. 104 (4): 955–63. doi:10.1016/0016-5085(93)90261-a. PMID 8385046.
  137. ^ Bradley, WH (1946). "Homologous Serum Jaundice". Proceedings of the Royal Society of Medicine. 39 (10): 649–654. doi:10.1177/003591574603901012. PMC 2181926. PMID 19993376.
  138. ^ Munson, Ronald (1996). Intervention and Reflection: Basic Issues in Medical Ethics. pp. 273–281.
  139. ^ Beecher, Henry (1966). "Ethics and Clinical Research". The New England Journal of Medicine. 274 (24): 1354–1360. doi:10.1056/nejm196606162742405. PMID 5327352.; Reprinted in Beecher HK (2001). "Ethics and clinical research. 1966". Bull World Health Organ. 79 (4): 367–72. PMC 2566401. PMID 11368058.
  140. ^ a b Purcell, RH (April 1993). "The discovery of the hepatitis viruses". Gastroenterology. 104 (4): 955–63. doi:10.1016/0016-5085(93)90261-a. PMID 8385046.
  141. ^ Emanuel, Ezekiel (2008). The Oxford Textbook of Clinical Research Ethics. Oxford University Press. pp. 80–85.
  142. ^ Odelberg, Wilhelm (1976). Les Prix Nobel.
  143. ^ Alter, Harvey J. (2014-01-01). "The road not taken or how I learned to love the liver: A personal perspective on hepatitis history". Hepatology. 59 (1): 4–12. doi:10.1002/hep.26787. ISSN 1527-3350. PMID 24123147.
  144. ^ Blumberg BS; Alter HJ (1965-02-15). "A "new" antigen in leukemia sera". JAMA. 191 (7): 541–546. doi:10.1001/jama.1965.03080070025007. ISSN 0098-7484. PMID 14239025.
  145. ^ "The Nobel Prize in Physiology or Medicine 1976". NobelPrize.org. Retrieved 2019-10-07.
  146. ^ a b c d Udompap, Prowpanga; Kim, Donghee; Kim, W. Ray (2015-11-01). "Current and Future Burden of Chronic Nonmalignant Liver Disease". Clinical Gastroenterology and Hepatology. 13 (12): 2031–2041. doi:10.1016/j.cgh.2015.08.015. ISSN 1542-7714. PMC 4618163. PMID 26291665.
  147. ^ a b Lemoine, Maud; Eholié, Serge; Lacombe, Karine (2015). "Reducing the neglected burden of viral hepatitis in Africa: Strategies for a global approach". Journal of Hepatology. 62 (2): 469–476. doi:10.1016/j.jhep.2014.10.008. PMID 25457207.
  148. ^ a b Koslap-Petraco, Mary Beth; Shub, Mitchell; Judelsohn, Richard (2008). "Hepatitis A: Disease Burden and Current Childhood Vaccination Strategies in the United States". Journal of Pediatric Health Care. 22 (1): 3–11. doi:10.1016/j.pedhc.2006.12.011. PMID 18174084.
  149. ^ Previsani, Nicoletta; Lavanchy, Daniel (2000). "Hepatitis A" (PDF). World Health Organization Global Alert and Response. World Health Organization. Retrieved March 5, 2016.
  150. ^ Anonychuk, Andrea M.; Tricco, Andrea C.; Bauch, Chris T.; Pham, Ba'; Gilca, Vladimir; Duval, Bernard; John-Baptiste, Ava; Woo, Gloria; Krahn, Murray (2008-01-01). "Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies". PharmacoEconomics. 26 (1): 17–32. doi:10.2165/00019053-200826010-00003. ISSN 1170-7690. PMID 18088156. S2CID 46965673.
  151. ^ Chan, Henry Lik-Yuen; Jia, Jidong (2011-01-01). "Chronic hepatitis B in Asia—new insights from the past decade". Journal of Gastroenterology and Hepatology. 26: 131–137. doi:10.1111/j.1440-1746.2010.06544.x. ISSN 1440-1746. PMID 21199524. S2CID 23548529.
  152. ^ a b Dan, Yock Young; Aung, Myat Oo; Lim, Seng Gee (2008-09-01). "The economics of treating chronic hepatitis B in Asia". Hepatology International. 2 (3): 284–295. doi:10.1007/s12072-008-9049-2. ISSN 1936-0533. PMC 2716880. PMID 19669256.
  153. ^ Lavanchy, D. (2004-03-01). "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures". Journal of Viral Hepatitis. 11 (2): 97–107. doi:10.1046/j.1365-2893.2003.00487.x. ISSN 1352-0504. PMID 14996343. S2CID 163757.
  154. ^ a b c Younossi, Z. M.; Kanwal, F.; Saab, S.; Brown, K. A.; El-Serag, H. B.; Kim, W. R.; Ahmed, A.; Kugelmas, M.; Gordon, S. C. (2014-03-01). "The impact of hepatitis C burden: an evidence-based approach". Alimentary Pharmacology & Therapeutics. 39 (5): 518–531. doi:10.1111/apt.12625. ISSN 1365-2036. PMID 24461160. S2CID 21263906.
  155. ^ Myers, Robert P.; Krajden, Mel; Bilodeau, Marc; Kaita, Kelly; Marotta, Paul; Peltekian, Kevork; Ramji, Alnoor; Estes, Chris; Razavi, Homie (2014-05-01). "Burden of disease and cost of chronic hepatitis C infection in Canada". Canadian Journal of Gastroenterology & Hepatology. 28 (5): 243–250. doi:10.1155/2014/317623. ISSN 2291-2797. PMC 4049256. PMID 24839620.
  156. ^ a b c d e f g Centers for Disease Control and Prevention (CDC) (2003-11-28). "Hepatitis A outbreak associated with green onions at a restaurant—Monaca, Pennsylvania, 2003". MMWR. Morbidity and Mortality Weekly Report. 52 (47): 1155–1157. ISSN 1545-861X. PMID 14647018.
  157. ^ Polgreen, Lydia (November 16, 2003). "Community Is Reeling From Hepatitis Outbreak". The New York Times. from the original on March 22, 2016. Retrieved March 10, 2016.
  158. ^ a b Jordan, Ashly E.; Perlman, David C.; Neurer, Joshua; Smith, Daniel J.; Des Jarlais, Don C.; Hagan, Holly (2016-01-28). "Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis". International Journal of STD & AIDS. 28 (2): 145–159. doi:10.1177/0956462416630910. ISSN 1758-1052. PMC 4965334. PMID 26826159.
  159. ^ a b c d Platt, Lucy; Easterbrook, Philippa; Gower, Erin; McDonald, Bethan; Sabin, Keith; McGowan, Catherine; Yanny, Irini; Razavi, Homie; Vickerman, Peter (2016-02-24). "Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis" (PDF). The Lancet. Infectious Diseases. 16 (7): 797–808. doi:10.1016/S1473-3099(15)00485-5. ISSN 1474-4457. PMID 26922272. (PDF) from the original on 2018-07-19.
  160. ^ a b c d e f Cunningham, F. Gary; et al. (2013). "Hepatic, Biliary, and Pancreatic Disorders." Williams Obstetrics, Twenty-Fourth Edition. New York, NY: McGraw-Hill.
  161. ^ Tassopoulos, NC; et al. (June 1987). "Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults". Gastroenterology. 92 (6): 1844–50. doi:10.1016/0016-5085(87)90614-7. PMID 3569758.
  162. ^ "A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents". www.cdc.gov. from the original on 2016-03-24. Retrieved 2016-03-16.
  163. ^ a b c Terrault, Norah A.; Bzowej, Natalie H.; Chang, Kyong-Mi; Hwang, Jessica P.; Jonas, Maureen M.; Murad, M. Hassan (2016-01-01). "AASLD guidelines for treatment of chronic hepatitis B". Hepatology. 63 (1): 261–283. doi:10.1002/hep.28156. ISSN 1527-3350. PMC 5987259. PMID 26566064.
  164. ^ Wang, Liming; Kourtis, Athena P.; Ellington, Sascha; Legardy-Williams, Jennifer; Bulterys, Marc (2013-12-01). "Safety of tenofovir during pregnancy for the mother and fetus: a systematic review". Clinical Infectious Diseases. 57 (12): 1773–1781. doi:10.1093/cid/cit601. ISSN 1537-6591. PMID 24046310.
  165. ^ Shi, Zhongjie; Yang, Yuebo; Ma, Lin; Li, Xiaomao; Schreiber, Ann (2010-07-01). "Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis". Obstetrics and Gynecology. 116 (1): 147–159. doi:10.1097/AOG.0b013e3181e45951. ISSN 1873-233X. PMID 20567182. S2CID 41784922.
  166. ^ a b c Benova, Lenka; Mohamoud, Yousra A.; Calvert, Clara; Abu-Raddad, Laith J. (2014-09-15). "Vertical transmission of hepatitis C virus: systematic review and meta-analysis". Clinical Infectious Diseases. 59 (6): 765–773. doi:10.1093/cid/ciu447. ISSN 1537-6591. PMC 4144266. PMID 24928290.
  167. ^ Jin, H.; Zhao, Y.; Zhang, X.; Wang, B.; Liu, P. (2016-03-01). "Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis". Epidemiology & Infection. FirstView (10): 2098–2106. doi:10.1017/S0950268816000418. ISSN 1469-4409. PMC 9150575. PMID 26939626.

External links

  • WHO fact sheet of hepatitis
  • Viral Hepatitis at the Centers for Disease Control

December 27, 2022
hepatitis, hepatite, redirects, here, mineral, that, name, baryte, inflammation, liver, tissue, some, people, animals, with, hepatitis, have, symptoms, whereas, others, develop, yellow, discoloration, skin, whites, eyes, jaundice, poor, appetite, vomiting, tir. Hepatite redirects here For the mineral of that name see Baryte Hepatitis is inflammation of the liver tissue 3 5 Some people or animals with hepatitis have no symptoms whereas others develop yellow discoloration of the skin and whites of the eyes jaundice poor appetite vomiting tiredness abdominal pain and diarrhea 1 2 Hepatitis is acute if it resolves within six months and chronic if it lasts longer than six months 1 6 Acute hepatitis can resolve on its own progress to chronic hepatitis or rarely result in acute liver failure 7 Chronic hepatitis may progress to scarring of the liver cirrhosis liver failure and liver cancer 3 HepatitisAlcoholic hepatitis as seen with a microscope showing fatty changes white circles remnants of dead liver cells and Mallory bodies twisted rope shaped inclusions within some liver cells H amp E stain SpecialtyInfectious disease gastroenterology hepatologySymptomsYellowish skin poor appetite abdominal pain 1 2 ComplicationsScarring of the liver liver failure liver cancer 3 DurationShort term or long term 1 CausesViruses alcohol toxins autoimmune 2 3 PreventionVaccination for viral hepatitis 2 avoiding excessive alcoholTreatmentMedication liver transplant 1 4 Frequency gt 500 million cases 3 Deaths gt One million a year 3 Hepatitis is most commonly caused by the virus hepatovirus A B C D and E 2 3 Other viruses can also cause liver inflammation including cytomegalovirus Epstein Barr virus and yellow fever virus Other common causes of hepatitis include heavy alcohol use certain medications toxins other infections autoimmune diseases 2 3 and non alcoholic steatohepatitis NASH 8 Hepatitis A and E are mainly spread by contaminated food and water 3 Hepatitis B is mainly sexually transmitted but may also be passed from mother to baby during pregnancy or childbirth and spread through infected blood 3 Hepatitis C is commonly spread through infected blood such as may occur during needle sharing by intravenous drug users 3 Hepatitis D can only infect people already infected with hepatitis B 3 Hepatitis A B and D are preventable with immunization 2 Medications may be used to treat chronic viral hepatitis 1 Antiviral medications are recommended in all with chronic hepatitis C except those with conditions that limit their life expectancy 9 There is no specific treatment for NASH physical activity a healthy diet and weight loss are recommended 8 Autoimmune hepatitis may be treated with medications to suppress the immune system 10 A liver transplant may be an option in both acute and chronic liver failure 4 Worldwide in 2015 hepatitis A occurred in about 114 million people chronic hepatitis B affected about 343 million people and chronic hepatitis C about 142 million people 11 In the United States NASH affects about 11 million people and alcoholic hepatitis affects about 5 million people 8 12 Hepatitis results in more than a million deaths a year most of which occur indirectly from liver scarring or liver cancer 3 13 In the United States hepatitis A is estimated to occur in about 2 500 people a year and results in about 75 deaths 14 The word is derived from the Greek hepar ἧpar meaning liver and itis ῖtis meaning inflammation 15 Contents 1 Signs and symptoms 1 1 Acute hepatitis 1 2 Fulminant hepatitis 1 3 Chronic hepatitis 2 Causes 2 1 Infectious 2 1 1 Viral hepatitis 2 1 2 Parasitic hepatitis 2 1 3 Bacterial hepatitis 2 2 Metabolic 2 2 1 Alcoholic hepatitis 2 2 2 Toxic and drug induced hepatitis 2 2 3 Non alcoholic fatty liver disease 2 3 Autoimmune 2 4 Genetic 2 5 Ischemic hepatitis 2 6 Other 3 Mechanism 3 1 Viral hepatitis 3 2 Steatohepatitis 4 Diagnosis 4 1 Viral hepatitis 4 2 Alcoholic versus non alcoholic 5 Virus screening 5 1 Hepatitis A 5 2 Hepatitis B 5 3 Hepatitis C 5 4 Hepatitis D 6 Prevention 6 1 Vaccines 6 1 1 Hepatitis A 6 1 2 Hepatitis B 6 1 3 Other 6 2 Behavioral changes 6 2 1 Hepatitis A 6 2 2 Hepatitis B and C 6 2 3 Hepatitis D 6 2 4 Hepatitis E 6 2 5 Alcoholic hepatitis 6 3 Successes 6 3 1 Hepatitis A 6 3 2 Hepatitis B 6 3 3 Hepatitis C 6 3 4 Alcoholic hepatitis 7 Treatment 7 1 Hepatitis A 7 2 Hepatitis B 7 2 1 Acute 7 2 2 Chronic 7 3 Hepatitis C 7 4 Hepatitis D 7 5 Hepatitis E 7 6 Alcoholic hepatitis 7 7 Autoimmune hepatitis 8 Prognosis 8 1 Acute hepatitis 8 1 1 Fulminant hepatitis 8 2 Chronic hepatitis 9 Epidemiology 9 1 Viral hepatitis 9 1 1 Hepatitis A 9 1 2 Hepatitis B 9 1 3 Hepatitis C 9 1 4 Hepatitis D 9 1 5 Hepatitis E 9 2 Alcoholic hepatitis 9 3 Non alcoholic steatohepatitis 10 History 10 1 Early observations 10 2 Willowbrook State School experiments 10 3 Australia antigen 11 Society and culture 11 1 Economic burden 11 2 2003 Monaca outbreak 12 Special populations 12 1 HIV co infection 12 2 Pregnancy 12 2 1 Hepatitis B 12 2 2 Hepatitis C 12 2 3 Hepatitis E 13 See also 14 References 15 External linksSigns and symptoms Edit Jaundiced eyes Hepatitis has a broad spectrum of presentations that range from a complete lack of symptoms to severe liver failure 16 17 18 The acute form of hepatitis generally caused by viral infection is characterized by constitutional symptoms that are typically self limiting 16 17 Chronic hepatitis presents similarly but can manifest signs and symptoms specific to liver dysfunction with long standing inflammation and damage to the organ 18 19 Acute hepatitis Edit Acute viral hepatitis follows three distinct phases The initial prodromal phase preceding symptoms involves non specific and flu like symptoms common to many acute viral infections These include fatigue nausea vomiting poor appetite joint pain and headaches 16 17 Fever when present is most common in cases of hepatitis A and E 16 Late in this phase people can experience liver specific symptoms including choluria dark urine and clay colored stools 16 17 Yellowing of the skin and whites of the eyes follow the prodrome after about 1 2 weeks and can last for up to 4 weeks 16 17 The non specific symptoms seen in the prodromal typically resolve by this time but people will develop an enlarged liver and right upper abdominal pain or discomfort 16 10 20 of people will also experience an enlarged spleen while some people will also experience a mild unintentional weight loss 16 18 The recovery phase is characterized by resolution of the clinical symptoms of hepatitis with persistent elevations in liver lab values and potentially a persistently enlarged liver 16 All cases of hepatitis A and E are expected to fully resolve after 1 2 months 16 Most hepatitis B cases are also self limiting and will resolve in 3 4 months Few cases of hepatitis C will resolve completely 16 Both drug induced hepatitis and autoimmune hepatitis can present very similarly to acute viral hepatitis with slight variations in symptoms depending on the cause 20 21 Cases of drug induced hepatitis can manifest with systemic signs of an allergic reaction including rash fever serositis inflammation of membranes lining certain organs elevated eosinophils a type of white blood cell and suppression of bone marrow activity 20 Fulminant hepatitis Edit Fulminant hepatitis or massive hepatic cell death is a rare and life threatening complication of acute hepatitis that can occur in cases of hepatitis B D and E in addition to drug induced and autoimmune hepatitis 16 20 21 The complication more frequently occurs in instances of hepatitis B and D co infection at a rate of 2 20 and in pregnant women with hepatitis E at rate of 15 20 of cases 16 17 In addition to the signs of acute hepatitis people can also demonstrate signs of coagulopathy abnormal coagulation studies with easy bruising and bleeding and encephalopathy confusion disorientation and sleepiness 16 17 Mortality due to fulminant hepatitis is typically the result of various complications including cerebral edema gastrointestinal bleeding sepsis respiratory failure or kidney failure 16 Chronic hepatitis Edit Acute cases of hepatitis are seen to be resolved well within a six month period When hepatitis is continued for more than six months it is termed chronic hepatitis 22 Chronic hepatitis is often asymptomatic early in its course and is detected only by liver laboratory studies for screening purposes or to evaluate non specific symptoms 18 19 As the inflammation progresses patients can develop constitutional symptoms similar to acute hepatitis including fatigue nausea vomiting poor appetite and joint pain 19 Jaundice can occur as well but much later in the disease process and is typically a sign of advanced disease 19 Chronic hepatitis interferes with hormonal functions of the liver which can result in acne hirsutism abnormal hair growth and amenorrhea lack of menstrual period in women 19 Extensive damage and scarring of the liver over time defines cirrhosis a condition in which the liver s ability to function is permanently impeded 18 This results in jaundice weight loss coagulopathy ascites abdominal fluid collection and peripheral edema leg swelling 19 Cirrhosis can lead to other life threatening complications such as hepatic encephalopathy esophageal varices hepatorenal syndrome and liver cancer 18 Causes EditCauses of hepatitis can be divided into the following major categories infectious metabolic ischemic autoimmune genetic and other Infectious agents include viruses bacteria and parasites Metabolic causes include prescription medications toxins most notably alcohol and non alcoholic fatty liver disease Autoimmune and genetic causes of hepatitis involve genetic predispositions and tend to affect characteristic populations citation needed Infectious Edit Viral hepatitis Edit Main article Viral hepatitis Viral hepatitis is the most common type of hepatitis worldwide especially in Asia and Africa 23 Viral hepatitis is caused by five different viruses hepatitis A B C D and E 16 Hepatitis A and hepatitis E behave similarly they are both transmitted by the fecal oral route are more common in developing countries and are self limiting illnesses that do not lead to chronic hepatitis 16 24 25 Hepatitis B hepatitis C and hepatitis D are transmitted when blood or mucous membranes are exposed to infected blood and body fluids such as semen and vaginal secretions 16 Viral particles have also been found in saliva and breastmilk Kissing sharing utensils and breastfeeding do not lead to transmission unless these fluids are introduced into open sores or cuts 26 Many families who do not have safe drinking water or live in unhygienic homes have contracted hepatitis because saliva and blood droplets are often carried through the water and blood borne illnesses spread quickly in unsanitary settings citation needed Hepatitis B and C can present either acutely or chronically 16 Hepatitis D is a defective virus that requires hepatitis B to replicate and is only found with hepatitis B co infection 16 In adults hepatitis B infection is most commonly self limiting with less than 5 progressing to chronic state and 20 to 30 of those chronically infected developing cirrhosis or liver cancer 27 Infection in infants and children frequently leads to chronic infection 27 Unlike hepatitis B most cases of hepatitis C lead to chronic infection 28 Hepatitis C is the second most common cause of cirrhosis in the US second to alcoholic hepatitis 29 In the 1970s and 1980s blood transfusions were a major factor in spreading hepatitis C virus 28 Since widespread screening of blood products for hepatitis C began in 1992 the risk of acquiring hepatitis C from a blood transfusion has decreased from approximately 10 in the 1970s to 1 in 2 million currently 16 Parasitic hepatitis Edit Echinococcus granulosus Parasites can also infect the liver and activate the immune response resulting in symptoms of acute hepatitis with increased serum IgE though chronic hepatitis is possible with chronic infections 30 Of the protozoans Trypanosoma cruzi Leishmania species and the malaria causing Plasmodium species all can cause liver inflammation 30 Another protozoan Entamoeba histolytica causes hepatitis with distinct liver abscesses 30 Of the worms the cestode Echinococcus granulosus also known as the dog tapeworm infects the liver and forms characteristic hepatic hydatid cysts 30 The liver flukes Fasciola hepatica and Clonorchis sinensis live in the bile ducts and cause progressive hepatitis and liver fibrosis 30 Bacterial hepatitis Edit Bacterial infection of the liver commonly results in pyogenic liver abscesses acute hepatitis or granulomatous or chronic liver disease 31 Pyogenic abscesses commonly involve enteric bacteria such as Escherichia coli and Klebsiella pneumoniae and are composed of multiple bacteria up to 50 of the time 31 Acute hepatitis is caused by Neisseria meningitidis Neisseria gonorrhoeae Bartonella henselae Borrelia burgdorferi salmonella species brucella species and campylobacter species 31 Chronic or granulomatous hepatitis is seen with infection from mycobacteria species Tropheryma whipplei Treponema pallidum Coxiella burnetii and rickettsia species 31 Metabolic Edit Alcoholic hepatitis Edit Main article Alcoholic hepatitis Excessive alcohol consumption is a significant cause of hepatitis and is the most common cause of cirrhosis in the U S 29 Alcoholic hepatitis is within the spectrum of alcoholic liver disease This ranges in order of severity and reversibility from alcoholic steatosis least severe most reversible alcoholic hepatitis cirrhosis and liver cancer most severe least reversible 29 Hepatitis usually develops over years long exposure to alcohol occurring in 10 to 20 of alcoholics 32 The most important risk factors for the development of alcoholic hepatitis are quantity and duration of alcohol intake 32 Long term alcohol intake in excess of 80 grams of alcohol a day in men and 40 grams a day in women is associated with development of alcoholic hepatitis 1 beer or 4 ounces of wine is equivalent to 12g of alcohol 29 Alcoholic hepatitis can vary from asymptomatic hepatomegaly enlarged liver to symptoms of acute or chronic hepatitis to liver failure 29 Toxic and drug induced hepatitis Edit Many chemical agents including medications industrial toxins and herbal and dietary supplements can cause hepatitis 33 34 The spectrum of drug induced liver injury varies from acute hepatitis to chronic hepatitis to acute liver failure 33 Toxins and medications can cause liver injury through a variety of mechanisms including direct cell damage disruption of cell metabolism and causing structural changes 35 Some drugs such as paracetamol exhibit predictable dose dependent liver damage while others such as isoniazid cause idiosyncratic and unpredictable reactions that vary by person 33 There are wide variations in the mechanisms of liver injury and latency period from exposure to development of clinical illness 29 Many types of drugs can cause liver injury including the analgesic paracetamol antibiotics such as isoniazid nitrofurantoin amoxicillin clavulanate erythromycin and trimethoprim sulfamethoxazole anticonvulsants such as valproate and phenytoin cholesterol lowering statins steroids such as oral contraceptives and anabolic steroids and highly active anti retroviral therapy used in the treatment of HIV AIDS 29 Of these amoxicillin clavulanate is the most common cause of drug induced liver injury and paracetamol toxicity the most common cause of acute liver failure in the United States and Europe 33 Herbal remedies and dietary supplements are another important cause of hepatitis these are the most common causes of drug induced hepatitis in Korea 36 The United States based Drug Induced Liver Injury Network linked more than 16 of cases of hepatotoxicity to herbal and dietary supplements 37 In the United States herbal and dietary supplements unlike pharmaceutical drugs are unregulated by the Food and Drug Administration 37 The National Institutes of Health maintains the LiverTox Archived 2019 07 24 at the Wayback Machine database for consumers to track all known prescription and non prescription compounds associated with liver injury 38 Exposure to other hepatotoxins can occur accidentally or intentionally through ingestion inhalation and skin absorption The industrial toxin carbon tetrachloride and the wild mushroom Amanita phalloides are other known hepatotoxins 33 34 39 Non alcoholic fatty liver disease Edit Main article Non alcoholic fatty liver disease Non alcoholic hepatitis is within the spectrum of non alcoholic liver disease NALD which ranges in severity and reversibility from non alcoholic fatty liver disease NAFLD to non alcoholic steatohepatitis NASH to cirrhosis to liver cancer similar to the spectrum of alcoholic liver disease 40 Non alcoholic liver disease occurs in people with little or no history of alcohol use and is instead strongly associated with metabolic syndrome obesity insulin resistance and diabetes and hypertriglyceridemia 29 Over time non alcoholic fatty liver disease can progress to non alcoholic steatohepatitis which additionally involves liver cell death liver inflammation and possible fibrosis 29 Factors accelerating progression from NAFLD to NASH are obesity older age non African American ethnicity female gender diabetes mellitus hypertension higher ALT or AST level higher AST ALT ratio low platelet count and an ultrasound steatosis score 29 In the early stages as with NAFLD and early NASH most patients are asymptomatic or have mild right upper quadrant pain and diagnosis is suspected on the basis of abnormal liver function tests 29 As the disease progresses symptoms typical of chronic hepatitis may develop 41 While imaging can show fatty liver only liver biopsy can demonstrate inflammation and fibrosis characteristic of NASH 42 9 to 25 of patients with NASH develop cirrhosis 29 NASH is recognized as the third most common cause of liver disease in the United States 41 Autoimmune Edit Main article Autoimmune hepatitis Autoimmune hepatitis is a chronic disease caused by an abnormal immune response against liver cells 43 The disease is thought to have a genetic predisposition as it is associated with certain human leukocyte antigens involved in the immune response 44 As in other autoimmune diseases circulating auto antibodies may be present and are helpful in diagnosis 45 Auto antibodies found in patients with autoimmune hepatitis include the sensitive but less specific anti nuclear antibody ANA smooth muscle antibody SMA and atypical perinuclear antineutrophil cytoplasmic antibody p ANCA 45 Other autoantibodies that are less common but more specific to autoimmune hepatitis are the antibodies against liver kidney microsome 1 LKM1 and soluble liver antigen SLA 45 Autoimmune hepatitis can also be triggered by drugs such as nitrofurantoin hydralazine and methyldopa after liver transplant or by viruses such as hepatitis A Epstein Barr virus or measles 29 Autoimmune hepatitis can present anywhere within the spectrum from asymptomatic to acute or chronic hepatitis to fulminant liver failure 29 Patients are asymptomatic 25 34 of the time and the diagnosis is suspected on the basis of abnormal liver function tests 45 Some studies show between 25 and 75 of cases present with signs and symptoms of acute hepatitis 29 46 As with other autoimmune diseases autoimmune hepatitis usually affects young females though it can affect patients of either sex of any age and patients can exhibit classic signs and symptoms of autoimmunity such as fatigue anemia anorexia amenorrhea acne arthritis pleurisy thyroiditis ulcerative colitis nephritis and maculopapular rash 29 Autoimmune hepatitis increases the risk for cirrhosis and the risk for liver cancer is increased by about 1 for each year of the disease 29 Many people with autoimmune hepatitis have other autoimmune diseases 47 Autoimmune hepatitis is distinct from the other autoimmune diseases of the liver primary biliary cirrhosis and primary sclerosing cholangitis both of which can also lead to scarring fibrosis and cirrhosis of the liver 29 45 Genetic Edit Genetic causes of hepatitis include alpha 1 antitrypsin deficiency hemochromatosis and Wilson s disease 29 In alpha 1 antitrypsin deficiency a co dominant mutation in the gene for alpha 1 antitrypsin results in the abnormal accumulation of the mutant AAT protein within liver cells leading to liver disease 48 Hemochromatosis and Wilson s disease are both autosomal recessive diseases involving abnormal storage of minerals 29 In hemochromatosis excess amounts of iron accumulate in multiple body sites including the liver which can lead to cirrhosis 29 In Wilson s disease excess amounts of copper accumulate in the liver and brain causing cirrhosis and dementia 29 When the liver is involved alpha 1 antitrypsin deficiency and Wilson s disease tend to present as hepatitis in the neonatal period or in childhood 29 Hemochromatosis typically presents in adulthood with the onset of clinical disease usually after age 50 29 Ischemic hepatitis Edit Main article Ischemic hepatitis Ischemic hepatitis also known as shock liver results from reduced blood flow to the liver as in shock heart failure or vascular insufficiency 49 The condition is most often associated with heart failure but can also be caused by shock or sepsis Blood testing of a person with ischemic hepatitis will show very high levels of transaminase enzymes AST and ALT The condition usually resolves if the underlying cause is treated successfully Ischemic hepatitis rarely causes permanent liver damage 50 Other Edit Main article Neonatal hepatitis Hepatitis can also occur in neonates and is attributable to a variety of causes some of which are not typically seen in adults 51 Congenital or perinatal infection with the hepatitis viruses toxoplasma rubella cytomegalovirus and syphilis can cause neonatal hepatitis 51 Structural abnormalities such as biliary atresia and choledochal cysts can lead to cholestatic liver injury leading to neonatal hepatitis 51 Metabolic diseases such as glycogen storage disorders and lysosomal storage disorders are also implicated 51 Neonatal hepatitis can be idiopathic and in such cases biopsy often shows large multinucleated cells in the liver tissue 52 This disease is termed giant cell hepatitis and may be associated with viral infection autoimmune disorders and drug toxicity 53 54 Mechanism EditThe specific mechanism varies and depends on the underlying cause of the hepatitis Generally there is an initial insult that causes liver injury and activation of an inflammatory response which can become chronic leading to progressive fibrosis and cirrhosis 16 Viral hepatitis Edit Stages of liver disease The pathway by which hepatic viruses cause viral hepatitis is best understood in the case of hepatitis B and C 16 The viruses do not directly activate apoptosis cell death 16 55 Rather infection of liver cells activates the innate and adaptive arms of the immune system leading to an inflammatory response which causes cellular damage and death including viral induced apoptosis via the induction of the death receptor mediated signaling pathway 16 55 56 57 Depending on the strength of the immune response the types of immune cells involved and the ability of the virus to evade the body s defense infection can either lead to clearance acute disease or persistence chronic disease of the virus 16 The chronic presence of the virus within liver cells results in multiple waves of inflammation injury and wound healing that over time lead to scarring or fibrosis and culminate in hepatocellular carcinoma 55 58 People with impaired immune response are at greater risk of developing chronic infection 16 Natural killer cells are the primary drivers of the initial innate response and create a cytokine environment that results in the recruitment of CD4 T helper and CD8 cytotoxic T cells 59 60 Type I interferons are the cytokines that drive the antiviral response 60 In chronic Hepatitis B and C natural killer cell function is impaired 59 Steatohepatitis Edit Steatohepatitis is seen in both alcoholic and non alcoholic liver disease and is the culmination of a cascade of events that began with injury In the case of non alcoholic steatohepatitis this cascade is initiated by changes in metabolism associated with obesity insulin resistance and lipid dysregulation 61 62 In alcoholic hepatitis chronic excess alcohol use is the culprit 63 Though the inciting event may differ the progression of events is similar and begins with accumulation of free fatty acids FFA and their breakdown products in the liver cells in a process called steatosis 61 62 63 This initially reversible process overwhelms the hepatocyte s ability to maintain lipid homeostasis leading to a toxic effect as fat molecules accumulate and are broken down in the setting of an oxidative stress response 61 62 63 Over time this abnormal lipid deposition triggers the immune system via toll like receptor 4 TLR4 resulting in the production of inflammatory cytokines such as TNF that cause liver cell injury and death 61 62 63 These events mark the transition to steatohepatitis and in the setting of chronic injury fibrosis eventually develops setting up events that lead to cirrhosis and hepatocellular carcinoma 61 Microscopically changes that can be seen include steatosis with large and swollen hepatocytes ballooning evidence of cellular injury and cell death apoptosis necrosis evidence of inflammation in particular in zone 3 of the liver variable degrees of fibrosis and Mallory bodies 61 64 65 Diagnosis EditMost elevated aminotransferase CauseALT Chronic hepatitis B C and DNonalcoholic liver diseaseAcute viral hepatitisMedications toxinsAutoimmune hepatitisWilson s diseaseAlpha 1 antitrypsin deficiencyHemochromatosisIschemic hepatitis severe elevation up to thousands AST Alcoholic liver diseaseCirrhosis Histopathology of acute hepatitis with lobular disarray and associated lymphocytic inflammation acidophil body formation arrow and bilirubinostasis Diagnosis of hepatitis is made on the basis of some or all of the following a person s signs and symptoms medical history including sexual and substance use history blood tests imaging and liver biopsy 29 In general for viral hepatitis and other acute causes of hepatitis the person s blood tests and clinical picture are sufficient for diagnosis 16 29 For other causes of hepatitis especially chronic causes blood tests may not be useful 29 In this case liver biopsy is the gold standard for establishing the diagnosis histopathologic analysis is able to reveal the precise extent and pattern of inflammation and fibrosis 29 Biopsy is typically not the initial diagnostic test because it is invasive and is associated with a small but significant risk of bleeding that is increased in people with liver injury and cirrhosis 66 Blood testing includes liver enzymes serology i e for autoantibodies nucleic acid testing i e for hepatitis virus DNA RNA blood chemistry and complete blood count 29 Characteristic patterns of liver enzyme abnormalities can point to certain causes or stages of hepatitis 67 68 Generally AST and ALT are elevated in most cases of hepatitis regardless of whether the person shows any symptoms 29 The degree of elevation i e levels in the hundreds vs in the thousands the predominance for AST vs ALT elevation and the ratio between AST and ALT are informative of the diagnosis 29 Ultrasound CT and MRI can all identify steatosis fatty changes of the liver tissue and nodularity of the liver surface suggestive of cirrhosis 69 70 CT and especially MRI are able to provide a higher level of detail allowing visualization and characterize such structures as vessels and tumors within the liver 71 Unlike steatosis and cirrhosis no imaging test is able to detect liver inflammation i e hepatitis or fibrosis 29 Liver biopsy is the only definitive diagnostic test that is able to assess inflammation and fibrosis of the liver 29 Viral hepatitis Edit Main article Viral hepatitis Viral hepatitis is primarily diagnosed through blood tests for levels of viral antigens such as the hepatitis B surface or core antigen anti viral antibodies such as the anti hepatitis B surface antibody or anti hepatitis A antibody or viral DNA RNA 16 29 In early infection i e within 1 week IgM antibodies are found in the blood 29 In late infection and after recovery IgG antibodies are present and remain in the body for up to years 29 Therefore when a patient is positive for IgG antibody but negative for IgM antibody he is considered immune from the virus via either prior infection and recovery or prior vaccination 29 In the case of hepatitis B blood tests exist for multiple virus antigens which are different components of the virion particle and antibodies 72 The combination of antigen and antibody positivity can provide information about the stage of infection acute or chronic the degree of viral replication and the infectivity of the virus 72 Alcoholic versus non alcoholic Edit The most apparent distinguishing factor between alcoholic steatohepatitis ASH and nonalcoholic steatohepatitis NASH is a history of excessive alcohol use 73 Thus in patients who have no or negligible alcohol use the diagnosis is unlikely to be alcoholic hepatitis In those who drink alcohol the diagnosis may just as likely be alcoholic or nonalcoholic hepatitis especially if there is concurrent obesity diabetes and metabolic syndrome In this case alcoholic and nonalcoholic hepatitis can be distinguished by the pattern of liver enzyme abnormalities specifically in alcoholic steatohepatitis AST gt ALT with ratio of AST ALT gt 2 1 while in nonalcoholic steatohepatitis ALT gt AST with ratio of ALT AST gt 1 5 1 73 Liver biopsies show identical findings in patients with ASH and NASH specifically the presence of polymorphonuclear infiltration hepatocyte necrosis and apoptosis in the form of ballooning degeneration Mallory bodies and fibrosis around veins and sinuses 29 Virus screening EditThe purpose of screening for viral hepatitis is to identify people infected with the disease as early as possible even before symptoms and transaminase elevations may be present This allows for early treatment which can both prevent disease progression and decrease the likelihood of transmission to others citation needed Hepatitis A Edit Hepatitis A causes an acute illness that does not progress to chronic liver disease Therefore the role of screening is to assess immune status in people who are at high risk of contracting the virus as well as in people with known liver disease for whom hepatitis A infection could lead to liver failure 74 75 People in these groups who are not already immune can receive the hepatitis A vaccine Those at high risk and in need of screening include 76 77 78 People with poor sanitary habits such as not washing hands after using the restroom or changing diapers People who do not have access to clean water People in close contact either living with or having sexual contact with someone who has hepatitis A People who use illicit drugs People with liver disease People traveling to an area with endemic hepatitis AThe presence of anti hepatitis A IgG in the blood indicates past infection with the virus or prior vaccination 79 Hepatitis B Edit Hepatitis B virus v2 The CDC WHO USPSTF and ACOG recommend routine hepatitis B screening for certain high risk populations 80 81 82 83 Specifically these populations include people who are Born in countries where the prevalence of hepatitis B is high defined as 2 of the population whether or not they have been vaccinated 80 81 Born in the United States whose parents are from countries where the prevalence of hepatitis B is very high defined as 8 of the population and who were not vaccinated 80 81 HIV positive 80 81 82 Intravenous drug users 80 81 82 Men who have sex with men 80 81 82 In close contact with i e live or have sex with people known to have hepatitis B 80 81 82 Pregnant 80 81 83 Beginning immunosuppressive or cytotoxic therapy 80 Found to have elevated liver enzymes without a known cause 80 Blood organ or tissue donors 82 Incarcerated 82 On hemodialysis 80 Screening consists of a blood test that detects hepatitis B surface antigen HBsAg If HBsAg is present a second test usually done on the same blood sample that detects the antibody for the hepatitis B core antigen anti HBcAg can differentiate between acute and chronic infection 80 84 People who are high risk whose blood tests negative for HBsAg can receive the hepatitis B vaccine to prevent future infection 80 81 82 83 Hepatitis C Edit HCV structure source source source source source source source source source source ABHD5CGI 58 the Chanarin Dorfman Syndrome Protein Mobilises Lipid Stores for Hepatitis C Virus ppat 1005568 s014 The CDC WHO USPSTF AASLD and ACOG recommend screening people at high risk for hepatitis C infection 83 85 86 87 9 These populations include people who are Intravenous drug users past or current 85 86 87 9 Intranasal illicit drug users 85 86 87 9 HIV positive 85 86 87 9 Men who have sex with men 9 Incarcerated or who have been in the past 85 86 87 9 On long term hemodialysis or who have been in the past 85 86 87 9 Recipients of tattoos in an unregulated setting 87 9 Recipients of blood products or organs prior to 1992 in the United States 85 87 9 Adults in the United States born between 1945 and 1965 87 9 Born to HCV positive mothers 9 Pregnant and engaging in high risk behaviors 83 Workers in a healthcare setting who have had a needlestick injury 9 Blood or organ donors 9 Sex workers 86 For people in the groups above whose exposure is ongoing screening should be periodic though there is no set optimal screening interval 87 The AASLD recommends screening men who have sex with men who are HIV positive annually 9 People born in the US between 1945 and 1965 should be screened once unless they have other exposure risks 85 87 9 Screening consists of a blood test that detects anti hepatitis C virus antibody If anti hepatitis C virus antibody is present a confirmatory test to detect HCV RNA indicates chronic disease 86 9 Hepatitis D Edit The CDC WHO USPSTF AASLD and ACOG recommend screening people at high risk for hepatitis D infection 83 85 86 87 9 These populations include people who are Intravenous drug users past or current 85 86 87 9 Intranasal illicit drug users 85 86 87 9 Incarcerated or who have been in the past 85 86 87 9 Workers in a healthcare setting who have had a needlestick injury 9 Blood or organ donors 9 Sex workers 86 Hepatitis D is extremely rare Symptoms include chronic diarrhea anal and intestinal blisters purple urine and burnt popcorn scented breath 80 81 82 Screening consists of a blood test that detects the anti hepitits D virus antibbody If anti hepitits D virus antibody is present a confirmatory test to detect HDV RNA DNA inidicates chronic disease 86 9 Prevention EditVaccines Edit Hepatitis A Edit Main article Hepatitis A vaccine Havrix vaccine The CDC recommends the hepatitis A vaccine for all children beginning at age one as well as for those who have not been previously immunized and are at high risk for contracting the disease 76 77 For children 12 months of age or older the vaccination is given as a shot into the muscle in two doses 6 18 months apart and should be started before the age 24 months 88 The dosing is slightly different for adults depending on the type of the vaccine If the vaccine is for hepatitis A only two doses are given 6 18 months apart depending on the manufacturer 78 If the vaccine is combined hepatitis A and hepatitis B up to 4 doses may be required 78 Hepatitis B Edit Main article Hepatitis B vaccine WHO UNICEF estimates of hepatitis B vaccine HepB BD coverage in countries from the European WHO region in the years 2000 2015 The CDC recommends the routine vaccination of all children under the age of 19 with the hepatitis B vaccine 89 They also recommend it for those who desire it or are at high risk 77 Routine vaccination for hepatitis B starts with the first dose administered as a shot into the muscle before the newborn is discharged from the hospital An additional two doses should be administered before the child is 18 months 88 For babies born to a mother with hepatitis B surface antigen positivity the first dose is unique in addition to the vaccine the hepatitis immune globulin should also be administered both within 12 hours of birth These newborns should also be regularly tested for infection for at least the first year of life 88 There is also a combination formulation that includes both hepatitis A and B vaccines 90 Other Edit There are currently no vaccines available in the United States for hepatitis C or E 86 91 92 In 2015 a group in China published an article regarding the development of a vaccine for hepatitis E 93 As of March 2016 the United States government was in the process of recruiting participants for the phase IV trial of the hepatitis E vaccine 94 Behavioral changes Edit Hepatitis A Edit Because hepatitis A is transmitted primarily through the oral fecal route the mainstay of prevention aside from vaccination is good hygiene access to clean water and proper handling of sewage 77 Hepatitis B and C Edit As hepatitis B and C are transmitted through blood and multiple bodily fluids prevention is aimed at screening blood prior to transfusion abstaining from the use of injection drugs safe needle and sharps practices in healthcare settings and safe sex practices 27 86 Hepatitis D Edit Worldwide prevalence of HDV among HBV carriers in 2015 Eight genotypes have been identified worldwide by comparative phylogenetic analysis Genotype 1 is the most frequent and has variable pathogenicity Genotypes 2 and 4 are found in East Asia causing relatively mild disease Genotype 3 is found in South America in association with severe hepatitis Genotypes 5 6 7 8 have been found only in Africa 95 The hepatitis D virus requires that a person first be infected with hepatitis B virus so prevention efforts should focus on limiting the spread of hepatitis B In people who have chronic hepatitis B infection and are at risk for superinfection with the hepatitis D virus the preventive strategies are the same as for hepatitis B 92 Hepatitis E Edit Hepatitis E is spread primarily through the oral fecal route but may also be spread by blood and from mother to fetus The mainstay of hepatitis E prevention is similar to that for hepatitis A namely good hygiene and clean water practices 91 Alcoholic hepatitis Edit As excessive alcohol consumption can lead to hepatitis and cirrhosis the following are maximal recommendations for alcohol consumption 96 Women 3 drinks on any given day and 7 drinks per week Men 4 drinks on any given day and 14 drinks per weekSuccesses Edit Hepatitis A Edit In the United States universal immunization has led to a two thirds decrease in hospital admissions and medical expenses due to hepatitis A 97 Hepatitis B Edit In the United States new cases of hepatitis B decreased 75 from 1990 to 2004 98 The group that saw the greatest decrease was children and adolescents likely reflecting the implementation of the 1999 guidelines 99 Hepatitis C Edit Hepatitis C infections each year had been declining since the 1980s but began to increase again in 2006 100 The data are unclear as to whether the decline can be attributed to needle exchange programmes 101 Alcoholic hepatitis Edit Depiction of a liver failure patient Because people with alcoholic hepatitis may have no symptoms it can be difficult to diagnose and the number of people with the disease is probably higher than many estimates 102 Programs such as Alcoholics Anonymous have been successful in decreasing death due to cirrhosis but it is difficult to evaluate their success in decreasing the incidence of alcoholic hepatitis 103 Treatment EditThe treatment of hepatitis varies according to the type whether it is acute or chronic and the severity of the disease Activity Many people with hepatitis prefer bed rest though it is not necessary to avoid all physical activity while recovering 16 Diet A high calorie diet is recommended 16 Many people develop nausea and cannot tolerate food later in the day so the bulk of intake may be concentrated in the earlier part of the day 16 In the acute phase of the disease intravenous feeding may be needed if patients cannot tolerate food and have poor oral intake subsequent to nausea and vomiting 16 Drugs People with hepatitis should avoid taking drugs metabolized by the liver 16 Glucocorticoids are not recommended as a treatment option for acute viral hepatitis and may even cause harm such as development of chronic hepatitis 16 Precautions Universal precautions should be observed Isolation is usually not needed except in cases of hepatitis A and E who have fecal incontinence and in cases of hepatitis B and C who have uncontrolled bleeding 16 Hepatitis A Edit Main article Hepatitis A Hepatitis A usually does not progress to a chronic state and rarely requires hospitalization 16 76 Treatment is supportive and includes such measures as providing intravenous IV hydration and maintaining adequate nutrition 16 76 Rarely people with the hepatitis A virus can rapidly develop liver failure termed fulminant hepatic failure especially the elderly and those who had a pre existing liver disease especially hepatitis C 16 76 Mortality risk factors include greater age and chronic hepatitis C 16 In these cases more aggressive supportive therapy and liver transplant may be necessary 16 Hepatitis B Edit Main article Hepatitis B Acute Edit In healthy patients 95 99 recover with no long lasting effects and antiviral treatment is not warranted 16 Age and comorbid conditions can result in a more prolonged and severe illness Certain patients warrant hospitalization especially those who present with clinical signs of ascites peripheral edema and hepatic encephalopathy and laboratory signs of hypoglycemia prolonged prothrombin time low serum albumin and very high serum bilirubin 16 In these rare more severe acute cases patients have been successfully treated with antiviral therapy similar to that used in cases of chronic hepatitis B with nucleoside analogues such as entecavir or tenofovir As there is a dearth of clinical trial data and the drugs used to treat are prone to developing resistance experts recommend reserving treatment for severe acute cases not mild to moderate 16 Chronic Edit Chronic hepatitis B management aims to control viral replication which is correlated with progression of disease 19 Seven drugs are approved in the United States 19 Injectable interferon alpha was the first therapy approved for chronic hepatitis B 19 It has several side effects most of which are reversible with removal of therapy but it has been supplanted by newer treatments for this indication 19 These include long acting interferon bound to polyethylene glycol pegylated interferon and the oral nucleoside analogues 19 Pegylated interferon PEG IFN is dosed just once a week as a subcutaneous injection and is both more convenient and effective than standard interferon 19 Although it does not develop resistance as do many of the oral antivirals it is poorly tolerated and requires close monitoring 19 PEG IFN is estimated to cost about 18 000 per year in the United States compared to 2 500 8 700 for the oral medications Its treatment duration is 48 weeks unlike oral antivirals which require indefinite treatment for most patients minimum one year 19 PEG IFN is not effective in patients with high levels of viral activity and cannot be used in immunosuppressed patients or those with cirrhosis 19 Lamivudine was the first approved oral nucleoside analogue 19 While effective and potent lamivudine has been replaced by newer more potent treatments in the Western world and is no longer recommended as first line treatment 19 It is still used in areas where newer agents either have not been approved or are too costly 19 Generally the course of treatment is a minimum of one year with a minimum of six additional months of consolidation therapy 19 Based on viral response longer therapy may be required and certain patients require indefinite long term therapy 19 Due to a less robust response in Asian patients consolidation therapy is recommended to be extended to at least a year 19 All patients should be monitored for viral reactivation which if identified requires restarting treatment 19 Lamivudine is generally safe and well tolerated 19 Many patients develop resistance which is correlated with longer treatment duration 19 If this occurs an additional antiviral is added 19 Lamivudine as a single treatment is contraindicated in patients coinfected with HIV as resistance develops rapidly but it can be used as part of a multidrug regimen 19 Adefovir dipivoxil a nucleotide analogue has been used to supplement lamivudine in patients who develop resistance but is no longer recommended as first line therapy 19 Entecavir is safe well tolerated less prone to developing resistance and the most potent of the existing hepatitis B antivirals it is thus a first line treatment choice 19 It is not recommended for lamivudine resistant patients or as monotherapy in patients who are HIV positive 19 Telbivudine is effective but not recommended as first line treatment as compared to entecavir it is both less potent and more resistance prone 19 Tenofovir is a nucleotide analogue and an antiretroviral drug that is also used to treat HIV infection 19 It is preferred to adefovir both in lamivudine resistant patients and as initial treatment since it is both more potent and less likely to develop resistance 19 First line treatments currently used include PEG IFN entecavir and tenofovir subject to patient and physician preference 19 Treatment initiation is guided by recommendations issued by The American Association for the Study of Liver Diseases AASLD and the European Association for the Study of the Liver EASL and is based on detectable viral levels HBeAg positive or negative status ALT levels and in certain cases family history of HCC and liver biopsy 19 In patients with compensated cirrhosis treatment is recommended regardless of HBeAg status or ALT level but recommendations differ regarding HBV DNA levels AASLD recommends treating at DNA levels detectable above 2x103 IU mL EASL and WHO recommend treating when HBV DNA levels are detectable at any level 19 82 In patients with decompensated cirrhosis treatment and evaluation for liver transplantation are recommended in all cases if HBV DNA is detectable 19 82 Currently multidrug treatment is not recommended in treatment of chronic HBV as it is no more effective in the long term than individual treatment with entecavir or tenofovir 19 Hepatitis C Edit Main article Hepatitis C The American Association for the Study of Liver Diseases and the Infectious Diseases Society of America AASLD IDSA recommend antiviral treatment for all patients with chronic hepatitis C infection except for those with additional chronic medical conditions that limit their life expectancy 9 Once it is acquired persistence of the hepatitis C virus is the rule resulting in chronic hepatitis C The goal of treatment is prevention of hepatocellular carcinoma HCC 104 The best way to reduce the long term risk of HCC is to achieve sustained virological response SVR 104 SVR is defined as an undetectable viral load at 12 weeks after treatment completion and indicates a cure 105 106 Currently available treatments include indirect and direct acting antiviral drugs 105 106 The indirect acting antivirals include pegylated interferon PEG IFN and ribavirin RBV which in combination have historically been the basis of therapy for HCV 105 106 Duration of and response to these treatments varies based on genotype 105 106 These agents are poorly tolerated but are still used in some resource poor areas 105 106 In high resource countries they have been supplanted by direct acting antiviral agents which first appeared in 2011 these agents target proteins responsible for viral replication and include the following three classes 105 106 NS3 4A protease inhibitors including telaprevir boceprevir simeprevir and others NS5A inhibitors including ledipasvir daclatasvir and others NS5B polymerase inhibitors including sofosbuvir dasabuvir and othersThese drugs are used in various combinations sometimes combined with ribavirin based on the patient s genotype delineated as genotypes 1 6 106 Genotype 1 GT1 which is the most prevalent genotype in the United States and around the world can now be cured with a direct acting antiviral regimen 106 First line therapy for GT1 is a combination of sofosbuvir and ledipasvir SOF LDV for 12 weeks for most patients including those with advanced fibrosis or cirrhosis 106 Certain patients with early disease need only 8 weeks of treatment while those with advanced fibrosis or cirrhosis who have not responded to prior treatment require 24 weeks 106 Cost remains a major factor limiting access to these drugs particularly in low resource nations the cost of the 12 week GT1 regimen SOF LDV has been estimated at US 94 500 105 Hepatitis D Edit Main article Hepatitis D Hepatitis D is difficult to treat and effective treatments are lacking Interferon alpha has proven effective at inhibiting viral activity but only on a temporary basis 107 Hepatitis E Edit Main article Hepatitis E Hepatitis E virus Similar to hepatitis A treatment of hepatitis E is supportive and includes rest and ensuring adequate nutrition and hydration 108 Hospitalization may be required for particularly severe cases or for pregnant women 108 Alcoholic hepatitis Edit First line treatment of alcoholic hepatitis is treatment of alcoholism 32 For those who abstain completely from alcohol reversal of liver disease and a longer life are possible patients at every disease stage have been shown to benefit by prevention of additional liver injury 32 63 In addition to referral to psychotherapy and other treatment programs treatment should include nutritional and psychosocial evaluation and treatment 32 63 109 Patients should also be treated appropriately for related signs and symptoms such as ascites hepatic encephalopathy and infection 63 Severe alcoholic hepatitis has a poor prognosis and is notoriously difficult to treat 32 63 109 Without any treatment 20 50 of patients may die within a month but evidence shows treatment may extend life beyond one month i e reduce short term mortality 32 109 110 Available treatment options include pentoxifylline PTX which is a nonspecific TNF inhibitor corticosteroids such as prednisone or prednisolone CS corticosteroids with N acetylcysteine CS with NAC and corticosteroids with pentoxifylline CS with PTX 109 Data suggest that CS alone or CS with NAC are most effective at reducing short term mortality 109 Unfortunately corticosteroids are contraindicated in some patients such as those who have active gastrointestinal bleeding infection kidney failure or pancreatitis 32 63 In these cases PTX may be considered on a case by case basis in lieu of CS some evidence shows PTX is better than no treatment at all and may be comparable to CS while other data show no evidence of benefit over placebo 109 110 Unfortunately there are currently no drug treatments that decrease these patients risk of dying in the longer term at 3 12 months and beyond 109 Weak evidence suggests milk thistle extracts may improve survival in alcoholic liver disease and improve certain liver tests serum bilirubin and GGT without causing side effects but a firm recommendation cannot be made for or against milk thistle without further study 111 The modified Maddrey s discriminant function may be used to evaluate the severity and prognosis in alcoholic hepatitis and evaluates the efficacy of using alcoholic hepatitis corticosteroid treatment Autoimmune hepatitis Edit Autoimmune hepatitis is commonly treated by immunosuppressants such as the corticosteroids prednisone or prednisolone the active version of prednisolone that does not require liver synthesis either alone or in combination with azathioprine and some have suggested the combination therapy is preferred to allow for lower doses of corticosteroids to reduce associated side effects 46 although the result of treatment efficacy is comparative 112 Treatment of autoimmune hepatitis consists of two phases an initial and maintenance phase The initial phase consists of higher doses of corticosteroids which are tapered down over a number of weeks to a lower dose If used in combination azathioprine is given during the initial phase as well Once the initial phase has been completed a maintenance phase that consists of lower dose corticosteroids and in combination therapy azathioprine until liver blood markers are normalized Treatment results in 66 91 of patients achieving normal liver test values in two years with the average being 22 months 46 Prognosis EditAcute hepatitis Edit Nearly all patients with hepatitis A infections recover completely without complications if they were healthy prior to the infection Similarly acute hepatitis B infections have a favorable course towards complete recovery in 95 99 of patients 16 Certain factors may portend a poorer outcome such as co morbid medical conditions or initial presenting symptoms of ascites edema or encephalopathy 16 Overall the mortality rate for acute hepatitis is low 0 1 in total for cases of hepatitis A and B but rates can be higher in certain populations super infection with both hepatitis B and D pregnant women etc 16 In contrast to hepatitis A amp B hepatitis C carries a much higher risk of progressing to chronic hepatitis approaching 85 90 113 Cirrhosis has been reported to develop in 20 50 of patients with chronic hepatitis C citation needed Other rare complications of acute hepatitis include pancreatitis aplastic anemia peripheral neuropathy and myocarditis 16 Fulminant hepatitis Edit Despite the relatively benign course of most viral cases of hepatitis fulminant hepatitis represents a rare but feared complication Fulminant hepatitis most commonly occurs in hepatitis B D and E About 1 2 of cases of hepatitis E can lead to fulminant hepatitis but pregnant women are particularly susceptible occurring in up to 20 of cases 114 Mortality rates in cases of fulminant hepatitis rise over 80 but those patients that do survive often make a complete recovery Liver transplantation can be life saving in patients with fulminant liver failure 115 Hepatitis D infections can transform benign cases of hepatitis B into severe progressive hepatitis a phenomenon known as superinfection 116 Chronic hepatitis Edit Acute hepatitis B infections become less likely to progress to chronic forms as the age of the patient increases with rates of progression approaching 90 in vertically transmitted cases of infants compared to 1 risk in young adults 19 Overall the five year survival rate for chronic hepatitis B ranges from 97 in mild cases to 55 in severe cases with cirrhosis 19 Most patients who acquire hepatitis D at the same time as hepatitis B co infection recover without developing a chronic infection In people with hepatitis B who later acquire hepatitis D superinfection chronic infection is much more common at 80 90 and liver disease progression is accelerated 107 117 Chronic hepatitis C progresses towards cirrhosis with estimates of cirrhosis prevalence of 16 at 20 years after infection 118 While the major causes of mortality in hepatitis C is end stage liver disease hepatocellular carcinoma is an important additional long term complication and cause of death in chronic hepatitis Rates of mortality increase with progression of the underlying liver disease Series of patients with compensated cirrhosis due to HCV have shown 3 5 and 10 year survival rates of 96 91 and 79 respectively 119 The 5 year survival rate drops to 50 upon if the cirrhosis becomes decompensated Epidemiology EditViral hepatitis Edit Hepatitis A Edit Hepatitis A is found throughout the world and manifests as large outbreaks and epidemics associated with fecal contamination of water and food sources 99 Hepatitis A viral infection is predominant in children ages 5 14 with rare infection of infants 99 Infected children have little to no apparent clinical illness in contrast to adults in whom greater than 80 are symptomatic if infected 120 Infection rates are highest in low resource countries with inadequate public sanitation and large concentrated populations 16 121 In such regions as much as 90 of children younger than 10 years old have been infected and are immune corresponding both to lower rates of clinically symptomatic disease and outbreaks 99 121 122 The availability of a childhood vaccine has significantly reduced infections in the United States with incidence declining by more than 95 as of 2013 123 Paradoxically the highest rates of new infection now occur in young adults and adults who present with worse clinical illness 16 Specific populations at greatest risk include travelers to endemic regions men who have sex with men those with occupational exposure to non human primates people with clotting disorders who have received clotting factors people with history of chronic liver disease in whom co infection with hepatitis A can lead to fulminant hepatitis and intravenous drug users rare 99 Hepatitis B Edit Main article Hepatitis B HBV replication Hepatitis B is the most common cause of viral hepatitis in the world with more than 240 million chronic carriers of the virus 1 million of whom are in the United States 27 99 In approximately two thirds of patients who develop acute hepatitis B infection no identifiable exposure is evident 16 Of those acutely infected 25 become lifetime carriers of the virus 99 Risk of infection is highest among intravenous drug users people with high risk sexual behaviors healthcare workers people who had multiple transfusions organ transplant patients dialysis patients and newborns infected during the birthing process 99 Close to 780 000 deaths in the world are attributed to hepatitis B 27 The most endemic regions are in sub Saharan Africa and East Asia where as many as 10 of adults are chronic carriers 27 Carrier rates in developed nations are significantly lower encompassing less than 1 of the population 27 In endemic regions transmission is thought to be associated with exposure during birth and close contact between young infants 16 27 Hepatitis C Edit Main article Hepatitis C HepC replication Chronic hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma 124 It is a common medical reason for liver transplantation due to its severe complications 124 It is estimated that 130 180 million people in the world are affected by this disease representing a little more than 3 of the world population 86 99 124 In the developing regions of Africa Asia and South America prevalence can be as high as 10 of the population 99 In Egypt rates of hepatitis C infection as high as 20 have been documented and are associated with iatrogenic contamination related to schistosomiasis treatment in the 1950s 1980s 16 99 Currently in the United States approximately 3 5 million adults are estimated to be infected 125 Hepatitis C is particularly prevalent among people born between 1945 and 1965 a group of about 800 000 people with prevalence as high as 3 2 versus 1 6 in the general U S population 16 Most chronic carriers of hepatitis C are unaware of their infection status 16 The most common mode of transmission of hepatitis C virus is exposure to blood products via blood transfusions prior to 1992 and intravenous drug injection 16 99 A history of intravenous drug injection is the most important risk factor for chronic hepatitis C 124 Other susceptible populations include those engaged in high risk sexual behavior infants of infected mothers and healthcare workers 99 Hepatitis D Edit Main article Hepatitis D The hepatitis D virus causes chronic and fulminant hepatitis in the context of co infection with the hepatitis B virus 99 It is primarily transmitted via non sexual contact and via needles 16 99 Susceptibility to hepatitis D differs by geographic region 16 99 In the United States and Northern Europe populations at risk are intravenous drug users and people who receive multiple transfusions 16 99 In the Mediterranean hepatitis D is predominant among hepatitis B virus co infected people 16 99 Hepatitis E Edit Main article Hepatitis E Similar to Hepatitis A hepatitis E manifests as large outbreaks and epidemics associated with fecal contamination of water sources 16 It accounts for more than 55 000 deaths annually with approximately 20 million people worldwide thought to be infected with the virus 91 It affects predominantly young adults causing acute hepatitis 16 126 In infected pregnant women Hepatitis E infection can lead to fulminant hepatitis with third trimester mortality rates as high as 30 99 126 Those with weakened immune systems such as organ transplant recipients are also susceptible 126 Infection is rare in the United States but rates are high in the developing world Africa Asia Central America Middle East 16 126 Many genotypes exist and are differentially distributed around the world 91 There is some evidence of hepatitis E infection of animals serving as a reservoir for human infection 99 Alcoholic hepatitis Edit Alcoholic hepatitis AH in its severe form has a one month mortality as high as 50 63 64 127 Most people who develop AH are men but women are at higher risk of developing AH and its complications likely secondary to high body fat and differences in alcohol metabolism 64 Other contributing factors include younger age lt 60 binge pattern drinking poor nutritional status obesity and hepatitis C co infection 64 It is estimated that as much as 20 of people with AH are also infected with hepatitis C 128 In this population the presence of hepatitis C virus leads to more severe disease with faster progression to cirrhosis hepatocellular carcinoma and increased mortality 64 128 129 Obesity increases the likelihood of progression to cirrhosis in cases of alcoholic hepatitis 64 It is estimated that 70 of people who have AH will progress to cirrhosis 64 Non alcoholic steatohepatitis Edit Non alcoholic steatohepatitis NASH is projected to become the top reason for liver transplantation in the United States by 2020 supplanting chronic liver disease due to hepatitis C 130 About 20 45 of the U S population have NAFLD and 6 have NASH 29 40 The estimated prevalence of NASH in the world is 3 5 131 Of NASH patients who develop cirrhosis about 2 per year will likely progress to hepatocellular carcinoma 131 Worldwide the estimated prevalence of hepatocellular carcinoma related to NAFLD is 15 30 132 NASH is thought to be the primary cause of cirrhosis in approximately 25 of patients in the United States representing 1 2 of the general population 132 History EditEarly observations Edit Initial accounts of a syndrome that we now think is likely to be hepatitis begin to occur around 3000 B C Clay tablets that served as medical handbooks for the ancient Sumerians described the first observations of jaundice The Sumerians believed that the liver was the home of the soul and attributed the findings of jaundice to the attack of the liver by a devil named Ahhazu 133 Around 400 B C Hippocrates recorded the first documentation of an epidemic jaundice in particular noting the uniquely fulminant course of a cohort of patients who all died within two weeks He wrote The bile contained in the liver is full of phlegm and blood and erupts After such an eruption the patient soon raves becomes angry talks nonsense and barks like a dog 134 Given the poor sanitary conditions of war infectious jaundice played a large role as a major cause of mortality among troops in the Napoleonic Wars the American Revolutionary War and both World Wars 135 During World War II estimates of soldiers affected by hepatitis were upwards of 10 million During World War II soldiers received vaccines against diseases such as yellow fever but these vaccines were stabilized with human serum presumably contaminated with hepatitis viruses which often created epidemics of hepatitis 136 It was suspected these epidemics were due to a separate infectious agent and not due to the yellow fever virus itself after noting 89 cases of jaundice in the months after vaccination out of a total 3 100 patients that were vaccinated After changing the seed virus strain no cases of jaundice were observed in the subsequent 8 000 vaccinations 137 Willowbrook State School experiments Edit A New York University researcher named Saul Krugman continued this research into the 1950s and 1960s most infamously with his experiments on mentally disabled children at the Willowbrook State School in New York a crowded urban facility where hepatitis infections were highly endemic to the student body Krugman injected students with gamma globulin a type of antibody After observing the temporary protection against infection this antibody provided he then tried injected live hepatitis virus into students Krugman also controversially took feces from infected students blended it into milkshakes and fed it to newly admitted children 138 His research was received with much controversy as people protested the questionable ethics surrounding the chosen target population Henry Beecher was one of the foremost critics in an article in the New England Journal of Medicine in 1966 arguing that parents were unaware to the risks of consent and that the research was done to benefit others at the expense of children 139 Moreover he argued that poor families with mentally disabled children often felt pressured to join the research project to gain admission to the school with all of the educational and support resources that would come along with it 140 Others in the medical community spoke out in support of Krugman s research in terms of its widespread benefits and understanding of the hepatitis virus and Willowbrook continues to be a commonly cited example in debates about medical ethics 141 Australia antigen Edit The next insight regarding hepatitis B was a serendipitous one by Dr Baruch Blumberg a researcher at the NIH who did not set out to research hepatitis but rather studied lipoprotein genetics He travelled across the globe collecting blood samples investigating the interplay between disease environment and genetics with the goal of designing targeted interventions for at risk people that could prevent them from getting sick 142 He noticed an unexpected interaction between the blood of a patient with hemophilia that had received multiple transfusions and a protein found in the blood of an indigenous Australian person 143 He named the protein the Australia antigen and made it the focus of his research He found a higher prevalence of the protein in the blood of patients from developing countries compared to those from developed ones and noted associations of the antigen with other diseases like leukemia and Down Syndrome 144 Eventually he came to the unifying conclusion that the Australia antigen was associated with viral hepatitis In 1970 David Dane first isolated the hepatitis B virion at London s Middlesex Hospital and named the virion the 42 nm Dane particle 140 Based on its association with the surface of the hepatitis B virus the Australia antigen was renamed to hepatitis B surface antigen or HBsAg Blumberg continued to study the antigen and eventually developed the first hepatitis B vaccine using plasma rich in HBsAg for which he received the Nobel Prize in Medicine in 1976 145 Society and culture EditEconomic burden Edit Overall hepatitis accounts for a significant portion of healthcare expenditures in both developing and developed nations and is expected to rise in several developing countries 146 147 While hepatitis A infections are self limited events they are associated with significant costs in the United States 148 It has been estimated that direct and indirect costs are approximately 1817 and 2459 respectively per case and that an average of 27 work days is lost per infected adult 148 A 1997 report demonstrated that a single hospitalization related to hepatitis A cost an average of 6 900 and resulted in around 500 million in total annual healthcare costs 149 Cost effectiveness studies have found widespread vaccination of adults to not be feasible but have stated that a combination hepatitis A and B vaccination of children and at risk groups people from endemic areas healthcare workers may be 150 Hepatitis B accounts for a much larger percentage of health care spending in endemic regions like Asia 151 152 In 1997 it accounted for 3 2 of South Korea s total health care expenditures and resulted in 696 million in direct costs 152 A large majority of that sum was spent on treating disease symptoms and complications 153 Chronic hepatitis B infections are not as endemic in the United States but accounted for 357 million in hospitalization costs in the year 1990 146 That number grew to 1 5 billion in 2003 but remained stable as of 2006 which may be attributable to the introduction of effective drug therapies and vaccination campaigns 146 147 People infected with chronic hepatitis C tend to be frequent users of the health care system globally 154 It has been estimated that a person infected with hepatitis C in the United States will result in a monthly cost of 691 154 That number nearly doubles to 1 227 for people with compensated stable cirrhosis while the monthly cost of people with decompensated worsening cirrhosis is almost five times as large at 3 682 154 The wide ranging effects of hepatitis make it difficult to estimate indirect costs but studies have speculated that the total cost is 6 5 billion annually in the United States 146 In Canada 56 of HCV related costs are attributable to cirrhosis and total expenditures related to the virus are expected to peak at CAD 396 million in the year 2032 155 2003 Monaca outbreak Edit The largest outbreak of hepatitis A virus in United States history occurred among people who ate at a now defunct Mexican food restaurant located in Monaca Pennsylvania in late 2003 156 Over 550 people who visited the restaurant between September and October 2003 were infected with the virus three of whom died as a direct result 156 The outbreak was brought to the attention of health officials when local emergency medicine physicians noticed a significant increase in cases of hepatitis A in the county 157 After conducting its investigation the CDC attributed the source of the outbreak to the use of contaminated raw green onion The restaurant was purchasing its green onion stock from farms in Mexico at the time 156 It is believed that the green onions may have been contaminated through the use of contaminated water for crop irrigation rinsing or icing or by handling of the vegetables by infected people 156 Green onion had caused similar outbreaks of hepatitis A in the southern United States prior to this but not to the same magnitude 156 The CDC believes that the restaurant s use of a large communal bucket for chopped raw green onion allowed non contaminated plants to be mixed with contaminated ones increasing the number of vectors of infection and amplifying the outbreak 156 The restaurant was closed once it was discovered to be the source and over 9 000 people were given hepatitis A immune globulin because they had either eaten at the restaurant or had been in close contact with someone who had 156 Special populations EditHIV co infection Edit Persons infected with HIV have a particularly high burden of HIV HCV co infection 158 159 In a recent study by the WHO the likelihood of being infected with hepatitis C virus was six times greater in those who also had HIV 159 The prevalence of HIV HCV co infection worldwide was estimated to be 6 2 representing more than 2 2 million people 159 Intravenous drug use was an independent risk factor for HCV infection 124 In the WHO study the prevalence of HIV HCV co infection was markedly higher at 82 4 in those who injected drugs compared to the general population 2 4 159 In a study of HIV HCV co infection among HIV positive men who have sex with men MSM the overall prevalence of anti hepatitis C antibodies was estimated to be 8 1 and increased to 40 among HIV positive MSM who also injected drugs 158 Pregnancy Edit Hepatitis B Edit Vertical transmission is a significant contributor of new HBV cases each year with 35 50 of transmission from mother to neonate in endemic countries 83 160 Vertical transmission occurs largely via a neonate s exposure to maternal blood and vaginal secretions during birth 160 While the risk of progression to chronic infection is approximately 5 among adults who contract the virus it is as high as 95 among neonates subject to vertical transmission 83 161 The risk of viral transmission is approximately 10 20 when maternal blood is positive for HBsAg and up to 90 when also positive for HBeAg 83 Given the high risk of perinatal transmission the CDC recommends screening all pregnant women for HBV at their first prenatal visit 83 162 It is safe for non immune pregnant women to receive the HBV vaccine 83 160 Based on the limited available evidence the American Association for the Study of Liver Diseases AASLD recommends antiviral therapy in pregnant women whose viral load exceeds 200 000 IU mL 163 A growing body of evidence shows that antiviral therapy initiated in the third trimester significantly reduces transmission to the neonate 160 163 A systematic review of the Antiretroviral Pregnancy Registry database found that there was no increased risk of congenital anomalies with Tenofovir for this reason along with its potency and low risk of resistance the AASLD recommends this drug 163 164 A 2010 systematic review and meta analysis found that Lamivudine initiated early in the third trimester also significantly reduced mother to child transmission of HBV without any known adverse effects 165 The ACOG states that the evidence available does not suggest any particular mode of delivery i e vaginal vs cesarean is better at reducing vertical transmission in mothers with HBV 83 The WHO and CDC recommend that neonates born to mothers with HBV should receive hepatitis B immune globulin HBIG as well as the HBV vaccine within 12 hours of birth 80 82 For infants who have received HBIG and the HBV vaccine breastfeeding is safe 83 160 Hepatitis C Edit Estimates of the rate of HCV vertical transmission range from 2 8 a 2014 systematic review and meta analysis found the risk to be 5 8 in HCV positive HIV negative women 83 166 The same study found the risk of vertical transmission to be 10 8 in HCV positive HIV positive women 166 Other studies have found the risk of vertical transmission to be as high as 44 among HIV positive women 83 The risk of vertical transmission is higher when the virus is detectable in the mother s blood 166 Evidence does not indicate that mode of delivery i e vaginal vs cesarean has an effect on vertical transmission 83 For women who are HCV positive and HIV negative breastfeeding is safe CDC guidelines suggest avoiding it if a woman s nipples are cracked or bleeding to reduce the risk of transmission 83 85 Hepatitis E Edit Pregnant women who contract HEV are at significant risk of developing fulminant hepatitis with maternal mortality rates as high as 20 30 most commonly in the third trimester 16 83 160 A 2016 systematic review and meta analysis of 47 studies that included 3968 people found maternal case fatality rates CFR of 20 8 and fetal CFR of 34 2 among women who developed fulminant hepatic failure CFR was 61 2 167 See also EditWorld Hepatitis DayReferences Edit a b c d e f Hepatitis MedlinePlus Archived from the original on 11 November 2016 Retrieved 10 November 2016 a b c d e f g What is hepatitis WHO July 2016 Archived from the original on 7 November 2016 Retrieved 10 November 2016 a b c d e f g h i j k l m Hepatitis NIAID Archived from the original on 4 November 2016 Retrieved 2 November 2016 a b Liver Transplant NIDDK April 2012 Archived from the original on 11 November 2016 Retrieved 10 November 2016 Hepatitis MedlinePlus 2020 05 20 Retrieved 2020 07 19 Your liver is the largest organ inside your body It helps your body digest food store energy and remove poisons Hepatitis is an inflammation of the liver Hepatitis Hepatitis A B and C ACG Patients patients gi org Archived from the original on 2017 02 23 Bernal W Wendon J 2013 Acute Liver Failure New England Journal of Medicine 369 26 2525 2534 doi 10 1056 nejmra1208937 PMID 24369077 S2CID 205116503 a b c Fatty Liver Disease Nonalcoholic Steatohepatitis NIDDK May 2014 Archived from the original on 11 November 2016 Retrieved 10 November 2016 a b c d e f g h i j k l m n o p q r s t u v w x y AASLD IDSA HCV Guidance Panel 2015 09 01 Hepatitis C guidance AASLD IDSA recommendations for testing managing and treating adults infected with hepatitis C virus Hepatology 62 3 932 954 doi 10 1002 hep 27950 ISSN 1527 3350 PMID 26111063 Autoimmune Hepatitis NIDDK March 2014 Archived from the original on 11 November 2016 Retrieved 10 November 2016 Vos Theo Allen Christine Arora Megha Barber Ryan M Bhutta Zulfiqar A Brown Alexandria Carter Austin Casey Daniel C Charlson Fiona J Chen Alan Z Coggeshall Megan Cornaby Leslie Dandona Lalit Dicker Daniel J Dilegge Tina Erskine Holly E Ferrari Alize J Fitzmaurice Christina Fleming Tom Forouzanfar Mohammad H Fullman Nancy Gething Peter W Goldberg Ellen M Graetz Nicholas Haagsma Juanita A Hay Simon I Johnson Catherine O Kassebaum Nicholas J Kawashima Toana et al October 2016 Global regional and national incidence prevalence and years lived with disability for 310 diseases and injuries 1990 2015 a systematic analysis for the Global Burden of Disease Study 2015 The Lancet 388 10053 1545 1602 doi 10 1016 S0140 6736 16 31678 6 PMC 5055577 PMID 27733282 Basra Sarpreet 2011 Definition epidemiology and magnitude of alcoholic hepatitis World Journal of Hepatology 3 5 108 13 doi 10 4254 wjh v3 i5 108 PMC 3124876 PMID 21731902 Wang Haidong Naghavi Mohsen Allen Christine Barber Ryan M Bhutta Zulfiqar A Carter Austin Casey Daniel C Charlson Fiona J Chen Alan Zian Coates Matthew M Coggeshall Megan Dandona Lalit Dicker Daniel J Erskine Holly E Ferrari Alize J Fitzmaurice Christina Foreman Kyle Forouzanfar Mohammad H Fraser Maya S Fullman Nancy Gething Peter W Goldberg Ellen M Graetz Nicholas Haagsma Juanita A Hay Simon I Huynh Chantal Johnson Catherine O Kassebaum Nicholas J Kinfu Yohannes et al October 2016 Global regional and national life expectancy all cause mortality and cause specific mortality for 249 causes of death 1980 2015 a systematic analysis for the Global Burden of Disease Study 2015 The Lancet 388 10053 1459 1544 doi 10 1016 S0140 6736 16 31012 1 PMC 5388903 PMID 27733281 Statistics amp Surveillance Division of Viral Hepatitis CDC CDC Archived from the original on 11 November 2016 Retrieved 10 November 2016 Online Etymology Dictionary Etymonline com Archived from the original on 2012 10 20 Retrieved 2012 08 26 a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl Dienstag JL 2015 Chapter 360 Acute Viral Hepatitis In Kasper D Fauci A Hauser S Longo D Jameson J Loscalzo J eds Harrison s Principles of Internal Medicine 19e New York NY McGraw Hill ISBN 978 0 07 180215 4 a b c d e f g Rutherford A Dienstag JL 2016 Chapter 40 Viral Hepatitis In Greenberger NJ Blumberg RS Burakoff R eds CURRENT Diagnosis amp Treatment Gastroenterology Hepatology amp Endoscopy 3e New York NY McGraw Hill ISBN 978 0 07 183772 9 a b c d e f Khalili M Burman B 2013 Chapter 14 Liver Disease In Hammer GD McPhee SJ eds Pathophysiology of Disease An Introduction to Clinical Medicine 7e McGraw Hill ISBN 978 1 25 925144 3 a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am Dienstag JL 2015 Chapter 362 Chronic Hepatitis In Kasper D Fauci A Hauser S Longo D Jameson J Loscalzo J eds Harrison s Principles of Internal Medicine 19e New York NY McGraw Hill ISBN 978 0 07 180215 4 a b c Fontana Robert Hayashi Paul 2014 05 01 Clinical Features Diagnosis and Natural History of Drug Induced Liver Injury Seminars in Liver Disease 34 2 134 144 doi 10 1055 s 0034 1375955 PMID 24879979 a b Manns Michael P Lohse Ansgar W Vergani Diego 2015 Autoimmune hepatitis Update 2015 Journal of Hepatology 62 1 S100 S111 doi 10 1016 j jhep 2015 03 005 PMID 25920079 Munjal Y P Sharm Surendra K 2012 API Textbook of Medicine Ninth Edition Two Volume Set JP Medical Ltd p 870 ISBN 9789350250747 Archived from the original on 2017 09 10 World Health Organization Hepatitis World Health Organization Archived from the original on 2 December 2013 Retrieved 25 November 2013 Hepatitis A Questions and Answers for the Public Division of Viral Hepatitis CDC www cdc gov Archived from the original on 2016 03 12 Retrieved 2016 03 14 Hepatitis E World Health Organization Archived from the original on 2016 03 12 Retrieved 2016 03 14 Centers for Disease Control amp Prevention June 2010 When Someone Close to You Has Hepatitis PDF Archived PDF from the original on March 6 2016 Retrieved March 14 2016 a b c d e f g h Hepatitis B World Health Organization Archived from the original on 2014 11 09 Retrieved 2016 03 09 a b Hepatitis C FAQs for the Public Division of Viral Hepatitis CDC www cdc gov Archived from the original on 2016 03 15 Retrieved 2016 03 14 a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am Friedman Lawrence S 2015 Chapter 16 Liver Biliary Tract amp Pancreas Disorders In Papadakis M McPhee SJ Rabow MW eds Current Medical Diagnosis amp Treatment 2016 55e McGraw Hill ISBN 978 0071845090 a b c d e Harder A Mehlhorn H 2008 Diseases Caused by Adult Parasites or Their Distinct Life Cycle Stages In Weber O Protzer U eds Comparative Hepatitis Birkhauser pp 161 216 ISBN 978 3764385576 a b c d Wisplinghoff H Appleton DL 2008 Bacterial Infections of the Liver In Weber O Protzer U eds Comparative Hepatitis Birkhauser pp 143 160 ISBN 978 3764385576 a b c d e f g h Mailliard ME Sorrell MF 2015 Chapter 363 Alcoholic Liver Disease In Kasper D Fauci A Hauser S Longo D Jameson J Loscalzo J eds Harrison s Principles of Internal Medicine 19e McGraw Hill ISBN 978 0 07 180215 4 a b c d e Lee WM Dienstag JL 2015 Chapter 361 Toxic and Drug Induced Hepatitis In Kasper D Fauci A Hauser S Longo D Jameson J Loscalzo J eds Harrison s Principles of Internal Medicine 19e McGraw Hill ISBN 978 0 07 180215 4 a b Malaguarnera Giulia Cataudella E Giordano M Nunnari G Chisari G Malaguarnera M 2012 Toxic hepatitis in occupational exposure to solvents World Journal of Gastroenterology 18 22 2756 66 doi 10 3748 wjg v18 i22 2756 PMC 3374978 PMID 22719183 Lee William M 31 July 2003 Drug Induced Hepatotoxicity New England Journal of Medicine 349 5 474 485 doi 10 1056 NEJMra021844 PMID 12890847 Suk Ki Tae Kim Dong Joon 2012 Drug induced liver injury present and future Clinical and Molecular Hepatology 18 3 249 57 doi 10 3350 cmh 2012 18 3 249 PMC 3467427 PMID 23091804 a b Herbals and Dietary Supplements livertox nih gov Archived from the original on 2016 05 08 Retrieved 2016 03 14 NIH launches free database of drugs associated with liver injury National Institutes of Health NIH 2015 09 30 Retrieved 2018 09 18 O Mara SR Gebreyes K 2011 Chapter 83 Hepatic Disorders Jaundice and Hepatic Failure Online In Cydulka RK Meckler GD eds Tintinalli s Emergency Medicine A Comprehensive Study Guide 7th ed New York McGraw Hill Archived from the original on 2 December 2013 Retrieved 26 November 2013 a b Abdelmalek MF Diehl AM 2015 Chapter 364 Nonalcoholic Liver Diseases and Nonalcoholic Steatohepatitis In Kasper D Fauci A Hauser S Longo D Jameson J Loscalzo J eds Harrison s Principles of Internal Medicine 19e McGraw Hill ISBN 978 0 07 180215 4 a b National Digestive Diseases Information Clearinghouse NDDIC Nonalcoholic Steatohepatitis National Digestive Diseases Information Clearinghouse NDDIC Archived from the original on 2 December 2013 Retrieved 27 November 2013 Masuoka Howard C Chalasani Naga April 2013 Nonalcoholic fatty liver disease an emerging threat to obese and diabetic individuals Annals of the New York Academy of Sciences 1281 1 106 122 Bibcode 2013NYASA1281 106M doi 10 1111 nyas 12016 PMC 3646408 PMID 23363012 National Digestive Diseases Information Clearinghouse NDDIC Autoimmune Hepatitis National Digestive Diseases Information Clearinghouse NDDIC Archived from the original on 15 September 2010 Retrieved 27 November 2013 Teufel Andreas Galle PR Kanzler S 2009 Update on autoimmune hepatitis World Journal of Gastroenterology 15 9 1035 41 doi 10 3748 wjg 15 1035 PMC 2655176 PMID 19266594 a b c d e Czaja Albert J 2016 Diagnosis and Management of Autoimmune Hepatitis Current Status and Future Directions Gut and Liver 10 2 177 203 doi 10 5009 gnl15352 PMC 4780448 PMID 26934884 a b c Czaja Albert J 2016 03 15 Diagnosis and Management of Autoimmune Hepatitis Current Status and Future Directions Gut and Liver 10 2 177 203 doi 10 5009 gnl15352 ISSN 1976 2283 PMC 4780448 PMID 26934884 Krawitt Edward L 2008 Clinical features and management of autoimmune hepatitis World Journal of Gastroenterology 14 21 3301 5 doi 10 3748 wjg 14 3301 PMC 2716584 PMID 18528927 Teckman Jeffrey H 2013 03 07 Liver Disease in Alpha 1 Antitrypsin Deficiency Current Understanding and Future Therapy COPD Journal of Chronic Obstructive Pulmonary Disease 10 sup1 35 43 doi 10 3109 15412555 2013 765839 ISSN 1541 2555 PMID 23527737 S2CID 35451941 Medline Plus 2012 08 10 Hepatic ischemia National Library of Medicine Archived from the original on 8 December 2013 Retrieved 4 December 2013 Feldman Friedman Feldman Brandt eds 2010 Chapter 83 Vascular Diseases of the Liver Online Sleisenger and Fordtran s Gastrointestinal and Liver Disease Saunders ISBN 978 1416061892 Archived from the original on 4 March 2016 Retrieved 4 December 2013 a b c d Samyn M Mieli Vergani G November 2015 Liver and Biliary Disease in Infancy Medicine 43 11 625 630 doi 10 1016 j mpmed 2015 08 008 Roberts Eve A 2003 10 01 Neonatal hepatitis syndrome Seminars in Neonatology 8 5 357 374 doi 10 1016 S1084 2756 03 00093 9 ISSN 1084 2756 PMID 15001124 Sokol Ronald J Narkewicz Michael R 2012 06 21 Chapter 22 Liver amp Pancreas In Hay William W et al eds Current diagnosis amp treatment pediatrics 21st ed New York McGraw Hill Medical ISBN 978 0 07 177970 8 Archived from the original on 10 December 2013 Retrieved 2 December 2013 Alexopoulou Alexandra Deutsch Melanie Ageletopoulou Johanna Delladetsima Johanna K Marinos Evangelos Kapranos Nikiforos Dourakis Spyros P May 2003 A fatal case of postinfantile giant cell hepatitis in a patient with chronic lymphocytic leukaemia European Journal of Gastroenterology amp Hepatology 15 5 551 555 doi 10 1097 01 meg 0000050026 34359 7c PMID 12702915 a b c Nakamoto Yasunari Kaneko Shuichi 2003 09 01 Mechanisms of viral hepatitis induced liver injury Current Molecular Medicine 3 6 537 544 doi 10 2174 1566524033479591 ISSN 1566 5240 PMID 14527085 Lin Shaoli Zhang Yan Jin August 2017 Interference of Apoptosis by Hepatitis B Virus Viruses 9 8 230 doi 10 3390 v9080230 PMC 5580487 PMID 28820498 Cao Lei Quan Xi Bing Zeng Wen Jiao Yang Xiao Ou Wang Ming Jie 2016 Mechanism of Hepatocyte Apoptosis Journal of Cell Death 9 19 29 doi 10 4137 JCD S39824 PMC 5201115 PMID 28058033 Wong Grace Lai Hung 2014 09 01 Prediction of fibrosis progression in chronic viral hepatitis Clinical and Molecular Hepatology 20 3 228 236 doi 10 3350 cmh 2014 20 3 228 ISSN 2287 285X PMC 4197170 PMID 25320725 a b Rehermann Barbara 2015 11 01 Natural Killer Cells in Viral Hepatitis Cellular and Molecular Gastroenterology and Hepatology 1 6 578 588 doi 10 1016 j jcmgh 2015 09 004 ISSN 2352 345X PMC 4678927 PMID 26682281 a b Heim Markus H Thimme Robert 2014 11 01 Innate and adaptive immune responses in HCV infections Journal of Hepatology 61 1 Suppl S14 25 doi 10 1016 j jhep 2014 06 035 ISSN 1600 0641 PMID 25443342 a b c d e f Hardy Timothy Oakley Fiona Anstee Quentin M Day Christopher P 2016 03 03 Nonalcoholic Fatty Liver Disease Pathogenesis and Disease Spectrum Annual Review of Pathology 11 451 96 doi 10 1146 annurev pathol 012615 044224 ISSN 1553 4014 PMID 26980160 permanent dead link a b c d Yoon Hye Jin Cha Bong Soo 2014 11 27 Pathogenesis and therapeutic approaches for non alcoholic fatty liver disease World Journal of Hepatology 6 11 800 811 doi 10 4254 wjh v6 i11 800 ISSN 1948 5182 PMC 4243154 PMID 25429318 a b c d e f g h i j Chayanupatkul Maneerat Liangpunsakul Suthat 2014 05 28 Alcoholic hepatitis a comprehensive review of pathogenesis and treatment World Journal of Gastroenterology 20 20 6279 6286 doi 10 3748 wjg v20 i20 6279 ISSN 2219 2840 PMC 4033465 PMID 24876748 a b c d e f g Basra Sarpreet Anand Bhupinderjit S 2011 05 27 Definition epidemiology and magnitude of alcoholic hepatitis World Journal of Hepatology 3 5 108 113 doi 10 4254 wjh v3 i5 108 ISSN 1948 5182 PMC 3124876 PMID 21731902 Haga Yuki Kanda Tatsuo Sasaki Reina Nakamura Masato Nakamoto Shingo Yokosuka Osamu 2015 12 14 Nonalcoholic fatty liver disease and hepatic cirrhosis Comparison with viral hepatitis associated steatosis World Journal of Gastroenterology 21 46 12989 12995 doi 10 3748 wjg v21 i46 12989 ISSN 2219 2840 PMC 4674717 PMID 26675364 Grant A Neuberger J 1999 Guidelines on the use of liver biopsy in clinical practice Gut 45 Suppl 4 1 11 doi 10 1136 gut 45 2008 iv1 PMC 1766696 PMID 10485854 The main cause of mortality after percutaneous liver biopsy is intraperitoneal haemorrhage as shown in a retrospective Italian study of 68 000 percutaneous liver biopsies in which all six patients who died did so from intraperitoneal haemorrhage Three of these patients had had a laparotomy and all had either cirrhosis or malignant disease both of which are risk factors for bleeding Green RM Flamm S October 2002 AGA technical review on the evaluation of liver chemistry tests Gastroenterology 123 4 1367 84 doi 10 1053 gast 2002 36061 PMID 12360498 Pratt DS Kaplan MM Apr 27 2000 Evaluation of abnormal liver enzyme results in asymptomatic patients The New England Journal of Medicine 342 17 1266 71 doi 10 1056 NEJM200004273421707 PMID 10781624 Ito Katsuyoshi Mitchell Donald G 2004 Imaging Diagnosis of Cirrhosis and Chronic Hepatitis Intervirology 47 3 5 134 143 doi 10 1159 000078465 PMID 15383722 S2CID 36112368 Allan Richard Thoirs Kerry Phillips Maureen 2010 07 28 Accuracy of ultrasound to identify chronic liver disease World Journal of Gastroenterology 16 28 3510 3520 doi 10 3748 wjg v16 i28 3510 ISSN 1007 9327 PMC 2909550 PMID 20653059 Sahani Dushyant V Kalva Sanjeeva P 2004 07 01 Imaging the Liver The Oncologist 9 4 385 397 doi 10 1634 theoncologist 9 4 385 ISSN 1083 7159 PMID 15266092 a b Villar LM Cruz HM Barbosa JR Bezerra CS Portilho MM Scalioni Lde P 2015 Update on hepatitis B and C virus diagnosis World Journal of Virology 4 4 323 42 doi 10 5501 wjv v4 i4 323 PMC 4641225 PMID 26568915 a b Neuman Manuela G French Samuel W French Barbara A Seitz Helmut K Cohen Lawrence B Mueller Sebastian Osna Natalia A Kharbanda Kusum K Seth Devanshi 2014 12 01 Alcoholic and non alcoholic steatohepatitis Experimental and Molecular Pathology 97 3 492 510 doi 10 1016 j yexmp 2014 09 005 PMC 4696068 PMID 25217800 Guidelines For Viral Hepatitis Surveillance And Case Management www cdc gov Archived from the original on 2016 03 10 Retrieved 2016 03 12 Longo DL Fauci AS Kasper DL Hauser SL Jameson J Loscalzo J eds 2013 Harrison s Manual of Medicine 18e Chapter 164 Chronic Hepatitis New York NY McGraw Hill a href Template Cite book html title Template Cite book cite book a last has generic name help CS1 maint multiple names authors list link a b c d e Hepatitis A Fact sheet N 328 WHO Media Centre Archived from the original on February 21 2014 Retrieved March 7 2016 a b c d Voise Nathan Oct 2011 Advisory Committee on Immunization Practices ACIP of the Centers for Disease Control and Prevention A shot at hepatitis prevention J Am Osteopath Assoc 111 10 Suppl 6 S13 6 PMID 22086888 a b c Adult Immunization Schedule by Vaccine and Age Group www CDC gov Archived from the original on March 5 2016 Retrieved March 7 2016 Longo Dan L et al 2013 Chapter 163 Acute Hepatitis Harrison s Manual of Medicine 18e New York NY McGraw Hill a b c d e f g h i j k l m n o Recommendations for Identification and Public Health Management of Persons with Chronic Hepatitis B Virus Infection www cdc gov Archived from the original on 2016 03 06 Retrieved 2016 03 11 a b c d e f g h i j Chou Roger Dana Tracy Bougatsos Christina Blazina Ian Zakher Bernadette Khangura Jessi 2014 01 01 Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults Systematic Review to Update the 2004 U S Preventive Services Task Force Recommendation U S Preventive Services Task Force Evidence Syntheses formerly Systematic Evidence Reviews Rockville MD Agency for Healthcare Research and Quality US PMID 24921112 a b c d e f g h i j k l Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection World Health Organization Archived from the original on 2016 02 20 Retrieved 2016 03 11 a b c d e f g h i j k l m n o p q r ACOG Practice Bulletin Clinical Management Guidelines for Obstetrician Gynecologists Viral Hepatitis in Pregnancy www acog org Retrieved 2016 03 12 Esherick JS Clark DS Slater ED et al 2015 CURRENT Practice Guidelines in Primary Care 2015 New York NY McGraw Hill a b c d e f g h i j k l m Recommendations for Prevention and Control of Hepatitis C Virus HCV Infection and HCV Related Chronic Disease MMWR 47 RR 19 1 39 October 16 1998 PMID 9790221 Archived from the original on March 24 2016 Retrieved March 16 2016 a b c d e f g h i j k l m n o p q Hepatitis C World Health Organization Archived from the original on 2016 01 31 Retrieved 2016 03 08 a b c d e f g h i j k l m n o Final Recommendation Statement Hepatitis C Screening US Preventive Services Task Force www uspreventiveservicestaskforce org Archived from the original on 2016 03 21 Retrieved 2016 03 21 a b c Birth 18 Years and Catchup Immunization Schedules for Providers www CDC gov Archived from the original on March 6 2016 Retrieved March 7 2016 Centers for Disease Control 1999 Update recommendations to prevent hepatitis B virus transmission United States MMWR 1999 48 33 4 Archived from the original on May 14 2016 Retrieved March 7 2016 a href Template Cite journal html title Template Cite journal cite journal a Cite journal requires journal help Hepatitis A And Hepatitis B Vaccine Intramuscular Route Mayo Clinic Retrieved 25 January 2018 a b c d Hepatitis E World Health Organization Archived from the original on 2016 03 06 Retrieved 2016 03 09 a b WHO Hepatitis D www who int Archived from the original on 2016 03 08 Retrieved 2016 03 09 Zhang et al March 5 2015 Long Term Efficacy of a Hepatitis E Vaccine NEJM 372 10 914 22 doi 10 1056 NEJMoa1406011 PMID 25738667 Phase IV Clinical Trial of Recombinant Hepatitis E Vaccine Hecolin Full Text View ClinicalTrials gov clinicaltrials gov Archived from the original on 2016 03 09 Retrieved 2016 03 09 Rizzetto M 2020 Epidemiology of the Hepatitis D virus WikiJournal of Medicine 7 7 doi 10 15347 wjm 2020 001 Drinking Levels Defined National Institute on Alcohol Abuse and Alcoholism NIAAA www niaaa nih gov 14 September 2011 Archived from the original on 2016 03 23 Retrieved 2016 03 09 Franco Elisabetta Meleleo Cristina Serino Laura Sorbara Debora Zaratti Laura 2012 03 27 Hepatitis A Epidemiology and prevention in developing countries World Journal of Hepatology 4 3 68 73 doi 10 4254 wjh v4 i3 68 ISSN 1948 5182 PMC 3321492 PMID 22489258 Pinkbook Hepatitis B Epidemiology of Vaccine Preventable Diseases CDC www cdc gov Archived from the original on 2016 03 07 Retrieved 2016 03 09 a b c d e f g h i j k l m n o p q r s t Carroll Karen 2015 Chapter 35 Hepatitis Viruses Medical Microbiology New York McGraw Hill ISBN 978 0071824989 Commentary U S 2013 Surveillance Data for Viral Hepatitis Statistics amp Surveillance Division of Viral Hepatitis CDC www cdc gov Archived from the original on 2016 03 05 Retrieved 2016 03 09 Wright NMJ Millson CE Tompkins CNE 2005 What is the evidence for the effectiveness of interventions to reduce hepatitis C infection and the associated morbidity Copenhagen WHO Regional Office for Europe Health Evidence Network report Archived copy PDF Archived PDF from the original on 2010 05 01 Retrieved 2016 03 09 a href Template Cite web html title Template Cite web cite web a CS1 maint archived copy as title link accessed 9 Mar 2016 Basra Sarpreet Anand Bhupinderjit S 2011 05 27 Definition epidemiology and magnitude of alcoholic hepatitis World Journal of Hepatology 3 5 108 113 doi 10 4254 wjh v3 i5 108 ISSN 1948 5182 PMC 3124876 PMID 21731902 The Epidemiology of Alcoholic Liver Disease pubs niaaa nih gov Archived from the original on 2016 03 03 Retrieved 2016 03 09 a b Messori Andrea Badiani Brigitta Trippoli Sabrina 2015 12 01 Achieving Sustained Virological Response in Hepatitis C Reduces the Long Term Risk of Hepatocellular Carcinoma An Updated Meta Analysis Employing Relative and Absolute Outcome Measures Clinical Drug Investigation 35 12 843 850 doi 10 1007 s40261 015 0338 y ISSN 1179 1918 PMID 26446006 S2CID 41365729 a b c d e f g Thiagarajan Prarthana Ryder Stephen D 2015 12 01 The hepatitis C revolution part 1 antiviral treatment options Current Opinion in Infectious Diseases 28 6 563 571 doi 10 1097 QCO 0000000000000205 ISSN 1473 6527 PMID 26524328 S2CID 11926260 a b c d e f g h i j Gogela Neliswa A Lin Ming V Wisocky Jessica L Chung Raymond T 2015 03 01 Enhancing our understanding of current therapies for Hepatitis C virus HCV Current HIV AIDS Reports 12 1 68 78 doi 10 1007 s11904 014 0243 7 ISSN 1548 3568 PMC 4373591 PMID 25761432 a b Abbas Zaigham Khan Muhammad Arsalan Salih Mohammad Jafri Wasim 2011 12 07 Interferon alpha for chronic hepatitis D Cochrane Database of Systematic Reviews 12 CD006002 doi 10 1002 14651858 cd006002 pub2 PMC 6823236 PMID 22161394 a b HEV FAQs for Health Professionals Division of Viral Hepatitis CDC www cdc gov Archived from the original on 2016 03 08 Retrieved 2016 03 17 a b c d e f g Singh Siddharth Murad Mohammad Hassan Chandar Apoorva K Bongiorno Connie M Singal Ashwani K Atkinson Stephen R Thursz Mark R Loomba Rohit Shah Vijay H 2015 10 01 Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis A Systematic Review and Network Meta analysis Gastroenterology 149 4 958 970 e12 doi 10 1053 j gastro 2015 06 006 ISSN 1528 0012 PMID 26091937 a b Thursz Mark Forrest Ewan Roderick Paul Day Christopher Austin Andrew O Grady John Ryder Stephen Allison Michael Gleeson Dermot 2015 12 01 The clinical effectiveness and cost effectiveness of STeroids Or Pentoxifylline for Alcoholic Hepatitis STOPAH a 2 2 factorial randomised controlled trial Health Technology Assessment 19 102 1 104 doi 10 3310 hta191020 ISSN 2046 4924 PMC 4781103 PMID 26691209 Rambaldi Andrea Jacobs Bradly P Gluud Christian 2007 10 17 Milk thistle for alcoholic and or hepatitis B or C virus liver diseases Protocols 2009 4 CD003620 doi 10 1002 14651858 cd003620 pub3 ISSN 1465 1858 PMC 8724782 PMID 17943794 Summerskill W H Korman M G Ammon H V Baggenstoss A H 1975 11 01 Prednisone for chronic active liver disease dose titration standard dose and combination with azathioprine compared Gut 16 11 876 883 doi 10 1136 gut 16 11 876 ISSN 0017 5749 PMC 1413126 PMID 1104411 Bartenschlager ed 2013 Hepatitis C Virus From Molecular Virology to Antiviral Therapy Springer Khuroo MS 1981 Incidence and severity of viral hepatitis in pregnancy Am J Med 70 2 252 5 doi 10 1016 0002 9343 81 90796 8 PMID 6781338 Gill RQ 2001 Acute Liver Failure J Clin Gastroenterol 33 3 191 8 doi 10 1097 00004836 200109000 00005 PMID 11500606 Smedile A et al 1981 Infection with the delta agent in chronic HBsAg carriers Gastroenterology 81 6 992 7 doi 10 1016 S0016 5085 81 80003 0 PMID 7286594 Abbas Zaigham Ali Syed Salman Shazi Lubna 2015 06 02 Interferon alpha versus any other drug for chronic hepatitis D Cochrane Database of Systematic Reviews doi 10 1002 14651858 cd011727 S2CID 70629280 Thein Hla Hla Yi Qilong Dore Gregory J Krahn Murray D 2008 08 01 Estimation of stage specific fibrosis progression rates in chronic hepatitis C virus infection a meta analysis and meta regression Hepatology 48 2 418 431 doi 10 1002 hep 22375 ISSN 1527 3350 PMID 18563841 S2CID 20771903 Fattovich G 1997 Morbidity and mortality in compensated cirrhosis type C a retrospective follow up study of 384 patients Gastroenterology 112 2 463 72 doi 10 1053 gast 1997 v112 pm9024300 PMID 9024300 Hepatitis A Information Division of Viral Hepatitis CDC www cdc gov Archived from the original on 2016 03 04 Retrieved 2016 03 08 a b Aggarwal Rakesh Goel Amit 2015 Hepatitis A Current Opinion in Infectious Diseases 28 5 488 496 doi 10 1097 qco 0000000000000188 PMID 26203853 S2CID 22340290 WHO Hepatitis A www who int Archived from the original on 2014 02 21 Retrieved 2016 03 08 Hepatitis A Questions and Answers for Health Professionals Division of Viral Hepatitis CDC www cdc gov Archived from the original on 2016 03 06 Retrieved 2016 03 08 a b c d e Rosen Hugo R 2011 06 23 Clinical practice Chronic hepatitis C infection The New England Journal of Medicine 364 25 2429 2438 doi 10 1056 NEJMcp1006613 ISSN 1533 4406 PMID 21696309 Edlin Brian R Eckhardt Benjamin J Shu Marla A Holmberg Scott D Swan Tracy 2015 11 01 Toward a more accurate estimate of the prevalence of hepatitis C in the United States Hepatology 62 5 1353 1363 doi 10 1002 hep 27978 ISSN 1527 3350 PMC 4751870 PMID 26171595 a b c d HEV FAQs for Health Professionals Division of Viral Hepatitis CDC www cdc gov Archived from the original on 2016 03 08 Retrieved 2016 03 09 Singal Ashwani K Kamath Patrick S Gores Gregory J Shah Vijay H 2014 04 01 Alcoholic hepatitis current challenges and future directions Clinical Gastroenterology and Hepatology 12 4 555 564 quiz e31 32 doi 10 1016 j cgh 2013 06 013 ISSN 1542 7714 PMC 3883924 PMID 23811249 a b Shoreibah Mohamed Anand Bhupinderjit S Singal Ashwani K 2014 09 14 Alcoholic hepatitis and concomitant hepatitis C virus infection World Journal of Gastroenterology 20 34 11929 11934 doi 10 3748 wjg v20 i34 11929 ISSN 2219 2840 PMC 4161778 PMID 25232227 Singal Ashwani K Anand Bhupinder S 2007 09 01 Mechanisms of synergy between alcohol and hepatitis C virus Journal of Clinical Gastroenterology 41 8 761 772 doi 10 1097 MCG 0b013e3180381584 ISSN 0192 0790 PMID 17700425 S2CID 19482895 Wree Alexander Broderick Lori Canbay Ali Hoffman Hal M Feldstein Ariel E 2013 11 01 From NAFLD to NASH to cirrhosis new insights into disease mechanisms Nature Reviews Gastroenterology amp Hepatology 10 11 627 636 doi 10 1038 nrgastro 2013 149 ISSN 1759 5053 PMID 23958599 S2CID 6899033 a b Weiss Johannes Rau Monika Geier Andreas 2014 06 27 Non alcoholic fatty liver disease epidemiology clinical course investigation and treatment Deutsches Arzteblatt International 111 26 447 452 doi 10 3238 arztebl 2014 0447 ISSN 1866 0452 PMC 4101528 PMID 25019921 a b Michelotti Gregory A Machado Mariana V Diehl Anna Mae 2013 11 01 NAFLD NASH and liver cancer Nature Reviews Gastroenterology amp Hepatology 10 11 656 665 doi 10 1038 nrgastro 2013 183 ISSN 1759 5053 PMID 24080776 S2CID 22315274 Trepo Christian February 2014 A brief history of hepatitis milestones Liver International 34 Supplement s1 29 37 doi 10 1111 liv 12409 PMID 24373076 S2CID 41215392 Oon GC July 2012 Viral hepatitis the silent killer Annals of the Academy of Medicine Singapore 41 7 279 80 PMID 22892603 Lee Christine A Thomas Howard C eds 1988 Classic papers in viral hepatitis Foreword by Dame Sheila Sherlock London England Science Press ISBN 978 1 870026 10 9 Purcell RH April 1993 The discovery of the hepatitis viruses Gastroenterology 104 4 955 63 doi 10 1016 0016 5085 93 90261 a PMID 8385046 Bradley WH 1946 Homologous Serum Jaundice Proceedings of the Royal Society of Medicine 39 10 649 654 doi 10 1177 003591574603901012 PMC 2181926 PMID 19993376 Munson Ronald 1996 Intervention and Reflection Basic Issues in Medical Ethics pp 273 281 Beecher Henry 1966 Ethics and Clinical Research The New England Journal of Medicine 274 24 1354 1360 doi 10 1056 nejm196606162742405 PMID 5327352 Reprinted in Beecher HK 2001 Ethics and clinical research 1966 Bull World Health Organ 79 4 367 72 PMC 2566401 PMID 11368058 a b Purcell RH April 1993 The discovery of the hepatitis viruses Gastroenterology 104 4 955 63 doi 10 1016 0016 5085 93 90261 a PMID 8385046 Emanuel Ezekiel 2008 The Oxford Textbook of Clinical Research Ethics Oxford University Press pp 80 85 Odelberg Wilhelm 1976 Les Prix Nobel Alter Harvey J 2014 01 01 The road not taken or how I learned to love the liver A personal perspective on hepatitis history Hepatology 59 1 4 12 doi 10 1002 hep 26787 ISSN 1527 3350 PMID 24123147 Blumberg BS Alter HJ 1965 02 15 A new antigen in leukemia sera JAMA 191 7 541 546 doi 10 1001 jama 1965 03080070025007 ISSN 0098 7484 PMID 14239025 The Nobel Prize in Physiology or Medicine 1976 NobelPrize org Retrieved 2019 10 07 a b c d Udompap Prowpanga Kim Donghee Kim W Ray 2015 11 01 Current and Future Burden of Chronic Nonmalignant Liver Disease Clinical Gastroenterology and Hepatology 13 12 2031 2041 doi 10 1016 j cgh 2015 08 015 ISSN 1542 7714 PMC 4618163 PMID 26291665 a b Lemoine Maud Eholie Serge Lacombe Karine 2015 Reducing the neglected burden of viral hepatitis in Africa Strategies for a global approach Journal of Hepatology 62 2 469 476 doi 10 1016 j jhep 2014 10 008 PMID 25457207 a b Koslap Petraco Mary Beth Shub Mitchell Judelsohn Richard 2008 Hepatitis A Disease Burden and Current Childhood Vaccination Strategies in the United States Journal of Pediatric Health Care 22 1 3 11 doi 10 1016 j pedhc 2006 12 011 PMID 18174084 Previsani Nicoletta Lavanchy Daniel 2000 Hepatitis A PDF World Health Organization Global Alert and Response World Health Organization Retrieved March 5 2016 Anonychuk Andrea M Tricco Andrea C Bauch Chris T Pham Ba Gilca Vladimir Duval Bernard John Baptiste Ava Woo Gloria Krahn Murray 2008 01 01 Cost effectiveness analyses of hepatitis A vaccine a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies PharmacoEconomics 26 1 17 32 doi 10 2165 00019053 200826010 00003 ISSN 1170 7690 PMID 18088156 S2CID 46965673 Chan Henry Lik Yuen Jia Jidong 2011 01 01 Chronic hepatitis B in Asia new insights from the past decade Journal of Gastroenterology and Hepatology 26 131 137 doi 10 1111 j 1440 1746 2010 06544 x ISSN 1440 1746 PMID 21199524 S2CID 23548529 a b Dan Yock Young Aung Myat Oo Lim Seng Gee 2008 09 01 The economics of treating chronic hepatitis B in Asia Hepatology International 2 3 284 295 doi 10 1007 s12072 008 9049 2 ISSN 1936 0533 PMC 2716880 PMID 19669256 Lavanchy D 2004 03 01 Hepatitis B virus epidemiology disease burden treatment and current and emerging prevention and control measures Journal of Viral Hepatitis 11 2 97 107 doi 10 1046 j 1365 2893 2003 00487 x ISSN 1352 0504 PMID 14996343 S2CID 163757 a b c Younossi Z M Kanwal F Saab S Brown K A El Serag H B Kim W R Ahmed A Kugelmas M Gordon S C 2014 03 01 The impact of hepatitis C burden an evidence based approach Alimentary Pharmacology amp Therapeutics 39 5 518 531 doi 10 1111 apt 12625 ISSN 1365 2036 PMID 24461160 S2CID 21263906 Myers Robert P Krajden Mel Bilodeau Marc Kaita Kelly Marotta Paul Peltekian Kevork Ramji Alnoor Estes Chris Razavi Homie 2014 05 01 Burden of disease and cost of chronic hepatitis C infection in Canada Canadian Journal of Gastroenterology amp Hepatology 28 5 243 250 doi 10 1155 2014 317623 ISSN 2291 2797 PMC 4049256 PMID 24839620 a b c d e f g Centers for Disease Control and Prevention CDC 2003 11 28 Hepatitis A outbreak associated with green onions at a restaurant Monaca Pennsylvania 2003 MMWR Morbidity and Mortality Weekly Report 52 47 1155 1157 ISSN 1545 861X PMID 14647018 Polgreen Lydia November 16 2003 Community Is Reeling From Hepatitis Outbreak The New York Times Archived from the original on March 22 2016 Retrieved March 10 2016 a b Jordan Ashly E Perlman David C Neurer Joshua Smith Daniel J Des Jarlais Don C Hagan Holly 2016 01 28 Prevalence of hepatitis C virus infection among HIV men who have sex with men a systematic review and meta analysis International Journal of STD amp AIDS 28 2 145 159 doi 10 1177 0956462416630910 ISSN 1758 1052 PMC 4965334 PMID 26826159 a b c d Platt Lucy Easterbrook Philippa Gower Erin McDonald Bethan Sabin Keith McGowan Catherine Yanny Irini Razavi Homie Vickerman Peter 2016 02 24 Prevalence and burden of HCV co infection in people living with HIV a global systematic review and meta analysis PDF The Lancet Infectious Diseases 16 7 797 808 doi 10 1016 S1473 3099 15 00485 5 ISSN 1474 4457 PMID 26922272 Archived PDF from the original on 2018 07 19 a b c d e f Cunningham F Gary et al 2013 Hepatic Biliary and Pancreatic Disorders Williams Obstetrics Twenty Fourth Edition New York NY McGraw Hill Tassopoulos NC et al June 1987 Natural history of acute hepatitis B surface antigen positive hepatitis in Greek adults Gastroenterology 92 6 1844 50 doi 10 1016 0016 5085 87 90614 7 PMID 3569758 A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States Recommendations of the Advisory Committee on Immunization Practices ACIP Part 1 Immunization of Infants Children and Adolescents www cdc gov Archived from the original on 2016 03 24 Retrieved 2016 03 16 a b c Terrault Norah A Bzowej Natalie H Chang Kyong Mi Hwang Jessica P Jonas Maureen M Murad M Hassan 2016 01 01 AASLD guidelines for treatment of chronic hepatitis B Hepatology 63 1 261 283 doi 10 1002 hep 28156 ISSN 1527 3350 PMC 5987259 PMID 26566064 Wang Liming Kourtis Athena P Ellington Sascha Legardy Williams Jennifer Bulterys Marc 2013 12 01 Safety of tenofovir during pregnancy for the mother and fetus a systematic review Clinical Infectious Diseases 57 12 1773 1781 doi 10 1093 cid cit601 ISSN 1537 6591 PMID 24046310 Shi Zhongjie Yang Yuebo Ma Lin Li Xiaomao Schreiber Ann 2010 07 01 Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus a systematic review and meta analysis Obstetrics and Gynecology 116 1 147 159 doi 10 1097 AOG 0b013e3181e45951 ISSN 1873 233X PMID 20567182 S2CID 41784922 a b c Benova Lenka Mohamoud Yousra A Calvert Clara Abu Raddad Laith J 2014 09 15 Vertical transmission of hepatitis C virus systematic review and meta analysis Clinical Infectious Diseases 59 6 765 773 doi 10 1093 cid ciu447 ISSN 1537 6591 PMC 4144266 PMID 24928290 Jin H Zhao Y Zhang X Wang B Liu P 2016 03 01 Case fatality risk of pregnant women with acute viral hepatitis type E a systematic review and meta analysis Epidemiology amp Infection FirstView 10 2098 2106 doi 10 1017 S0950268816000418 ISSN 1469 4409 PMC 9150575 PMID 26939626 External links EditWHO fact sheet of hepatitis Viral Hepatitis at the Centers for Disease Control Retrieved from https en wikipedia org w index php title Hepatitis amp oldid 1125057980, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.